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Section I 
 
Introduction 
2 
 
The nervous system (NS) is probably the most elaborated structure of living creatures. 
It allows the body to receive information coming from surroundings, to analyse them and to 
adjust the body response to them. Since the first description of glial cells in the treaty of 
Theodor Schwann in 1839 (for review Kosinski, 2004) and neurons thanks to Heinrich 
Wilhelm Waldeyer and Santiago Ramón y Cajal at the end of the 19th /beginning of the 20th 
century (for review Lopez-Munoz et al., 2006; Winkelmann, 2007), knowledge about the 
structure and functions of the NS has been constantly growing over the years, and at an 
exponential rate during the last decade. Nevertheless, numerous unresolved questions persist 
notably concerning the mechanisms of the NS’s response to injury or the role of newly 
discovered molecules in nervous functions. Our research project was conceived with the aim 
to increase knowledge in these two areas by studying the role of a specific molecule in the 
normal and lesioned NS. This introduction is meant to set the stage and to present the state of 
the art in our research domain, also for readers who are not neuroscience experts.    
 
I.1. Central and Peripheral Nervous System: anatomical and cellular 
differences. 
The NS is made up of two parts, the central (CNS) and the peripheral (PNS) nervous 
system (figure I.1). The CNS includes on the one hand the encephalon, located in the skull 
and formed by the brain, the brain stem and the cerebellum, that interpret information coming 
from the environment and regulate complex processes such as homeostasis, perception, 
emotions and cognition, and on the other hand the spinal cord, located in the spinal canal, 
that conveys information coming from peripheral structures to the encephalon and transmits 
motor and autonomic commands coming from the encephalon to peripheral targets. The PNS 
allows the CNS to interact with the rest of the body and the environment. It includes cranial 
nerves, spinal nerves, autonomic nerves and their respective ganglia.  
Two main cell types are found within the NS: neurons and glial cells. Neurons are 
highly specialized cells that transmit electrical signals across the NS. Glial cells are the most 
numerous cells in the NS, representing about 90% of the total cell population. They are vital 
to neurons and neuronal functions providing them support, protection, myelination and 
metabolic homeostasis.  
Astrocytes, oligodendrocytes and microglia are the glial cells specific to the CNS, 
while Schwann cells (SCs) and satellite cells are specific to the PNS. This different glial cell 
composition has been considered responsible for one of the major functional differences 
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between CNS and PNS, that puzzles neuroscience researchers worldwide since many years: 
axons regenerate readily in the injured PNS, whereas the regenerative capacity of 
injured neurons in the adult mammalian CNS is extremely limited. The next paragraph 
clarifies this difference in post-injury outcome between CNS and PNS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.1: Anatomy of the nervous system (Biol 492/592 Human Neuroanatomy-Keith A.Carson) 
 
 
I.1.1. The outcome of NS injuries depends on the localization of the lesion: CNS versus 
PNS 
Since Ramón y Cajal’s famous works at the beginning of the 20th century (Ramón y 
Cajal, 1928), it is well known that axon regeneration in the mature mammalian CNS is 
extremely limited after injury, contrasting with the remarkable ability of PNS axons to 
regenerate and to allow for recovery of function after peripheral nerve damage. The reasons 
for which the outcomes of PNS and CNS injury are so strikingly different have been 
extensively studied. At first, the inability of CNS axons to regenerate after a lesion was 
attributed to a lack of intrinsic growth capacity of mature CNS neurons. In fact, it has 
been shown that CNS neurons do not up-regulate growth-associated genes such as GAP-43 to 
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the same extent as do PNS neurons after injury (Fernandes et al., 1999). GAP-43 is a target 
gene of KLF-7, one of the members of the Krüppel-like factor family (Kajimura et al., 2007), 
a group of transcription factors that regulate intrinsic axon regeneration ability. It is now 
established that coordinated activities of different KLFs regulate the regenerative capacity of 
CNS neurons (Moore et al., 2009). Also, numerous experiments have shown that CNS axons 
are able to regenerate under certain conditions, as for example when they can grow through 
PNS nerve implants (Aguayo et al., 1981; Lavdas et al., 2008; Huebner & Strittmatter, 2009). 
This finding suggests that the PNS environment is permissive while the CNS environment is 
inhibitory for axon growth, and one of the main causes of this permissive or inhibitory 
environment is the difference in glial cells between PNS and CNS. Hereafter, we will discuss 
the essential roles of SCs in PNS regeneration and the detrimental roles of oligodendrocytes, 
microglia, and astrocytes on CNS regeneration. Figure I.2 summarizes the main differences 
between post-injury responses in PNS and CNS.
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Figure I.2: Main differences in post-injury responses between the PNS (A) and the CNS (B.) 
From:“Neuroscience 2nd edition” The changing brain” Chapter 25: Plasticity of Mature Synapses 
and Circuits” recovery from neural injury. Purves D, Augustine GJ, Fitzpatrick D, et al., editors. 
Sunderland (MA): Sinauer Associates; 2001. 
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I.1.2. Permissive environment for axonal regeneration created by Schwann cells 
After nerve injury, SCs proliferate and express a multitude of factors supporting 
axonal regeneration through three different mechanisms: (I) neuronal survival and neurite 
growth improvement, (II) axonal and myelin debris phagocytosis, and (III) axonal guidance. 
To improve neuronal survival after injury, SCs secrete neurotrophic factors (see 
section 2.4) that are retrogradely transported towards the neuronal cell body to induce the 
expression of anti-apoptotic (Culmsee et al., 2002; Almeida et al., 2005; Pazyra-Murphy et 
al., 2009) and regeneration-associated genes (Cafferty et al., 2001; Cafferty et al., 2004). 
SCs play another key role after injury. They initiate the phenomenon of Wallerian 
degeneration (WD) (see section I.2) that leads to a rapid clearance of myelin debris, the 
overriding step to assure axonal regeneration. Indeed, PNS and CNS myelin sheaths contain 
axonal growth inhibitory proteins such as myelin-associated glycoprotein (MAG) 
(McKerracher et al., 1994; Mukhopadhyay et al., 1994; Shen et al., 1998), Nogo (Huber & 
Schwab, 2000) as well as oligodendrocyte myelin glycoprotein (OMgp) (Kottis et al., 2002). 
SCs promote rapid myelin clearance via two mechanisms. First, they participate to both the 
breakdown of their own myelin sheath into small ovoids and the phagocytosis of the resulting 
debris (Stoll et al., 1989; Fernandez-Valle et al., 1995). Secondly, SCs release a wide variety 
of chemo- and cyto-kines (see section I.2.3) that enhance the recruitment towards the lesion 
site of the second cell type essential for a rapid myelin clearance, the blood-derived 
monocytes. 
Finally, SCs also promote axonal regrowth and remyelination by providing structural 
guidance through their migration and alignment to form guiding tubes called “bands of 
Büngner” (Weinberg & Spencer, 1978) and by producing a basal lamina (Sketelj et al., 1989), 
which contains extracellular matrix proteins that interact with integrins expressed on the 
surface of axons (see section I.2.4). 
 
I.1.3. Inhibitory environment for axonal regeneration in the injured CNS: the coalition 
of oligodendrocytes, astrocytes and microglia. 
In contrast to SCs, oligodendrocytes do not participate in the establishment of a 
permissive environment for axonal regrowth. Indeed, after a CNS injury, the loss of axonal 
contact leads to oligodendrocyte apoptosis (Shuman et al., 1997; Casha et al., 2001). Even if 
oligodendrocyte precursors are recruited at the lesion site, they possess a limited 
remyelination capacity (Blakemore & Keirstead, 1999). Contrary to the PNS where myelin 
debris are rapidly eliminated thanks to SCs and monocyte-derived macrophages, in the CNS, 
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oligodendrocytes do not clear myelin ovoids (Ludwin, 1990) and haematogenous macrophage 
recruitment is limited and occurs later than in injured PNS (Avellino et al., 1995; Popovich & 
Hickey, 2001). This slower clearance of myelin in CNS compared to PNS results in the 
prolonged presence of inhibitory myelin proteins that contribute to the failure of CNS axonal 
regeneration (Vargas & Barres, 2007). 
Resident microglia represents the main population of phagocytic cells after CNS 
injury (Popovich & Hickey, 2001). However, compared to macrophages, rapidly recruited and 
active after PNS injury, microglial cells have a weak phagocytic activity (Milligan et al., 
1991) and their number increases later (Lawson et al., 1994) leading to an extremely slow 
myelin clearance. In addition, microglia is also responsible for neuronal death through the 
secretion of several neurotoxic agents such as reactive oxygen species, nitric oxyde (NO), and 
glutamate, leading to further extension of the primary lesion (Giulian et al., 1993; Langmann, 
2007). 
 
After CNS injury, astrocytes proliferate and become hypertrophic. This leads to the 
phenomenon of astrogliosis, resulting in the formation of an astroglial scar, a physical and 
chemical barrier to axonal regeneration. Indeed, in addition to the physical barrier created by 
the cells themselves, reactive astrocytes secrete inhibitory molecules of which the main ones 
are chondroitin sulfate proteoglycans such as neurocan, versican, and phosphacan 
(Morgenstern et al., 2002). 
Despite this accruing knowledge on the factors facilitating PNS regeneration and those 
that limit CNS regeneration, many questions remain about the molecular and cellular 
mechanisms responsible for the success of axon regrowth in the PNS, and about possible 
novel therapeutic strategies to promote CNS regeneration, underlining the need for more 
research.  
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I.2. Wallerian degeneration in the PNS 
Injury to the NS initiates an organized sequence of degenerative cellular and molecular 
events in the segment distal to the lesion site, named the Wallerian degeneration (WD), 
critical for successful repair (Waller, 1850). In the PNS, WD consists of axonal rupture and 
fragmentation, loss of contact between axon and myelin, debris removal by phagocyting SCs, 
which also dedifferentiate, proliferate and migrate to form the bands of Büngner along which 
regenerating fibres will regrow (figure I.3). Due to chemokine secretion by SCs, monocyte-
derived macrophages are recruited from the circulation and participate, along with SCs, in 
axonal and myelin debris clearance. SCs and macrophages also secrete several inflammatory 
and neurotrophic factors beneficial to neuronal survival and to axonal regeneration. These 
main steps will be described in more details in this paragraph. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.3: Schematic representation of Wallerian degeneration 
(www.neuroanatomie.at/uploads/pics/4.jpg) 
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I.2.1. Axonal breakdown 
The degradation of axolemma and axoplasm is an early step of WD. Axonal 
breakdown is an active and rapid process that occurs as soon as 36 to 44 hours after injury, 
due to intrinsic properties involving homeostatic mechanisms, and is completed after 48h. 
WD progresses as a wave which sequentially affects adjacent regions of the axon. However 
its orientation depends of the lesion type; axonal degeneration is anterograde after transection, 
but retrograde after a crush (Beirowski et al., 2005). Propagation of axon degradation is 
asynchronous among the axonal population of a peripheral nerve and is directly correlated 
with fibre diameter and internodal length (Lubinska, 1977; Veronesi & Boyes, 1988). The 
major early axonal changes include fragmentation of rough endoplasmic reticulum and 
dissolution of neurofilaments and microtubules. Nerve injury disrupts the integrity of the 
axoplasm and exposes it to the external ionic environment. Consequently, intra-axonal 
calcium increases and activates cystein proteases called calpains. These enzymes are 
responsible for the degradation of neurofilaments (Glass et al., 2002). The ubiquitin 
proteasome system (UPS) is also involved in neurofilament dissolution as well as in 
microtubule depolymerization (Zhai et al., 2003). Part of the evidence for the implication of 
UPS in WD comes from the discovery of the spontaneous mutant strain WldS in the C57Bl/6 
mouse. In WldS mice transected axons live and thrive for weeks independently of their native 
cell body (Lunn et al., 1989). This phenotype of slow WD is due to the expression of a novel 
chimeric protein consisting of the N-terminal portion of the ubiquitin regulatory enzyme 
UFD2 and the nicotinamide mononucleotide adenylyltransferase (Nmnat). The ability of 
UFD2 for multi-ubiquitination is therefore impaired, which suppresses the neurofilament and 
microtubule targeting by the UPS hence preventing their degradation (Mack et al., 2001). 
 
I.2.2. Glial response and myelin fragmentation 
In response to this axonal degeneration, SCs undergo molecular and cellular changes 
called dedifferentiation. SCs downregulate myelin gene expression like P0, MBP and MAG 
(LeBlanc & Poduslo, 1990), fragment their own myelin sheaths into ovoids and phagocyte the 
resulting debris (Stoll et al., 1989; Fernandez-Valle et al., 1995). Concomitantly, they up-
regulate several specific genes of the immature SC phenotype, such the cytoskeletal protein 
GFAP, the low affinity nerve growth factor receptor (p75 NGFr), as well as cell adhesion 
molecules like N-CAM and L1 (Taniuchi et al., 1988; Thomson et al., 1993; Martini, 1994). 
These changes of the SC phenotype require several environmental signals. The initiation of 
SC dedifferentiation and proliferation is consecutive to the loss of axonal contacts (Lunn et 
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al., 1989). Injured neurons also release several factors such as the type II and III isoforms of 
neuregulin-1 (NRG1) (Carroll et al., 1997; Kwon et al., 1997; Osheroff et al., 1999; Guertin 
et al., 2005), as well as TGF-β1 (Rogister et al., 1993), which induce SC demyelination and 
proliferation. Moreover the blood-nerve barrier breakdown after the injury induces a fibrin 
deposit that stimulates p75 NGFr expression in SCs, maintains them in a non-myelinating 
state and prevents the synthesis of myelin proteins (Akassoglou et al., 2002). Dedifferentiated 
SCs also exert an autocrine activity to maintain their unmyelinating and proliferating state by 
the expression of several molecules and their receptors such as Epo/Epo-R (Li et al., 2005), 
vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Sondell et al., 1999a). 
In this dedifferentiated and proliferating state, SCs also induce the inflammatory response (see 
section I.2.3) and provide the favourable environment for axonal regeneration by organising 
themselves into axonal guiding tubes called bands of Büngner, and by secreting neurotrophic 
factors (see section I.2.4.).  
 
I.2.3. Inflammatory reaction 
In both CNS and PNS, traumatic injuries lead to a local inflammatory response 
regulated by numerous signalling molecules. Their production and local effects influence the 
outcome of trauma. In the PNS, the well-organized inflammatory process that follows 
axotomy plays a beneficial role for nerve repair. Indeed, it induces a rapid clearance of axonal 
and myelin debris by recruited macrophages and SCs, thus contributing to the establishment 
of a permissive environment for regrowth.  
 
 Initiation of inflammatory response 
Following a nerve lesion, injured glial and neuronal cells release several molecules 
named “damage signals”. These endogenous molecules rapidly stimulate SCs through two 
types of receptors, the Toll-Like Receptors (TLRs) and type-2 Purinergic Receptors (P2Rs) 
(Pineau & Lacroix, 2009), leading to the activation of transcription factors NF-κB and c-Jun 
(figure I.4). These factors induce the synthesis and release of pro-inflammatory 
cyto/chemokines controlling the recruitment and the activation of both glial cells and blood-
derived immune cells (Camara-Lemarroy et al., 2010). The endogenous TLR ligands present 
within the lesion site include several heat shock proteins (Willis et al., 2005; Lehnardt et al., 
2008), as well as self-derived RNA, DNA and associated proteins (Scaffidi et al., 2002; 
Barrat et al., 2005; Kim et al., 2006; Park et al., 2006). P2Rs are activated by nucleotides 
such as ATP and UTP, also released after injury (Inoue, 2002; Tsuda et al., 2003).  
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Figure I.4: Receptors and signalling pathways initiating neuro-inflammation after injury (Pineau & 
Lacroix, 2009). 
 
 
 Cyto/chemokine network 
Molecules derived from damaged neurons stimulate nearby Schwann cells that initiate 
the process of WD by releasing pro-inflammatory cytokines and chemokines involved in 
leukocyte recruitment and activation. Fibroblasts and thereafter, more importantly, recruited 
macrophages also take part in the development of this complex cyto/chemokine network 
(figure I.5). The three first cytokines secreted by SCs a few hours after the nerve injury are 
TNF-α, IL-1α and IL-β (Taskinen et al., 2000; Shamash et al., 2002; Perrin et al., 2005). 
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These cytokines are essential for WD. They initiate and control the cyto/chemokine network 
by the induction of several other pro-inflammatory cytokines and chemokines such as MCP-1 
and MIP-1α (Taskinen & Roytta, 2000; Subang & Richardson, 2001; Tofaris et al., 2002; 
Perrin et al., 2005), but also anti-inflammatory molecules such as IL-10 (Shamash et al., 
2002).  
 
                       
 
 
 
 
 
 
 
 
 
 
 
Figure I.5: Schematic representation of the cyto/chemokine network of Wallerian degeneration 
(modified from Shamash et al., 2002). The early secretion of TNF-α, IL-1α and IL-β by SCs induces 
the expression of other pro-inflammatory cytokines and chemokines by macrophages and fibroblasts 
(arrows) but also the anti-inflammatory cytokine IL-10 that, in turn, downregulates the expression of 
pro-inflammatory molecules (dotted lines).  
 
Cytokines promote macrophage recruitment (see below), and, indirectly, myelin clearance; 
they induce the secretion of neurotrophic factors like NGF, which promote axonal 
regeneration (Lindholm et al., 1987; Hattori et al., 1994; Golz et al., 2006). 
The chemokines MCP-1 and MIP-1α, in addition to their chemotactic effect on macrophages 
(Toews et al., 1998; Siebert et al., 2000; Perrin et al., 2005), are able to induce the expression 
of numerous cytokines among which IL-1β, TGF-β and IL-10 (Perrin et al., 2005). GM-CSF, 
another cytokine induced during WD, is mainly expressed by fibroblasts in the nerve (Saada 
et al., 1996; Be'eri et al., 1998). GM-CSF induces up-regulation of galectin-3 (MAC-2) in 
macrophages and SCs, which enhances the phagocytic activity of these cells (Saada et al., 
1996). The cytokine network is also regulated by IFN-γ, that stimulates TNF-α and IL-1 
production in macrophages, fibroblasts and endothelial cells (Collart et al., 1986; Murwani & 
Armati, 1998; Ruohonen et al., 2005). Finally, the upregulation of the IL-6 cytokine family 
members such as LIF and IL-6 contributes to neuronal survival and regenerative responses 
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(Curtis et al., 1994; Bourde et al., 1996; Kurek et al., 1996; Reichert et al., 1996). These 
neuropoietic cytokines influence the expression of neurotrophins like NGF and NT-4 (Marz et 
al., 1999; Golz et al., 2006) that are major actors in axonal outgrowth after lesioning. IL-6 and 
LIF also act on macrophages, by repressing the expression of TNF-α (Shamash et al., 2002), 
itself implicated in neuropathic pain (Sommer et al., 1998; George et al., 1999; Leung & 
Cahill, 2010). Lastly, LIF is retrogradely transported towards neuronal cell bodies and 
improves neuronal survival by the induction of anti-apoptotic genes (Curtis et al., 1994; 
Kurek et al., 1996; Schweizer et al., 2002; Moon et al., 2009). 
 
 Macrophage recruitment and myelin phagocytosis 
As mentioned above, the main functions of pro-inflammatory cytokines and 
chemokines are to recruit and to activate blood-derived monocytes at the lesion site, for a 
rapid clearance of myelin debris. 
Inflammatory cytokines and chemokines, in addition to their chemotactic effect on 
monocytes, induce the expression of several classes of molecules involved in the recruitment 
of blood-derived macrophages: (I) matrix metalloproteinases such as MMP-9 by SCs that 
opens the blood-nerve barrier (Siebert et al., 2001; Shubayev et al., 2006), (II) NO via the 
inducible nitric oxyde synthase (iNOS) activation in both SCs and macrophages to increase 
permeability of the blood-nerve-barrier (Gonzalez-Hernandez & Rustioni, 1999; de la Hoz et 
al., 2003), and (III) adhesion molecules that mediate monocyte and endothelial cell 
interactions to allow the trans-endothelial migration of circulating monocytes. For example, 
the intercellular adhesion molecule-1 (ICAM-1), expressed on endothelial cell surface, 
mediates migration of monocytes (Schafers et al., 2002; Siebert & Bruck, 2003) through its 
interactions with several surface receptors like the integrin αMβ2 (= type 3 complement 
receptor, also called MAC-1 or CD11b), the integrin α4β1 also named VLA-4, as well as the 
lymphocyte function-associated antigen-1 (LFA-1) (Brown et al., 1997; Avellino et al., 
2004).  
Once arrived at the injury site, macrophages, assisted by SCs, phagocyte axonal and 
myelin debris. There are two main mechanisms of phagocytosis dependent or not on 
opsonisation.  The opsonin-dependent phagocytosis is mediated by macrophages expressing 
the MAC-1 receptor, that recognizes particles opsonised by the complement component C3, 
or the Fc receptors that bind to auto-antibodies opsonising lipid-rich myelin debris. The 
opsonin-independent phagocytosis involves a carbohydrate receptor, expressed on 
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macrophages and SCs, the galactose-specific lectin called MAC-2 (Bruck & Friede, 1990; 
Reichert et al., 1994; Hirata & Kawabuchi, 2002).  
The phagocytic activity of macrophages can be enhanced by the chemokines MCP-1 
and MIP-1α that induce the expression of MAC-1 (Conklyn et al., 1996; Weber et al., 1999; 
Nicholson et al., 2007). 
 
 Inflammation “turned-off” 
As described above, the inflammatory response plays an important role in Wallerian 
degeneration after peripheral nerve injury. For this response to be optimal, however, pro-
inflammatory signals have to be “turned-off” in a timely manner in order to limit the 
inflammatory process and avoid adverse effects such as neuropathic pain. Inflammation is 
down-regulated via two mechanisms. First, macrophages are cleared from the lesioned nerve 
by a local apoptosis after myelin debris phagocytosis, and by their migration towards lymph 
nodes and spleen (Kuhlmann et al., 2001). Second, pro-inflammatory cyto/chemokines are 
downregulated by several anti-inflammatory factors, the production of which is stimulated in 
two different manners. Pro-inflammatory cytokines such as TNF-α and IL-1 induce the 
expression of anti-inflammatory cytokines like IL-10 and TGF-β in SCs, macrophages and 
fibroblasts (Scherer et al., 1993; Jander et al., 1996; Be'eri et al., 1998; Gillen et al., 1998; 
Taskinen et al., 2000; Perrin et al., 2005; Sawada et al., 2007), and of SOCS (suppressors of 
cytokine signalling) in SCs (Girolami et al., 2010). In addition, myelin-laden macrophages 
adopt an anti-inflammatory phenotype and secrete anti-inflammatory molecules like IL-10 
and TGF-β (Boven et al., 2006).  
 
I.2.4. Axonal regeneration and remyelination 
Following axotomy, injured neurons try to promote their survival by the expression of 
neurotrophins such as BDNF and GDNF (Kobayashi et al., 1996; Gordon, 2009), and their 
ability to regrow by the upregulation of growth-associated genes like tubulin, actin and GAP-
43 (Bisby & Tetzlaff, 1992). However, the sole efforts of neurons are not sufficient to insure 
axonal regeneration. Denervated SCs, which dedifferentiate and secrete several molecules, are 
crucial to promote and guide axonal regeneration, as well as remyelination. 
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 Axonal regeneration   
The specific ability of SCs to provide a favourable environment for axonal 
regeneration is mainly due to their secretion of neurotrophic factors, their organisation in 
bands of Büngner, as well as their expression of cell adhesion molecules and neuronal 
guidance molecules. 
As mentioned in section I.2.3, SCs secrete neuropoietic cytokines such as LIF and IL-
6 that improve neuronal survival and axonal regeneration by binding to their gp 130 receptor. 
They also synthesize neurotrophins such as NGF, NT-4, BDNF, GDNF, and their low affinity 
receptor p75 NGFr (Heumann et al., 1987; Taniuchi et al., 1988; Funakoshi et al., 1993; 
Hammarberg et al., 1996). The upregulation of p75NGFr on the SC surface is accompanied 
by its down-regulation on axons (Zhou et al., 1996) that, unlike SCs, express the neurotrophin 
high-affinity tyrosine kinase (Trk) receptors (Frisen et al., 1993; Funakoshi et al., 1993; 
Kobayashi et al., 1996; Hammarberg et al., 2000). Thus, following injury, p75NGFr 
expressing SCs migrate and align to form bands of Büngner. Through an autocrine 
mechanism, SC released-neurotrophins bind to p75NGFr on the SC surface. This creates a 
local concentration gradient of trophic factors along which fibres can regenerate by the 
displacement of neurotrophins from SC p75NGFr to axonal Trk receptors (figure I.6) (Zhou et 
al., 1996; Ramer et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.6: Schematic representation of axonal regeneration mechanism (simplified scheme modified 
from Ramer et al., 1999. Released neurotrophic factors create a local concentration gradient, 
allowing growth cone (GC) progression. Thereafter, they are retrogradely transported towards 
neuronal cell bodies to improve neuronal survival (arrow within axon).  
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The formation of Büngner’s bands results from a complex mechanism that involves a wide 
variety of ligand-receptor interactions such as NGF and its binding to p75NGFr (Anton et al., 
1994), MMP-9 and its LDL receptor-related protein (LRP-1) binding (Mantuano et al., 2008), 
NRG-1 and its erbB2/3 binding (Lai, 2005; Yamauchi et al., 2008), ephrin-B and its binding 
to EphB2 (Parrinello et al., 2010) and the class 3 semaphorin receptor neuropilin-2 (NRP-2) 
(Ara et al., 2005). 
In addition, cell adhesion molecules, underlying neuron-glia interactions, are also 
important for axonal regeneration after nerve injury. Under regenerative conditions, SCs and 
neurons up-regulate adhesion molecules such as N-CAM, L1/Ng-CAM, N-cadherin and 
carbohydrates, like polysialic acid or L2/HNK-1, that can form “homo- or hetero-philic” 
interactions to promote axonal growth (Bixby et al., 1988; Martini, 1994; Fu & Gordon, 
1997). SCs also elaborate a basement membrane containing many ECM proteins, such as 
laminin, fibronectin, collagen and tenascin that can interact with integrins expressed on the 
surface of axons to support axonal regeneration and guidance (Sketelj et al., 1989; Martini, 
1994; Fu & Gordon, 1997). 
Next to neurotrophic factors and cell adhesion molecules, other molecules also play a 
role in axonal guidance during nerve regeneration such as semaphorins and their neuropilin 
receptors (Scarlato et al., 2003), as well as netrins that can exert both attractive and repulsive 
effects on regenerating axons depending on their receptors (Madison et al., 2000). 
 
 Remyelination 
For optimal functional recovery after peripheral nerve regeneration, axons need to 
reconnect with their original targets but also to be correctly remyelinated by SCs for a rapid 
conduction of electrical signals. The remyelination program recapitulates development in 
many ways and requires a large number of signals between neurons and SCs. Among the 
numerous axonal molecules involved in the interactions with SCs, the neurotrophin BDNF 
and the neuregulin NRG1 type III play important roles in axonal remyelination.  
As mentioned above, injured neurons secrete the neurotrophic factor BDNF that  binds 
to p75 NGFr on the SC surface and promotes myelin formation by inducing the expression of 
myelin proteins such as MAG and P0 (Cosgaya et al., 2002; Tolwani et al., 2004). 
Myelination is also regulated via the level of neuregulin NRG1 type III expressed on the 
axonal surface that can interact with the erbB2/B3 receptor on the SC surface. In fact, small 
neurons with unmyelinated axons are characterized by a very low level of NRG1 type III, 
whereas large neurons express high levels of NRG1 type III allowing to generate a thick 
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myelin sheath. NRG1 type III acts therefore as a biochemical sensor of axon size to control 
axonal ensheathment and myelin thickness (Michailov et al., 2004; Taveggia et al., 2005). 
All these interaction signals between axons and SCs lead to the activation of a gene 
regulatory network that will drive the pro-myelinating to myelinating transition of SCs 
(Svaren & Meijer, 2008). The transcription factors implicated in the myelination program 
include the neural crest transcription factor Sox10 (Britsch et al., 2001) as well as the POU 
domain factor Oct6/Scip and Brn2 (Jaegle et al., 2003), that regulate the activation of the 
transcription factor Krox20/Egr2 (Svaren & Meijer, 2008). These transcription factors control 
the expression of genes coding for myelin proteins such as Pmp22, P0, MBP, MAG and 
connexin 32, and for proteins required for lipid synthesis like the3-hydroxy-3-
methylglutarylcoenzyme A (HMG-CoA) reductase, the rate-limiting enzyme for cholesterol 
biosynthesis (Pertusa et al., 2007; Svaren & Meijer, 2008; Quintes et al., 2010). 
As mentioned in section I.2.2, SCs dedifferentiate and proliferate after nerve injury to 
support the growth of regenerating axons. When axons make contact with SCs, only one out 
of five of the latter participates in remyelination. The remaining SCs without axonal contact 
are eliminated by apoptosis. The induction of this apoptosis is mediated by two main 
mechanisms. First, SC death is promoted by the absence of the survival signal induced by the 
interaction between axonal NRG1 type III and SC receptor erbB2/B3 (Grinspan et al., 1996; 
Garratt et al., 2000). Moreover, an apoptotic signal can be induced in the supernumerary SCs 
by the binding of NGF to its p75 NGFr (Hirata et al., 2001), when this neurotrophin is not 
displaced towards the axonal Trk receptors to promote axonal regeneration (see figure I.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
I.3. The transcription factor “nuclear factor kappa B” 
Nuclear factor kappa B (NF-κB) is an ubiquitous and inducible transcription factor. In 
mammals, the NF-κB/Rel family comprises five members: p50, p52, p65 (Rel-A), c-Rel and 
Rel-B, that share a N-terminal 300 amino acid Rel homology domain allowing DNA binding, 
dimerization and nuclear localization (O'Dea & Hoffmann, 2010). These proteins form homo 
or heterodimers that are retained inactive in the cytoplasm by interaction with inhibitory 
molecules, called IκBs. IκBs mask both the NF-κB nuclear localization and DNA binding 
domains (Zabel & Baeuerle, 1990). Upon various cellular stimulations described below in 
section I.3.1, NF-κB is activated once the inhibitory molecules are phosphorylated and 
subsequently degraded. There are two main NF-κB activation pathways: the canonical and the 
alternative pathways. The classical pathway, triggered by pro-inflammatory cytokines such as 
TNF-α, involves the recruitment and activation of the classical IκB kinase (IKK) complex, 
which includes the scaffold protein NF-κB essential modulator (NEMO; also named IKKγ). 
As for the alternative pathway, triggered by cytokines such as lymphotoxin B, B-cell 
activating factor or CD40 ligand, and by viruses such as human T-cell leukemia virus and the 
Epstein-Barr virus, it is NEMO-independent. In both pathways the IKK complex 
phosphorylates specific amino acids of IκBs, leading to their polyubiquitination and 
degradation through the proteasome pathway (figure I.7) (Viatour et al., 2005).  
 
 
 
 
 
      
 
 
 
 
 
 
 
Figure I.7: General mechanism of NF-κB activation 
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The released NF-κB dimers migrate to the nucleus and bind to κB motifs whose consensus 
sequence is GGGRNNYYCC (C = cytosine, G = guanine, N = any base, R = purine, and Y = 
pyrimidine), in the promoter or enhancer regions of target genes (Ghosh et al., 1998). 
The NF-κB functions in the immune system and host defence mechanisms have been 
well characterized, contrary to its roles in the nervous system that are less well understood. 
 
I.3.1. Activation factors and target genes of NF-κB 
In 1999, Pahl compiled bravely about 150 stimuli and 150 target genes of NF-κB 
(Pahl, 1999). This ever growing list of activators and targets of NF-κB is updated on a 
website (www.nf-kb.org) created by the Dr. T.D. Gilmore who dedicated his research to the 
NF-κB-activating pathways.  
Because its activation is induced by a wide array of stimuli including pro-
inflammatory cytokines, infection, injury, ischemia, irradiations as well as oxidative stress, 
NF-κB represents a central regulator of stress responses (Pahl, 1999). In addition to these 
general NF-κB activators, some stimuli characteristic of the NS such as neurotrophins (Wood, 
1995; Carter et al., 1996), glutamate (Kaltschmidt et al., 1995; Scholzke et al., 2003), 
membrane depolarization (Lilienbaum & Israel, 2003), amyloid β peptide (Behl et al., 1994), 
neural cell adhesion molecule (N-CAM) (Krushel et al., 1999), as well as sleep deprivation 
(Brandt et al., 2004) were described as NF-κB-activating molecules. Moreover, some cell 
type and stimulus specificities have been reported. For example, Il-1β induces NF-κB activity 
in astrocytes but not in neurons (Srinivasan et al., 2004) while glutamate activates NF-κB 
only in neurons (Guerrini et al., 1995). NGF activates NF-κB only in SCs (Carter et al., 
1996), but all neurotrophins induce its activation in microglia (Nakajima et al., 1998).  
In response to the stress stimulus, NF-κB activation promotes the transcription of 
genes whose products tend to protect against the stressor. The majority of proteins encoded by 
NF-κB target genes participate in the host immune response. These include, for example, 27 
different cytokines and chemokines (Pahl, 1999), as well as receptors required for immune 
recognition, such as MHC molecules (Israel et al., 1989). Other genes regulated by NF-κB, 
are those encoding IκBs (de Martin et al., 1993; Sun et al., 1993), therefore providing a 
negative feedback mechanism whereby resynthesized IκBs bind to DNA-bound NF-kB 
dimers and export them out to the cytosol. 
Knowledge about the genes regulated by NF-κB in the nervous system is scarce and 
largely extrapolated from the immune system. However, a limited number of genes regulated 
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by NF-κB in the NS and with direct relevance for nervous functions were identified. These 
include N-CAM (Simpson & Morris, 2000), iNOS (Madrigal et al., 2001), amyloid precursor 
protein (Grilli et al., 1996), opioid receptors (Kraus et al., 2003), BDNF (Lipsky et al., 2001) 
and calcium/calmodulin-dependent protein kinase II (Kassed et al., 2004). 
 
I.3.2. NF-κB functions during Wallerian degeneration 
The transcriptionally active form of NF-κB in the NS is primarily the p65/p50 
heterodimer, although other dimers, containing the c-Rel subunit, have been described 
(Memet, 2006). After a PNS injury, there are two peaks of NF-κB activation. A first peak is 
observed in neurons (Fernyhough et al., 2005) and SCs (Smith et al., 2009). This early NF-κB 
activation wave is principally caused by axonal “damage signals” that activate TLRs and 
P2Rs (see section I.2.3.) (Ferrari et al., 1997; Lee et al., 2006; Boivin et al., 2007), 
mechanical stress caused by the injury (Lan et al., 1994) and SC cytokines (Moynagh et al., 
1993; Wood, 1995). The second peak occurs only in SCs during remyelination. This late NF-
κB activation is mainly caused by the interactions of NRG1 type III with erbB2/B3 (Limpert 
& Carter, 2010), and of NGF with p75 NGFr (Carter et al., 1996; Hirata et al., 2001). The 
three main targets of NF-κB activation after a nerve injury are regulation of neuronal survival, 
inflammation and neuropathic pain, and remyelination of regenerating fibers. These three 
different functions of NF-κB activation will be described below. 
 
 Regulation of neuronal survival  
NF-κB exhibits major and opposed functions in neurons as it can both promote and 
protect against cell death. These conflicting neuroprotective and neurodegenerative roles have 
been discussed in several articles and reviews and depend notably on the neuronal cell type 
and the stimulus origin and duration (Kaltschmidt et al., 2002; Mattson & Meffert, 2006; 
Memet, 2006). Moreover, different NF-κB dimers drive opposite effects on neuronal survival. 
While p50/p65 acts as a transcriptional inducer of proapoptotic genes such as Bim and Noxa, 
c-Rel dimers promote transcription of anti-apoptotic genes like Bcl-2 and Bcl-xL (Tamatani et 
al., 1999; Pizzi et al., 2002; Inta et al., 2006; Sarnico et al., 2009). During WD (see section 
I.2.), injured neurons and SCs release several cytokines of which TGF-β1 and TNF-α. In 
several experimental models, these two molecules have a neuroprotective effect that requires 
NF-κB activation (Zhu et al., 2004; Fernyhough et al., 2005; Konig et al., 2005). The 
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promotion of neuronal survival by NF-κB activation during WD improves the subsequent 
regeneration of injured fibers. 
 
 Induction of cytokine expression and neuropathic pain 
PNS and CNS injuries induce the production of pro-inflammatory cyto- and 
chemokines, such as TNF-α, IL-1β, IL-6 and MCP-1 by glial cells. As mentioned in section 
I.2.3, this inflammatory response has beneficial effects on axonal regeneration. However, it 
has also been shown that the pro-inflammatory molecules can have negative effects like the 
development of neuropathic pain (Wagner & Myers, 1996; Sweitzer et al., 1999; Gao & Ji, 
2010). Numerous experiments have shown the role of NF-κB activation in the transcriptional 
induction of genes encoding inflammation- and pain-related molecules (Tegeder et al., 2004; 
Ledeboer et al., 2005; Niederberger & Geisslinger, 2008) illustrating that NF-κB, besides its 
beneficial effect in neuronal regeneration, is also involved in neuropathic pain. Consequently, 
it was suggested that selective inactivation of NF-κB in inflammatory glial cells may be a 
therapeutic option for neuropathic pain (Meunier et al., 2007; Fu et al., 2010). This novel 
approach for pain therapy would, however, reduce the synthesis of neuropoietic cytokines like 
LIF or IL-6 (Fan et al., 2004) which are beneficial for axonal regeneration. 
 
 Regulation of remyelination and Schwann cell number  
As mentioned previously, during WD, SCs proliferate and migrate to form bands of 
Büngner that serve as guiding tubes for regenerating axons. This cellular alignment and the 
extra-cellular matrix deposit across the injury site allow the interaction between regenerating 
axons and SCs that favours axonal remyelination. Axonal signals promoting remyelination 
(see section I.2.4.) converge on a complex network of transcription factors, including the POU 
domain factors Oct6/Scip and Brn2, the high mobility group protein Sox10 and the zinc-
finger protein Krox20/Egr2, that drives the transition of SCs from an unmyelinating 
proliferating to a myelinating state and the induction of myelin protein synthesis (see section 
I.2.4.). The implication of NF-κB in myelination is a more recent finding. It was shown that 
NF-κB is required for activation of the Oct6/Scip transcription factor in SCs (Nickols et al., 
2003). After remyelination, excessive SCs without axonal contact die by apoptosis that is 
partly mediated by the binding of NGF to its receptor p75 NGFr, which in turn activates NF-
κB, leading to the induction of the apoptotic signal (Carter et al., 1996; Hirata et al., 2001). 
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I.4. The Vascular Endothelial Growth Factor Family 
Recently, it was demonstrated that the nervous and the vascular systems share a 
common molecular basis for the control of their patterning during development but also their 
remodelling during pathological conditions (Carmeliet & Tessier-Lavigne, 2005). The most 
popular angiogenic factors belong to the VEGF family. While VEGF family proteins and their 
receptors are the primary mediators of the neo-vascularisation process both during 
development and pathological conditions, other roles, particularly in the nervous system, 
begin to be recognized.  
The VEGF family includes seven secreted glycoproteins, designated VEGF-A, VEGF-
B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental growth factor (PlGF). They share a 
common structure of eight characteristically spaced cysteine residues in a VEGF homology 
domain (Muller et al., 1997), but have different physical and biological properties and act 
through specific receptors. The receptors of the VEGF family consist of three protein–tyrosine 
kinases (VEGFR-1, VEGFR-2, and VEGFR-3) and two non-protein kinase co-receptors 
(neuropilin-1 and neuropilin-2) (figure I.8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.8: VEGF family members and receptors. The Trk receptor VEGFR-1 binds VEGF-A, VEGF-
B and PlGF with high affinity. VEGFR-2 binds VEGF-A, VEGF-C, VEGF-D, VEGF-E and VEGF-F. 
VEGFR-3 is a tyrosine kinase receptor with only six Ig-homology domains, which preferentially binds 
VEGF-C and VEGF-D. Neuropilin-1 and -2 (NRP-1 and NRP-2), the two non-tyrosine kinase-type co-
receptors, respectively bind VEGF-A165, VEGF-B and PlGF, and VEGF-A165, VEGF-C, VEGF-D and 
PlGF. 
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I.4.1. Members  
 
 VEGF-A 
Discovered first (Senger et al., 1983; Leung et al., 1989), VEGF-A is one of the key 
regulators of angiogenesis, vasculogenesis, and developmental hematopoiesis. The deletion of 
the VEGF-A gene is lethal, resulting in vascular defects and cardiovascular abnormalities 
(Carmeliet et al., 1996; Ferrara et al., 1996). VEGF-A exerts its effects primarily by 
activating VEGFR-1 (de Vries et al., 1992) and VEGFR-2 (Quinn et al., 1993) but its major 
isoform that triggers VEGF-A actions, the VEGF-A165, also binds to neuropilins (Soker et al., 
1998; Gluzman-Poltorak et al., 2000). 
VEGF-A is produced in various organs such as lung, kidney, heart and liver (Berse et al., 
1992), and in cell types, including endothelial cells (ECs) (Ladoux & Frelin, 1993a), 
leucocytes (Berse et al., 1992; Shen et al., 1993; Freeman et al., 1995), smooth muscle cells 
(Ferrara et al., 1991; Kuzuya et al., 1995), as well as neurons (Kovacs et al., 1996; Sondell & 
Kanje, 2001), astrocytes (Stone et al., 1995; Bartholdi et al., 1997) and SCs (Sondell et al., 
1999a; Gupta et al., 2005). VEGF-A expression is stimulated under pathological conditions 
such as hypoxia (Shweiki et al., 1992; Ladoux & Frelin, 1993b), hypoglycemia (Satake et al., 
1998) or inflammation (Ben-Av et al., 1995; Ito et al., 1995). 
VEGF-A has similar effects on the development of the vascular and nervous systems and on 
adult angiogenesis and neurogenesis. VEGF-A is a mitogen for ECs (Connolly et al., 1989), 
vascular smooth muscle cells (Bhardwaj et al., 2005), neuronal precursors (Jin et al., 2002), 
astrocytes (Krum et al., 2002) and SCs (Sondell et al., 1999a). VEGF-A promotes survival of 
ECs (Gerber et al., 1998) and neurons (Sondell et al., 1999a) by inducing the expression of 
anti-apoptotic proteins. VEGF-A stimulates chemotaxis of ECs and vascular smooth muscle 
cells to induce vessel formation (Kanno et al., 2000; Gerhardt et al., 2003; Bhardwaj et al., 
2005), of monocytes during inflammatory response (Clauss et al., 1990; Zhao et al., 2002), of 
neurons during brain development (Schwarz et al., 2004; Balenci et al., 2007), and of SCs 
during WD (Sondell et al., 1999b). VEGF-A also guides angiogenic (Gerhardt et al., 2003) 
and axonal sprouting (Sondell et al., 1999a; Cheng et al., 2004). Finally, VEGF-A causes 
vasodilatation by inducing NO synthesis (Yang et al., 1996) and exerts pro-coagulant activity 
(Clauss et al., 1990). 
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 VEGF-B 
VEGF-B expression begins early during fetal development and is abundant 
particularly in heart, brain and spinal cord. During adulthood, VEGF-B is additionally 
expressed in kidney and testis (Lagercrantz et al., 1998).  
VEGF-B binds to VEGFR-1 and NRP-1 but not VEGFR-2 or VEGFR-3 (Olofsson et al., 
1998; Makinen et al., 1999). VEGF-B modulates cell proliferation and vessel growth 
(Olofsson et al., 1996; Silvestre et al., 2003), but it has no vascular permeability activity 
(Abraham et al., 2002; Brkovic & Sirois, 2007). Some studies indicate, however, that VEGF-
B can form stable heterodimers with VEGF-A when co-expressed with the latter (Olofsson et 
al., 1996; Tammela et al., 2005; Nash et al., 2006). These heterodimers might cause the 
angiogenic activity of VEGF-B. Studies with mice deficient in VEGF-B reported 
development of smaller hearts and impaired recovery after induced myocardial infarction 
(Bellomo et al., 2000). Moreover, studies of inflammatory disease models in knock-out mice 
suggest a role of VEGF-B in inflammatory angiogenesis (Mould et al., 2003).  
In the nervous system, VEGF-B is not essential for the development or survival of 
neurons under normal conditions. However it exerts a neuroprotective activity in several 
pathological conditions (Sun et al., 2004; Li et al., 2009) and stimulates adult neurogenesis 
(Sun et al., 2006).  
 
 VEGF-C 
VEGF-C is primarily a lymphangiogenic growth factor and its lymphangiogenic 
effects are mediated by VEGFR-3 and NRP-2 (Oh et al., 1997; Karpanen et al., 2006). 
VEGF-C null mice show failure in lymphatic vessel development and die of oedema during 
the embryonic stage (Karkkainen et al., 2004). During development, VEGF-C is expressed 
along with its receptor VEGFR-3 mainly in regions where lymphatic vessels develop. During 
adulthood, the expression decreases in most tissues but remains high in lymph nodes (Kukk et 
al., 1996; Lymboussaki et al., 1999). 
VEGF-C has also angiogenic effects. It induces mitogenesis, migration and survival of ECs 
(Saharinen et al., 2004) and increases vascular permeability. The latter effect is mediated by 
VEGFR-2 (Joukov et al., 1998). VEGF-C is also chemotactic for macrophages (Skobe et al., 
2001). 
 With regard to the nervous system, VEGF-C regulates expansion of the population of 
oligodendrocyte precursor cells and neural progenitors in vitro and acts as a trophic factor for 
these cells in vivo (Le Bras et al., 2006). 
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 VEGF-D 
VEGF-D is present in most tissues, most abundantly in the lungs and skin during 
embryogenesis. During adulthood, it is expressed in many tissues including the vascular 
endothelium, heart, skeletal muscle, lung, and bowel (Farnebo et al., 1999; Roy et al., 2006). 
Similar to VEGF-C, VEGF-D also shows lymphangiogenic and angiogenic activities through 
its binding to VEGFR-2 and VEGFR-3 to induce proliferation and migration of ECs (Achen 
et al., 1998; Rissanen et al., 2003).  
In the nervous system, akin to VEGF-C, VEGF-D induces the proliferation of glial 
precursor cells and exerts a chemotactic effect on these cells during brain development 
(Kranich et al., 2009). 
 
 VEGF-E 
Viral VEGFs (also called VEGF-E) are found in various strains of viruses. These 
VEGF-E variants exhibit significant variation in their VEGFR-2 and NRP-1-binding abilities. 
Viral VEGFs play a critical role in viral infections because of their effects on EC proliferation 
and vascular permeability (Ogawa et al., 1998; Wise et al., 1999; Roy et al., 2006; Shibuya, 
2009). 
 
 VEGF-F 
Discovered in viper venom (Komori et al., 1999), VEGF-F has a unique property: it 
blocks specifically VEGF-A165 activity both in vitro and in vivo (Yamazaki et al., 2005). 
However, it stimulates strongly EC proliferation and vascular permeability, and induces 
hypotension (Yamazaki et al., 2003). VEGF-F members are classified into 3 groups: VEGF-
F1 specifically binds to VEGFR-2, VEGF-F2 predominantly binds to VEGFR-1 and weakly 
to VEGFR-2, and VEGF-F3 binds VEGFR-1, VEGFR-2 and NRP-1 (Yamazaki & Morita, 
2006). 
 
 PlGF 
Although originally discovered in the placenta (Maglione et al., 1991), PlGF is 
expressed in a wide variety of tissues and organs such as heart, lungs, thyroid, skeletal muscle 
(Maglione et al., 1993), adipose tissue (Voros et al., 2005), and brain (Beck et al., 2002; 
Hayashi et al., 2003), as well as in cells like activated angiogenic ECs, inflammatory cells, 
bone marrow cells (Autiero et al., 2003a), and neurons (Beck et al., 2002). PlGF expression is 
upregulated during a number of pathological conditions including some cancers (Takahashi et 
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al., 1994; Nomura et al., 1998), wound healing (Failla et al., 2000), hypoxia (Simpson et al., 
1999; Green et al., 2001), or inflammatory diseases (Perelman et al., 2003; Yoo et al., 2009). 
There are four human isoforms of PlGF (PlGF-1, -2, -3 and -4) (Maglione et al., 1993; Cao et 
al., 1997; Yang et al., 2003), but only one, PlGF-2, is present in mouse (DiPalma et al., 
1996). The PlGF isoforms differ in size and binding affinity. They all bind VEGFR-1 (Park et 
al., 1994) but only PlGF-2 binds NRPs and heparan sulfate proteoglycans thanks to the 
insertion of 21 basic amino acids at the carboxy terminal (Migdal et al., 1998; Neufeld et al., 
2002b). Similar to VEGF-B, PlGF can form heterodimers with VEGF-A (Cao et al., 1996). 
Loss of PlGF does not affect development, reproduction, or normal postnatal life. However, 
PlGF knockout mice have impaired angiogenesis and collateral vascular growth during 
ischemia, wound healing, cancer or inflammation (Carmeliet et al., 2001). 
PlGF contributes to angiogenesis via several mechanisms (figure I.9): (I) by affecting ECs 
directly through VEGFR-1; (II) by displacing VEGF-A from the “VEGFR-1 sink” and thus 
increasing the fraction of VEGF-A available to activate VEGFR-2; (III) by intermolecular 
transphosphorylation of VEGFR-2 via VEGFR-1 activation, increasing VEGF-A action; (IV) 
by PlGF/VEGF-A heterodimerization, which can act on VEGFR-1/VEGFR-2 receptors 
(Carmeliet et al., 2001; Autiero et al., 2003b; Ribatti, 2008). 
 
 
Figure I.9: Schematic representation of the role of VEGF and PlGF in angiogenesis (from Tjwa et al., 
2003). 
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PlGF is also a pro-inflammatory molecule. It has a powerful chemotactic effect on monocytes 
(Carmeliet et al., 2001; Pipp et al., 2003) and induces secretion of pro-inflammatory 
cyto/chemokines like IL-1b, IL-8, MCP-1, and VEGF by monocytes (Bottomley et al., 2000; 
Perelman et al., 2003; Selvaraj et al., 2003). 
Concerning the nervous system, some studies have suggested a potential 
neuroprotective/neurotrophic effect of PlGF through NRP binding (Beck et al., 2002; Cheng 
et al., 2004; Liu et al., 2006). 
 
I.4.2. Receptors 
 
 VEGFR-1 
VEGFR-1 (fms-like tyrosine kinase, Flt-1) is composed of seven extracellular 
immunoglobulin homology domains, a single transmembrane region and an intracellular 
tyrosine kinase domain (Shibuya et al., 1990). VEGFR-1 binds VEGF-A, VEGF-B and PlGF 
with high affinity, however its tyrosine kinase activity is weak following stimulation by 
VEGF (Klagsbrun & D'Amore, 1996).  
VEGFR-1 is expressed in ECs as well as in pericytes, placental trophoblasts, osteoblasts, 
monocytes/macrophages, renal mesangial cells, some hematopoietic stem cells (Zachary & 
Gliki, 2001) and SCs (Schratzberger et al., 2000). Its expression is upregulated during 
angiogenesis (Plate et al., 1993; Tsopanoglou & Maragoudakis, 1999) and by hypoxia 
(Gerber et al., 1997). VEGFR-1 expression is also strongly upregulated in reactive astrocytes 
in response to CNS injury (Choi et al., 2007; Krum et al., 2008). 
VEGFR-1 knockout mice die at early stages of embryogenesis due to disorganization of blood 
vessels (Fong et al., 1995). Deletion of VEGFR-1 also reduces vessel proliferation and 
induces premature senescence of ECs (Hiratsuka et al., 2005). Because of its weak tyrosine 
kinase activity, VEGFR-1 was believed to function as a “decoy” receptor for VEGF (Park et 
al., 1994). However, even if VEGFR-1 transmits weak mitogenic signals to ECs, it can form 
heterodimers with VEGFR-2, increasing its signalling properties (Sato et al., 2000). 
Other studies indicated that VEGFR-1 has an active functional role in monocyte (Barleon et 
al., 1996; Clauss et al., 1996) and vascular EC migration (Kanno et al., 2000). 
In the nervous system, VEGFR-1 mediates astroglial and microglial proliferation (Choi et al., 
2007; Krum et al., 2008). Recent findings reveal that VEGFR-1 exerts neuroprotective effects 
during pathological conditions (Poesen et al., 2008).  
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A soluble form of VEGFR-1, which contains the six first extracellular immunoglobulin-like 
domains, also exists and mediates inhibition of VEGF-induced EC proliferation with high 
affinity (Kendall & Thomas, 1993). This soluble receptor could act as an efficient specific 
antagonist of VEGF-A or PlGF.  
 
 VEGFR-2 
VEGFR-2 (kinase-insert domain receptor, KDR/fetal liver kinase, Flk-1) mediates the 
major biological activities of VEGF-A.  Despite its lower affinity for VEGF than VEGFR-1, 
VEGFR-2 exhibits robust protein–tyrosine kinase activity when bound to its ligands 
(Klagsbrun & D'Amore, 1996). Like VEGFR-1, VEGFR-2 bears an extracellular region with 
seven immunoglobulin-like domains, a transmembrane domain and a Trk domain with a 70-
amino-acid insert (Matthews et al., 1991). VEGFR-2 binds VEGF-A, VEGF-C, VEGF-D and 
VEGF-E (Quinn et al., 1993; Joukov et al., 1996; Achen et al., 1998; Yamazaki & Morita, 
2006).  
Besides by ECs (Quinn et al., 1993) VEGFR-2 is also expressed by pancreatic duct cells 
(Oberg et al., 1994), retinal progenitor cells (Yang & Cepko, 1996), hematopoietic stem cells 
(Matthews et al., 1991), neurons (Sondell et al., 2000; Ogunshola et al., 2002) and some glial 
cells (Schratzberger et al., 2000; Krady et al., 2002; Lafuente et al., 2006). 
VEGFR-2 null mice die between embryonic days 8.5 and 9.5 as a result of defects in the 
development of hematopoietic and endothelial precursors (Shalaby et al., 1995). 
In the vascular system, the VEGFR-2 signalling pathway mediates EC migration (Gerhardt et 
al., 2003), proliferation (Keyt et al., 1996), survival (Shalaby et al., 1995), and enhances 
vascular permeability (Prewett et al., 1999) and vasodilatation (He et al., 1999). 
In the nervous system, VEGFR-2 also stimulates migration, proliferation, and survival of 
various neural cell types such as neural progenitors (Ogunshola et al., 2002; Zhu et al., 2003; 
Balenci et al., 2007) or SCs (Sondell et al., 1999b; a).  
 
 VEGFR-3 
VEGFR-3 (fms-like tyrosine kinase 4, Flt4) is a Trk receptor with only six Ig-like 
domains (Pajusola et al., 1993; Agnes et al., 1997). VEGFR-3 preferentially binds VEGF-C 
and VEGF-D (Joukov et al., 1996; Achen et al., 1998). 
VEGFR-3 is present on all endothelia during development (Kukk et al., 1996) but in 
adulthood it becomes restricted to lymphatic ECs and certain fenestrated blood vascular ECs 
(Partanen et al., 2000) where it is upregulated in pathological conditions such as vascular 
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tumors (Kubo et al., 2000). During embryogenesis, VEGFR-3 plays various roles in 
cardiovascular development and remodelling of primary vascular networks (Dumont et al., 
1998). In adults, it is the primary receptor inducing lymphangiogenesis (Oh et al., 1997), but 
it also modulates angiogenesis by transmitting sprouting signals in endothelial tip cells 
(Tammela et al., 2008). In the nervous system, VEGFR-3 induces proliferation of 
oligodendrocyte precursors and certain other neural progenitors (Le Bras et al., 2006). 
 
 Neuropilins 
NRPs were identified initially as cell-surface glycoproteinic receptors for the 
semaphorin/collapsins (Kolodkin et al., 1997), a large family of secreted and transmembrane 
proteins that serve as repulsive guidance signals in axonal and neuronal development (Puschel 
et al., 1995). These non-tyrosine kinase-type receptors also bind some members of the VEGF 
family. NRP-1 binds VEGF-A165, VEGF-B and PlGF (Makinen et al., 1999; Mamluk et al., 
2002) while NRP-2 binds VEGF-A165, VEGF-C, VEGF-D and PlGF (Gluzman-Poltorak et 
al., 2000; Neufeld et al., 2002b; Karpanen et al., 2006).  
In adults, NRPs are expressed in various organs like lung, heart, liver, kidney, pancreas, 
bones, skeletal muscles and brain (Otrock et al., 2007). In the vascular system, NRP-1 
expression is mainly restricted to arteries, whereas NRP-2 is primarily expressed in veins 
(Herzog et al., 2001). NRP-2 is also expressed on lymphatic endothelial cells (Yuan et al., 
2002). In the CNS and PNS, both neuronal and glial cells express NRPs (Fujisawa et al., 
1997; Fujita et al., 2001; Scarlato et al., 2003). 
NRPs have roles in immune functions (Romeo et al., 2002), neuronal development and repair 
by the regulation of axon outgrowth, and also in angiogenesis (Neufeld et al., 2002a; 
Bannerman et al., 2008; Fantin et al., 2009). NRPs enhance VEGF signalling by acting as co-
receptors for VEGF receptors (Soker et al., 1998; Bagnard et al., 2001; Neufeld et al., 2002b). 
However, it has recently been reported that NRP-1 mediates some types of intracellular 
signalling via its short C-terminal tail and its interaction with intracellular binding partners 
(Zachary et al., 2009; Jiang et al., 2010). 
 
I.4.3. Therapeutic uses 
VEGF family members have been implicated in several pathologies, in which they can 
trigger either negative or positive effects, depending on the context. Therefore, two types of 
opposite therapeutic strategies have been developed: “anti-VEGF” and “pro-VEGF” 
therapies. 
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 Anti-VEGF therapy 
Since a few years, VEGF/VEGF-receptor inhibition strategies have emerged to treat 
diseases associated with pathological angiogenesis like cancers (Borgstrom et al., 1996; Inoue 
et al., 2000) and age-related macular degeneration (Schmucker et al., 2010), or with 
pathological inflammatory response like autoimmune diseases (Carvalho et al., 2007), in 
which serum VEGF levels correlate with disease severity, e.g. rheumatoid arthritis (Harada et 
al., 1998; Sone et al., 2001) or multiple sclerosis (Su et al., 2006; Zhu et al., 2008). Currently 
there are several clinical trials testing drugs that inhibit VEGF receptors or neutralize VEGF 
to treat various types of cancer (Rosen, 2001; Grothey & Galanis, 2009) and rheumatoid 
arthritis (Khong et al., 2007; Schoettler & Brahn, 2009). Some studies have also demonstrated 
that monoclonal antibodies directed against PlGF or its receptor VEGFR-1 can have anti-
angiogenic and anti-inflammatory properties and substitute or augment the effect of anti-
VEGF therapy (Luttun et al., 2002c; Fischer et al., 2007). VEGF/VEGF-receptor inhibition 
could be a useful therapy for autoimmune nervous system diseases such as multiple sclerosis 
by reducing the pathological angiogenic and inflammatory reaction (Kirk & Karlik, 2003; Zhu 
et al., 2008). However, the neuroprotective and neurotrophic effects of VEGF (Sun et al., 
2003) will be also reduced by such treatments. 
 
 Pro-VEGF therapy 
By contrast, the administration of VEGF might be a promising treatment for ischemic 
disorders like myocardial infarction (Pearlman et al., 1995; Goncalves et al., 2010) or brain 
ischemia (Zhang et al., 2000; Hermann & Zechariah, 2009) by improving angiogenesis. In an 
animal model of brain ischemia, VEGF treatment favoured recovery via neurotrophic and 
neuroprotective effects, in addition to its angiogenic action (Sun et al., 2003). These 
neurotrophic/neuroprotective effects of VEGF might also useful for the treatment of 
neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 
For example, in an ALS rodent model, it was shown that VEGF increases the survival of 
motoneurons and slows motor function decline (Lambrechts et al., 2003; Azzouz et al., 2004). 
Such a neuroprotective effect of VEGF has been also demonstrated for dopaminergic neurons 
in a rodent model of Parkinson’s disease (Yasuhara et al., 2004).  
Unfortunately, because of its angiogenic properties VEGF can cause, as treatment side 
effects, hypotension, oedema, fibrin deposition, or formation of hemangiomas (Pettersson et 
al., 2000; Luttun et al., 2002c; Valable et al., 2005). These adverse effects of VEGF may limit 
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its therapeutic usefulness. An alternative to VEGF-A therapy would be the use of other VEGF 
family members such as VEGF-B or PlGF, which have less harmful angiogenic effects than 
VEGF-A (Luttun et al., 2002b; Poesen et al., 2008; Ruiz de Almodovar et al., 2009). 
32 
 
 
 
  
Section II 
 
Objectives 
and 
Experimental 
approach 
33 
 
This research project was designed to better understand and decipher the mechanisms 
responsible for the successful axonal repair in the PNS, reasoning that this might also be 
helpful to develop therapeutic strategies to promote axonal regeneration after CNS injuries. 
Numerous molecules such as cytokines or neurotrophic factors are modulators of axonal 
regrowth. Among them, the angiogenic factors of the VEGF family play beneficial roles in 
nervous system trauma/disease. Most attention has been focused on the main representative 
member of this family, VEGF-A. As mentioned in the introduction, however, other members 
of this family, such as PlGF, play a role in nervous system injury and could have a more 
favourable side effect profile than VEGF-A in future therapeutic trials. Because of its 
chemoattractive effect on monocytes, and its capacity to induce cyto/chemokine secretion by 
monocytes, PlGF merits indeed attention particularly as a novel actor in the complex 
molecular network regulating Wallerian degeneration where it has not been studied up 
to now. To try to fill in this gap in scientific knowledge, the major objective of our project 
was to find answers to the following 3 questions: 
 
 Is PlGF expressed in the peripheral nervous system, in physiological and pathological 
conditions? 
 Does PlGF play a role in the cellular and molecular events of WD and its functional 
consequences? 
 If yes, what are the underlying molecular mechanisms?  
 
To answer these questions, we have used in vivo and in vitro experimental approaches 
(described in detail in section VI. “Materials and Methods”). 
 
II.1. PlGF expression  
As PlGF expression in the PNS was totally unknown when we started this project, the 
first part of our work has focused on the identification of the cell types and cellular structures 
expressing PlGF in the normal peripheral nerve and, in a second step (see below) in the 
injured nerve. The main method used for this study was double immunofluorescent staining, 
using a specific anti-PlGF antibody (Ab) and Abs for axons, myelinating and proliferating 
SCs, myelin sheaths, nodes of Ranvier, fibroblasts, endothelial cells and macrophages. The 
results on the anatomical localization of the PlGF protein were completed by the study of its 
mRNA expression using in situ hybridization (ISH) and RT-PCR. 
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II.2. PlGF functions  
An interesting method to study the roles of a protein in the whole organism is the use 
of knock-out mice, wherein the gene of interest is “deleted”. Thus, the function of a protein 
can be explored by the comparison of biological phenomena in the presence (wild-type) or 
absence (knock-out) of this protein. Thanks to a collaboration with the research group 
Professor P. Carmeliet from the Vesalius Research Centre at the Katholieke Universiteit of 
Leuven, we were fortunate to raise and study a colony of knock-out mice for PlGF (Pgf -/-). 
II.3. The model of Wallerian degeneration 
The most simple and reproducible model of peripheral WD consists of the complete 
transection of the sciatic nerve, which is the longest and the largest sensory-motor nerve. The 
advantage of transection compared to compression of the nerve is the better reproducibility of 
the injury. Moreover, it is easier to follow the sequence of events of axonal degeneration after 
a transection where it is anterograde than after compression where the axonal fragmentation 
progresses retrogradely (Beirowski et al., 2005). Finally, axotomy is a more appropriate 
model for the clinical situation of traumatic nerve injury in humans.  
II.4. The experimental protocol 
To explore the hypothesis of a potential role of PlGF in WD, we have compared the 
main steps of WD between wild-type (wt) and Pgf -/- mice, using the complete sciatic nerve 
transection model: 
 SC proliferation explored in vivo and in vitro by Ki67 and bromodeoxyuridine 
(BrdU) immunofluorescent (IF) stainings. 
 SC upregulation of p75 NGFr and c-Fos evaluated by immunostaining. 
 Macrophage recruitment evaluated by CD11b immunostaining. 
 Cyto/chemokine expression studied by cytokine arrays. 
 Myelin sheaths degradation explored by toluidine blue staining on semi-thin 
sections. 
 Bands of Büngner formation assessed in vivo by the p75NGFr expression pattern 
and in vitro by the “scratch” migration assay. 
 Axonal regeneration explored by neurofilament immunostaining. 
 Remyelination evaluated by toluidine blue staining and teasing. 
 Functional motor recovery assessed with the behavioural footprint test. 
Given our first results on PlGF expression, two additional research questions were raised and 
explored: 
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 Does PlGF play a role in the formation and/or the preservation of myelin sheaths? 
 Which signalling pathway regulates PlGF expression during WD? 
 
The potential PlGF influence on the structure of myelin sheaths was explored at the 
ultra-structural level by electron microscopy on cross-sections of sciatic nerves and spinal 
cords comparing wt and Pgf -/- mice. 
Concerning the signalling pathway that regulates PlGF expression after injury, we 
have focused our attention on NF-κB, a transcription factor known to be involved in the 
regulation of cyto/chemokine expression during WD (see section I.3.2.). In particular, we 
have studied the NF-κB binding on Pgf promoter after injury by the chromatin 
immunoprecipitation (IP) assay.                                                         
 
Our objectives are summed up in the figure II.1 which represents an overview of the 
known implications of VEGF and NF-κB during the WD and the possible actions of PlGF 
that we want to study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.1: Actions of VEGF (blue arrows) and NF-κB (green arrows) on the cellular and molecular 
events of the Wallerian degeneration. Hypothetic actions of PlGF (red arrows). 
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Section III 
 
Results 
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III.1. PlGF expression pattern in the adult murine nervous system. 
The first part of our work is focused on the characterization of PlGF expression 
patterns in normal and injured adult mouse sciatic nerves. As the sciatic nerve contains motor 
fibres originating from spinal motoneurons, and sensitive fibres whose cell bodies are located 
in the dorsal root ganglion (DRG), we’ve also studied PlGF expression in those nervous 
structures.  
This study was mainly performed by double IF stainings. To validate the specificity of the 
PlGF Ab, we performed various types of controls: 
 Negative controls:  
• IF staining with the PlGF Ab pre-incubated or not with its specific blocking 
peptide prior its application on the tissue (figure III.1A and B).  
• IF staining on a tissue section negative for PlGF, the liver (Yano et al., 2006) 
(figure III.1D). 
 Positive control:  
• IF staining on tissue section positive for PlGF, the placenta (figure III.1C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.1: PlGF antibody specificity. (A) PlGF immunostaining on transverse section of sciatic 
nerve. (B) Negative control: sciatic nerve section stained with PlGF Ab pre-incubated with its specific 
blocking peptide. (C) PlGF immunostaining on mouse placental section. (D) PlGF immunostaining on 
mouse liver section. Scale bar: 60 µm. 
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III.1.1. PlGF expression in normal and injured adult mouse sciatic nerves 
To investigate PlGF expression in the normal nerve and after axotomy, we performed 
various double IF stainings in order to screen all cell types and/or structures present in the 
nerve: axons (heavy neurofilament subunit (NF-H)), myelin (P0), Schwann cells (S100 or the 
low-affinity receptor of nerve growth factor (p75NGFr)), nodes of Ranvier (voltage-gated 
sodium channels 1.6 (Nav1.6)), fibroblasts (patched-1, (Ptc-1)), endothelial cells (von 
Willebrandt factor (vWF)), and invading macrophages (CD11b).   
Based on PlGF/NF double staining, PlGF is found on the axons of the normal sciatic 
nerve (figure III.2A). More precisely, it is located at the periphery of axons (figure III.2B), in 
close contact with, but not within the myelin sheath, as no co-localization can be seen with the 
P0/PlGF double staining (figure III.2C). Interestingly, PlGF/Nav1.6 staining reveals that PlGF 
expression in axons is interrupted at the level of the nodes of Ranvier (figure III.2D). 
Myelinating SCs do not express PlGF, as shown by the PlGF/S100 staining (figure III.2E). 
Fibroblasts labeled with the Ptc-1 Ab (Sharghi-Namini et al., 2006) express PlGF in the 
endoneurium, but not in epi- or perineurial areas (figure III.2G). Finally, vWF Ab, used to 
identify ECs, never co-localized with PlGF (figure III.2F). ISH performed on transverse 
sciatic nerve sections confirmed that PlGF mRNA is concentrated at the periphery of axons 
(figure III.2H).   
After nerve transection, a progressive decrease of PlGF staining appears in the distal 
stump, corresponding to the degradation of axons (figure III.3C). When axonal regeneration 
occurs, starting as soon as 14 days post-injury, PlGF-positive fibres re-appear in the distal 
segment of the sciatic nerve (figure III.3D). Interestingly, the double staining with p75NGFr 
shows that PlGF appears in SCs as soon as 1 day post-axotomy; these cells have a 
dedifferentiating and proliferating phenotype. PlGF expression in SCs persists during the first 
3 days after injury, and is not detectable anymore after 7 days (figures III.3E-H). PlGF in 
endoneurial fibroblasts, as detected with Ptc-1 immunostaining, also decreases after injury 
(figures III.3I-L). Finally, after injury, no PlGF was observed in invading macrophages nor in 
ECs (figures III.4A and B).  
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Figure III.2: Double IF stainings and ISH on uninjured sciatic nerve sections. PlGF (rhodamine) 
and NF (A, B), P0 (C), Nav1.6 (D), S100 (E), vWF (F) or Ptc-1 (G) (FITC) double IF stainings, and 
PlGF ISH (H), on longitudinal (A, C, E and F) and transversal sections (B, D, G and H) of uninjured 
sciatic nerve. PlGF is expressed in axons (A) and has a periaxonal expression pattern (B and H), 
which is interrupted at nodes of Ranvier (C, arrows). However, PlGF is not present in myelin (D) 
neither in SCs (E). It is also not expressed in ECs (F). Finally, besides its axonal localization, PlGF is 
also expressed by fibroblasts but only in the endoneurium (G; E=endoneurium, P=perineurium, 
Ep=epineurium). The white dashed boxes in B and C represent enlargements of selected zones. Scale 
bar A-G: 60 µm; scale bar H: 10 µm. 
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Figure III.3: Double IF stainings on injured sciatic nerve sections. PlGF (rhodamine) and NF (A-
D), S100 (E), p75NGFr (F-H) or Ptc-1 (I-L) (FITC) double immunostainings, on longitudinal (A-H) 
and cross-sections (I-L) of uninjured (UI) (A, E, I) and injured (distal segment) sciatic nerves. Axonal 
PLGF expression decreases progressively after injury, following the time course of axonal 
degradation (B, C). 28 days post-injury, PlGF reappears in the regenerating fibres (D). SCs, which 
dedifferentiate and proliferate after loss of axonal contact, express PlGF from the first day after injury 
(F). This co-expression disappears after 7 days (H). PlGF expression in endoneurial fibroblasts also 
decreases with time after injury, as does Ptc-1 (J-L). The white dashed boxes in D and F represent 
enlargements of selected zones. Scale bar: 60µm.  
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Figure III.4: Double IF stainings on injured sciatic nerve sections. PlGF (rhodamine) and CD11b 
(A) or vWF (B) (FITC) expression on longitudinal sections of sciatic nerves (3 days post-injury, distal 
segment). PlGF expression never co-localized with CD11b nor vWF during WD. 
 
 
III.1.2. PlGF expression in ventral spinal gray matter and dorsal root ganglia 
Using NeuN (“neuronal nuclei”) as a neuronal marker, we observed that PlGF is 
expressed in perikarya and neurites of several neurons in the ventral horn of the spinal cord, 
both in large motoneurons and small interneurons (figure III.5A). Through ISH, PlGF mRNA 
is detected in neurons and displays a perinuclear pattern (figure III.5B). Neuronal expression 
of PlGF is also seen in the DRG, in cell bodies and nerve fibres, where again its localization is 
peri-axonal (figures III.5C and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.5: PlGF expression in the ventral spinal gray matter and in the dorsal root ganglia. (A) 
Double IF PlGF (rhodamine)/NeuN (FITC) staining and (B) PlGF ISH of transverse spinal cord 
sections. PlGF is expressed in both motoneurons (arrows) and smaller interneurons (stars). Neurites 
also express PlGF (arrowheads). (C) PlGF (rhodamine)/NeuN (FITC) and (D) PlGF (rhodamine)/NF 
(FITC) in the DRG, showing its neuronal and peri-axonal localization (white arrows). Scale bars: A, 
B and D: 20µm; C: 50µm. 
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III.2. Signalling pathways regulating PlGF expression during WD: the role 
of NF-κB. 
During Wallerian degeneration, one of the main signalling pathways regulating the 
cyto- and chemokine expression implicates the transcription factor NF-κB (Subang & 
Richardson, 2001; Fu et al., 2010). Few data are available concerning signalling pathways 
that regulate PlGF expression. However, it has been shown that NF-κB is involved in the 
induction of PlGF expression in hypoxia conditions (Cramer et al., 2005). So we decided to 
investigate the implication of NF-κB activation in the induction of PlGF expression after 
nerve injury. 
 
III.2.1. Prediction of NF-κB binding sites in mouse Pgf  gene promoter 
The κB motif localization on human Pgf promoter was published a few years ago 
(Cramer et al., 2005). However, currently, nothing is known about κB motif presence on 
mouse Pgf promoter. To identify putative κB motifs on mouse Pgf promoter (Green et al., 
2001), we used four transcription factor binding site prediction programs (MatInspector, 
Match™, Promo and TFSEARCH). We have detected the presence of two potential NF-κB 
binding sites within the mouse Pgf promoter region (figure III.6). 
 
 
 
 
 
 
 
 
 
Figure III.6: Detection of κB motifs in the mouse Pgf gene promoter. The prediction of NF-κB 
binding sites has revealed two putative κB motifs (gray letters) located 994-1004 (κB1) and 1075-
1084 (κB2) bps upstream the ATG translation initiation site of mouse Pgf gene promoter. 
 
 
III.2.2. PlGF expression regulation by NF-κB during Wallerian degeneration 
In figure III.3, we have shown that SCs express PlGF as soon as 1 day after injury. 
Interestingly, it has been shown that NF-κB is activated in SCs within a few hours following 
nerve injury (Smith et al., 2009). Thus, to explore the potential implication of NF-κB in the 
induction of PlGF expression during WD, we investigated the NF-κB binding to the two 
putative κB motifs (figure III.6) by IP of chromatin, from UI and one day-injured sciatic 
nerves, using an anti-p65 Ab. DNA fragments of immunoprecipitated chromatin were 
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amplified by quantitative real-time PCR (qRT-PCR), using primers specifically designed to 
amplify predicted κB1 or κB2 site or both (see section VI.14, table VI.4). The figure III.7 
shows an about 3-fold induction of NF-κB binding for the κB2 and κB1-2 primers compared 
to UI nerve controls. We observed no induction for the κB1 primers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.7: NF-κB binding on Pgf gene promoter after sciatic nerve injury. p65 is specifically 
recruited to the Pgf gene promoter after injury, as examined by chromatin IP assays using UI sciatic 
nerves or 1 day-injured sciatic nerves. After normalization to inputs and to negative flag IP, signal in 
UI condition was set to 1 and the one obtained in injured condition was expressed relative to it. 
Results are from 3 independent experiments and error bars denote standard deviation. We observed 
no induction for the κB1 primers. 
 
 
 
To further prove that the sites were functional in activating gene expression, they were 
inserted into a luciferase reporter vector, transfected into 293 cells and NF-κB activation was 
assessed upon co-transfection with two NF-κB subunits, p50 and p65. As shown in the figure 
III.8, the κB sites found in the Pgf promoter (Pgf-κB) were indeed functional, as the p50/p65 
heterodimer induced luciferase gene expression (about 4-5 fold).  
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Figure III.8: Luciferase assay. The κB sites found in the Pgf promoter are functional in activating 
NF-κB, as examined by Luciferase assay. Pgf-kB or Ig-kB (positive control) vectors were transfected 
in 293 cells, with or without the p50/p65 expression vectors, as indicated. Signals were normalized by 
measuring Renilla activity of a co-transfected pRL vector. For each vector, the value obtained in the 
absence of p50/p65 was set to 1 and the other was expressed relative to it. Results are from 3 
independent experiments and error bars denote standard deviation. 
 
 
 
III.3. PlGF and myelin sheath structure 
 In the section III.1.1 of this work, we have exposed our results on the expression 
pattern of PlGF in normal sciatic nerves. We have shown a specific PlGF localization at the 
periphery of axons (figure III.2B), in close contact with the myelin sheath (figure III.2C), with 
interruption at nodes of Ranvier (figure III.2D). This periaxonal localization could infer a 
function of PlGF in glia-axon interactions, as already described for other axonal molecules 
such as microtubule-associated protein 1B (MAP1B) (Franzen et al., 2001). Thus, PlGF could 
play a role in the maintenance of axon/myelin structure, and a lack of PlGF could induce 
some modifications in myelin sheath structure. To investigate these hypotheses, we performed 
a morphological analysis on electronic cross-sections of wt and Pgf -/- sciatic nerves and 
ventral horns of spinal cords. We examined the morphology and the ultra-structure of 
peripheral (figures III.9A and B) and central (figures III.9C and D) myelin sheaths. This 
analysis reveals no obvious abnormalities of peripheral and central myelin sheath morphology 
in Pgf -/- mice (figures III.9B and D). 
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Figure III.9: Electronic microscopy analysis of myelin sheaths. Electron micrograph analysis of 
cross-section of wt (A, C) and Pgf -/- (B, D) sciatic nerves (A, B) and ventral horns of spinal cords (C, 
D) reveals no abnormalities of peripheral and central myelin sheath morphology in Pgf -/- mice (scale 
bar: 4µm). 
 
 
 
In addition to the general structure of myelin sheaths, we also examined the myelin sheath 
thickness that could be influenced by impairment of myelin sheath folding and/or compaction 
mechanisms (Martini & Schachner, 1997). Myelin sheath thickness also depends on axonal 
calibre (Michailov et al., 2004), so we calculated the regression curves representing myelin 
thickness as a function of axonal diameter for wt and Pgf -/- mice (figure III.10). We observed 
absolutely no difference between the two groups of animals concerning the evolution of 
myelin thickness as a function of axonal diameter. 
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Figure III.10: Relationship between myelin sheath thickness and axonal area in mouse sciatic 
nerves. (A) Electronic picture of transversal section of sciatic nerve (scale bar: 4µm). The axonal area 
(=aa, A) and the mean myelin thickness (measurement at four random points of the myelin, red lines) 
were measured on wt and Pgf -/- ultrathin cross-sections of sciatic nerves (N=3). (B) Regression curves 
representing myelin thickness as a function of axonal area for wt (dotted line) and Pgf -/- (full line) 
nerves. We observed no difference between wt and Pgf -/- sciatic nerves. 
 
 
 
III.4. PlGF functional roles in Wallerian degeneration 
 
III.4.1. PlGF role on Schwann cell proliferation and formation of bands of Büngner 
 
 Proliferation of Schwann cells is decreased in transected Pgf -/- nerves 
The WD process in the distal stump of the injured nerve is associated with activation 
and proliferation of SCs, which form the bands of Büngner and express p75NGFr.  To assess 
the role of PlGF in these processes, we compared the proliferation of SCs within the sciatic 
nerves of wt and Pgf -/- mice after axotomy. Using immunofluorescent staining against Ki67, a 
nuclear protein expressed in cells undergoing proliferation, we quantified the number of 
proliferating cells at 1, 3 and 7 days after axotomy in the distal stump of nerves from wt and 
Pgf -/- mice (figures III.11A-B). We found a significant decrease of cell proliferation in Pgf -/- 
mice at 1 and 3 days post-injury (Fig III.11B). Because of a conflict between Abs, we were 
not able to perform the double immunofluorescent staining Ki67/p75NGFr to identify the 
proliferating cells as SCs. We can nevertheless attest that the Ki67-positive cells are not 
inflammatory cells, such as invading macrophages, as we have only taken into account Ki67-
positive cells that do not express CD11b. 
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Figure III.11: In vivo cell proliferation. (A) Ki67 immunoreactivity on longitudinal sections of wt and 
Pgf -/- sciatic nerves 3 days after axotomy (scale bar: 50µm). (B) Cell quantification shows a 
significant difference between wt and Pgf -/- mice in the number of Ki67 positive cells 1 and 3 days 
post-injury. ** P < 0.01; * P < 0.05 (mean ± standard error (SE); N= 5 mice per group). 
 
 
 Proliferating Schwann cells are decreased in Pgf -/- SC cultures 
In order to confirm the in vivo finding of decreased SC proliferation in mice lacking 
PlGF, we compared the proliferation of primary cultures of SCs isolated from wt or Pgf -/- 
mice. The purity of our primary SC cultures was evaluated by a p75 NGFr immunostaining 
(figure III.12A) and the quantification of p75 NGFr-positive cells reveals a SC purity of about 
95% (figure III.12B). Using BrdU incorporation and double immunofluorescent staining 
against BrdU and p75NGFr (figure III.13A), we counted the mean number of proliferating 
SCs. The number of BrdU positive Pgf -/- SC nuclei was decreased by about 10 % (figure 
III.13B).   
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Figure III.12: Purity evaluation of SC cultures: (A) P75 NGFr (FITC)/DAPI immunostaining of SC 
cultures (scale bar: 50µm). (B) Quantification of the number of p75 NGFr-positive cells reveals that 
the purity of our SC cultures is about 95% (94.93 ± 1.41; N=2 wt cultures and 2 Pgf -/- cultures).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.13: In vitro SC proliferation. (A) BrdU (rhodamine)/p75NGFr (FITC) 
immunocytofluorescent staining of wt and Pgf -/- SCs after BrdU incorporation (scale bar: 50µm). (B) 
Quantification shows a significant decrease of Pgf -/- SC proliferation. * P < 0.05 (mean ±SE; N= 3 
culture experiments). 
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SCs in culture adopt a proliferating phenotype, as do SCs in vivo after injury. We thus 
verified that in culture conditions, SCs do also express PlGF, as observed 24 hours after 
sciatic nerve section. We performed a RT-PCR for PlGF (P) and GAPDH (G), as 
housekeeping gene, on RNA extracts from wt and Pgf -/- SC cultures, and also on DRG as 
positive control. The polyacrylamide gel with RT-PCR amplification products (figure III.14) 
shows that PlGF mRNA is expressed in DRG (as is its corresponding protein (figure III.5C-
D)), and confirms a PlGF expression in wt cultured SCs and no expression in Pgf -/- SCs. 
 
 
Figure III.14: Representative polyacrylamide gel showing PlGF (P) and GAPDH (G) RT-PCR 
amplification products from wt and Pgf -/- cultured SCs, and DRG. PlGF RT-PCR confirmed PlGF 
expression in DRG and wt SCs in culture conditions and no expression in Pgf -/- SCs. 
 
 
 
 Schwann cell alignment is delayed in transected Pgf -/- nerves 
We then assessed p75NGFr expression in wt and Pgf -/- mice after various post-
transection survival times. As illustrated in figure III.15A, p75NGFr is weakly expressed in 
UI nerves. In wt animals, its expression increases 3 days after axotomy and reaches a peak at 
day 7 (figure III.15B). At that time, the longitudinal aspect of the p75NGFr staining is likely 
due to the alignment of SCs to form the bands of Büngner. In Pgf -/- mice, the peak of 
expression of p75NGFr is only reached 14 days after the lesion, and decreases more rapidly 
afterwards. Also, at day 7, the longitudinal aspect of the staining is much less pronounced 
than in tissue sections of wt animals. 
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Figure III.15: P75NGFr immunostaining and quantification. (A) P75NGFr immunoreactivity on 
longitudinal sections of wt and Pgf -/- sciatic nerves before (UI) and after axotomy (scale bar: 100µm). 
(B) Histogram of the quantification of p75NGFr staining. A significant difference is observed between 
wt and Pgf -/- mice in the intensity of p75NGFr staining 7, 21 and 28 days post-injury. ** P < 0.01; * 
P < 0.05 (mean ± SE; N =5-9 mice per group). 
 
 
 
 Migration of Pgf -/- Schwann cells in vitro is non significantly decreased  
As the p75NGFr staining revealed a delay in SC alignment between wt and Pgf -/- 
mice, we hypothesised that the migration potential of Pgf -/- SCs could be decreased. To test 
this, we performed a “scratch migration assay” in cultured SCs (figure III.16A). Time-lapse 
experimentation was performed to follow the migration of wt and Pgf -/- SCs every 2 hours 
during 28h. The percentage of cell-free area was quantified every 2 hours. This cell-free area 
was higher, at each time, in the Pgf -/- assay than in the wt one (figure III.16B), indicating a 
decreased migration potential for Pgf -/- SC. However, this difference was not statistically 
significant.  
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Figure III.16: Scratch migration assay on wt and Pgf -/- purified SCs. (A) Full black lines represent 
the initial edges of the scratch, while dotted lines were traced 28h later, at the front of migration of the 
SCs. (B) The surface of the initial scratch was measured (=100%) and compared to the cell-free 
surface every 2h during 28h. The percentage of cell-free area was calculated and revealed that the 
area from Pgf -/- SCs assay was always higher than the one from wt SCs, however this difference is not 
statistically significant (p=0.4; mean ± SE; N=4 culture experiments). Scale bar: 100µm. 
 
 
 
III.4.2. PlGF role on macrophage recruitment  
The other main cell type involved in the WD process are macrophages, which 
accumulate within the degenerating nerve segment and accelerate the removal of axonal and 
myelin debris.  As PlGF plays a role in the chemo-attraction of macrophages (Clauss et al., 
1996), we first quantified the number of invading macrophages within the degenerating distal 
segment at several post-injury delays, comparing wt and Pgf -/- mice. CD11b immunostaining 
of longitudinal nerve sections revealed a clear delay in the macrophage infiltration in Pgf -/- 
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nerves respective to wt nerves (figure III.17A).  While infiltration peaked between the 3rd and 
the 7th day post-injury in wt mice, it did so only between 14 and 21 days in Pgf -/- tissue 
(figure III.17B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.17: CD11b immunostaining and quantification. (A) CD11b immunostaining of 
longitudinal sections of wt and Pgf -/- sciatic nerves before (UI) and 7 days after axotomy (scale bar: 
200µm). (B) Cell quantification shows a significant difference between wt and Pgf -/- mice in the 
number of invading macrophages 1, 3 and 7 days post-injury. *** P < 0.001; ** P < 0.01; * P < 0.05 
(mean ± SE; N =5-12 mice per group). 
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III.4.3. PlGF role on cytokine and chemokine expression  
WD is orchestrated by a large cyto-/chemokine network, which regulates SC and 
macrophage functions. As PlGF invalidation affects these two cell types, and more 
particularly at the early stages of WD, we compared the expression of 10 cyto/chemokines in 
extracts of UI, and 1, 3 and 7 days- injured sciatic nerves (distal part) from wt and Pgf -/- mice.  
The following molecules were studied: IL-1α, IL-1β, IL-6, IL-10, TNF-α, VEGF, VEGFR-1, 
MCP-1, MIP-1α and pro-MMP-9. The quantitative analysis of the signal intensity revealed 
significant decreases in Pgf -/- extracts of IL1-α, MCP-1 and IL-10 at 1 day (figure III.18A-
C), of MIP-1α  at 3 days, (figure III.18D) and pro-MMP9 at 7 days post-injury (figure 
III.18E).  
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Figure III.18: Cytokine-array on sciatic nerve extracts from wt and Pgf -/- mice. (A) IL-1α,(B) 
MCP-1 and (C) IL-10 don’t increase their expression in Pgf -/- nerve as much as in wt nerves 1 day 
after injury. (D) MIP-1α expression increases after injury in wt mice, and remains low in Pgf -/- mice. 
(E) Pro-MMP-9 peaks at 7 days post-injury only in wt nerves. (F) The VEGF expression is absolutely 
not affected in Pgf -/- during WD. Concerning (G) IL-1b, (H) IL-6, (I) TNF-a and (J) VEGFr1, their 
expressions after injury tend to be lesser in Pgf -/- mice compared to the wt one. However, these 
differences are not statistically significant. * P <0.05 (mean ± SE; N=6 mice per group). 
 
 
 
III.4.4. PlGF effect on myelin sheath degradation 
To verify if the delay in SC proliferation and in macrophage recruitment affects the 
degradation speed of myelin sheaths, we stained these latter with toluidine blue and counted 
them over semi-thin transverse sections from wt and Pgf -/- nerves from various post-injury 
delays (figure III.19A). These counts revealed that the degradation of myelin sheaths is slower 
in Pgf -/- mice (figure III.19B). 
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Figure III.19: Myelin sheath quantification. (A) Toluidine blue staining on semi-thin cross-sections 
from wt and Pgf -/- sciatic nerves before (UI) and 7 days after axotomy (scale bar: 20µm). (B) 
Quantification shows a significant difference between wt and Pgf -/- mice in the number of intact 
myelin (white arrowheads) sheaths 3 and 7 days post-injury. * P < 0.05 (mean ± SE; N =5-9 mice per 
group). 
 
 
III.4.5. PlGF effect on the phagocytic phenotype of SC as indexed by c-Fos expression 
In addition to the number of phagocytic cells present in the injured site, the 
degradation of myelin sheaths is also influenced by the acquisition of phagocytic activity by 
SCs. It has been shown that this phenotype acquisition is closely associated with the 
expression of the cellular immediate early gene c-Fos (Liu et al., 1995). Moreover, PlGF is 
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able to induce c-Fos expression in cells expressing its receptor Flt-1 (Holmes & Zachary, 
2004). Thus, to assess the role of PlGF in SC acquisition of a phagocytic phenotype through 
c-Fos activation, we compared by immunofluorescent staining c-Fos expression within the 
sciatic nerves of wt and Pgf -/- mice one day after axotomy (figure III.20A). The quantification 
of the percentage of c-Fos positive cells reveals that there is no difference between wt and Pgf 
-/- mice concerning c-Fos expression after nerve injury (figure III.20B). Because of a conflict 
between Abs, we were not able to perform the double immunofluorescent staining c-
Fos/p75NGFr to identify c-Fos-positive SCs. However, we can attest that the c-Fos-positive 
cells are neither macrophage, as they do not express CD11b, nor fibroblast, as the 
quantification excludes epi-perineurial c-Fos-positive cells described to be the two types of 
fibroblasts expressing c-Fos in the distal segment during WD (Pyykonen & Koistinaho, 
1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.20: c-Fos activation after nerve injury. (A) c-Fos immunoreactivity on longitudinal 
sections of wt and Pgf -/- sciatic nerves 1 day after axotomy (scale bar: 50µm). Cell quantification 
shows no difference between wt and Pgf -/- mice in the percentage of c-Fos positive SCs 1 day post-
injury (mean ± SE; N= 2 mice per group). 
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III.4.6. PlGF role on axonal regeneration 
As SC and macrophage functions are delayed during WD in Pgf -/- animals, axonal 
regeneration might also be altered. To test this hypothesis, we compared the NF 
immunostainings of transected sciatic nerves from wt and Pgf -/- mice. At 7 days post-injury, 
all axons are degraded in both wt and Pgf -/- nerve distal parts, as illustrated by the high 
number of axonal debris (figure III.21). At 14 days, regeneration starts in wt nerves, as more 
longitudinal profiles can be observed in wt than in Pgf -/- nerves. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.21: Neurofilament immunostaining.  NF immunostaining on longitudinal sections of wt 
and Pgf -/- sciatic nerves 7, 14 and 21 days after axotomy (scale bar: 100µm). Inserts illustrate 
representative fields considered as “debris (*)” or “fibers (**)” used for the semi-quantitative 
analysis illustrated in figure III.22.  
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This observation was confirmed by counting the proportion of fields containing either 
axonal debris (dotted aspect of NF staining), axonal profiles (longitudinal profiles on NF 
staining), or both (figure III.22A). After 14 days post-injury, almost 60% of the total length of 
the nerve corresponds to fields containing only axonal debris in Pgf -/- mice, while debris-
containing fields occupy less than 10% in wt mice. As a corollary, fields with higher 
proportions of regenerating axons occupy 50% of the nerve length in wt mice compared to 
less than 5% in Pgf -/- mice. No field containing only axonal profiles was observed at this 
time. After 21 days, regenerating profiles were more numerous, reflecting the repair progress, 
and there were no more difference between wt and Pgf -/- mice (figure III.22B). This finding 
suggests therefore that absence of PlGF leads to a transient delay of axonal regeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.22: Neurofilament semi-quantification. Quantification shows that after 14 days (A), Pgf -/- 
nerves contain a significant higher proportion of debris than wt nerves, while more regenerating 
profiles are observed in wt nerves than Pgf -/- ones. *** P < 0.001; ** P < 0.01 (mean ± SE; N =5-7 
mice per group). (B) No more differences were found after 21 days. 
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III.4.7. PlGF role on remyelination 
As SC proliferation and axonal regeneration are delayed during WD in Pgf -/- animals, 
remyelination might also be altered. However, as observed in the figure III.19B, the number 
of intact myelin sheath 21 days after injury didn’t differ between wt and Pgf -/- mice.  
It is known that after remyelination, the distance between two adjacent nodes of Ranvier 
(figure III.23A) is reduced (Hildebrand et al., 1985). Thus, SC proliferation could influence 
the internodal length during remyelination. We measured this internodal length 28 days after 
the nerve section: no difference was observed between wt and Pgf-/- nerves (figure III.23B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.23: Internodal length measure. (A) The distance between two nodes of Ranvier (NR) along 
an axon determines the internodal length. (B) Comparison of average internodal lengths from UI or 
regenerated axons (28 days following sciatic nerve axotomy) between wt and Pgf -/- mice shows no 
difference between the two groups. The means ± SE were calculated from 3-10 myelin segments (n=3 
animals per group). 
 
 
III.4.8. PlGF role on motor recovery 
To assess the consequence of this delayed axonal regeneration on functional recovery, 
we finally evaluated motor recovery after sciatic nerve axotomy in Pgf -/- compared to wt 
mice, using the walking track method in which foot-prints are analysed (Fig III.24A). The 
print-lengths of uninjured (NPL) and injured (OPL) sciatic nerves were measured 
preoperatively, as well as 3, 7, 10, 14, 17 and 21 days after axotomy and were used to 
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calculate the print-length factor (PLF, described in section VI.4). During the first week 
following injury, this PLF increases and reaches after 7 days the value of about 0.5 and 0.35 
for wt and Pgf -/- mice respectively, indicating a marked disability in the injured paw. At day 
10, the PLF of wt mice starts to decrease and reaches a value of about 0.3 at 21 days after 
injury, whereas the PLF of Pgf -/- mice continues to get worse and reaches a value of about 0.6 
at 21 days (figure III.24B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.24: Functional recovery. A) Representative footprints obtained from wt and Pgf -/- mice, 21 
days after unilateral left sciatic nerve transection. Measures of OPL and the NPL were used to 
calculate the PLF. (B) Graph showing the recovery of motor function after sciatic nerve transection 
determined by the PLF. Worse recovery is evident in mice lacking PlGF compared to their wt 
controls. ** P < 0.01; * P < 0.05 (mean±SE; N= 5 mice per group). 
 
 
To summarize, we have shown that in Pgf -/- mice: 
1.   Proliferation of SCs is decreased; 
2.   Alignment of SCs to form Büngner’s band is delayed; 
3.   Inflammatory response is delayed; 
4.   Myelin degradation is slower; 
5.   Axonal regeneration is delayed; 
6.   Motor recovery is impaired. 
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Section IV 
 
Discussion 
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This project was designed to study the potential role of the PlGF in axonal remodeling. 
We hypothesized that PlGF was likely to be involved in the post-injury inflammatory process 
that follows an axonal lesion, i.e. the WD, because of its known effects on monocyte 
chemoattraction and cytokine secretion. WD in the PNS is followed by successful axon 
regeneration and functional recovery, while in the CNS, its slower and different progression is 
in part the culprit for the failure of efficient axonal regrowth.  
We thus decided to study the role of PlGF in the WD process induced by injury to the PNS, 
and in the subsequent axonal regeneration. 
As only scarce data were available on PlGF in the nervous system at the time we started this 
project, we have dedicated the first part of our study to expression of PlGF in the PNS under 
physiological and pathological conditions. We then tested the hypothesis that NF-κB might 
mediate PlGF transcription. The major part of our work is devoted to the study of the role of 
PlGF in the cellular and molecular processes involved in WD and in axonal regeneration and 
functional recovery, using a PlGF knock-out mouse model. We will discuss these results in 
sequence. 
 
IV.1 PlGF is expressed in the normal nervous system 
Since its initial discovery in the placenta in 1991 (Maglione et al., 1991), PlGF has 
been detected in other organs, including the brain (Beck et al., 2002; Hayashi et al., 2003) and 
the spinal cord (Hedlund et al., 2010).  
Ten years ago, Beck et al. had shown that PlGF mRNA and protein were detectable in 
neurons throughout the normal mouse brain (Beck et al., 2002). Using double 
immunofluorescent stainings, ISH and RT-PCR, we provide evidence that PlGF is also 
expressed in intact as well as in injured mouse sciatic nerves.  
In the intact sciatic nerve, PlGF is expressed in all axons, as it is the case for the 
VEGF (Sondell et al., 2000), and in endoneurial fibroblasts, but not in ECs, SCs or myelin 
sheaths. PlGF is also expressed in the perikarya of the neurons of origin of sciatic nerve axons 
in lumbar DRGs and spinal ventral gray matter neurons. At the subcellular level we report for 
the first time a peculiar periaxonal expression pattern of PlGF on sciatic nerve and DRG 
sections. This localization of PlGF could be due to its particular basic carboxyl terminal that 
allows it to bind polyanionic molecules like acidic phopholipids of the cell membranes 
(Persico et al., 1999; De Falco et al., 2002; Autiero et al., 2003a). In addition to this 
periaxonal localization, our results show an interruption of PlGF expression at the nodes of 
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Ranvier. It is known that, at the nodal level, the axolemma is composed of molecules highly 
specialized for the electrical signal transduction. The molecular difference in membrane 
composition between the internodal and nodal regions, particularly in the proportion between 
phospholipids and ionic channels, probably explains the absence of PlGF at the nodes of 
Ranvier.  
 
IV.2 PlGF expression changes during Wallerian Degeneration 
Sciatic nerve transection results in axonal breakdown and disintegration, which can 
explain the decrease of PlGF expression observed in injured axons during the first week post-
injury. Thereafter, WD in the PNS leads to successful axonal repair, explaining the re-
expression of PlGF in regenerating axons. Our results also show that SCs transiently express 
PlGF after nerve injury.  
An induction of VEGF expression in SCs was previously reported after peripheral 
nerve injury (Scarlato et al., 2003). Axonal rupture causes a loss of contact between the 
axolemma and its ensheathing SCs that switch from a differentiated state to an 
undifferentiated, proliferating state. This SC response is, among others, due to a neuronal 
release of the cytokine TGF-β1, which induces SC proliferation (Rogister et al., 1993). 
Interestingly, TGF-β1 has been shown to activate PlGF expression in cultured keratinocytes 
(Failla et al., 2000) and in retinal pigment epithelial cells (Hollborn et al., 2006). Hence, the 
transient expression of PlGF in SC observed after injury might be due to axonal released 
TGF-β1. The PlGF expression in proliferating SCs is confirmed by our RT-PCR results on 
primary SC cultures.  
In addition to the post-injury expression of PlGF in SCs, our results reveal a decrease 
of PlGF expression in fibroblasts concomitantly with the down-regulation of Ptc-1, the 
fibroblast marker. It is known that the signalling molecule desert hedgehog (Dhh) and its 
receptors, Ptc-1 and 2, are down-regulated during WD (Parmantier et al., 1999; Bajestan et 
al., 2006; Sharghi-Namini et al., 2006). Moreover, it has been demonstrated that the VEGF 
gene is a target of Ptc-1 signalling in cancers (Liao et al., 2009). Hence, the reduction of Dhh 
signalling during WD might cause the PlGF decrease in fibroblasts.  
Finally, in none of our experiments we found PlGF expression in ECs or macrophages. 
These results contrast with those showing that PlGF is expressed in inflammatory cells and 
vessels after injury (MCAO-induced stroke) to the CNS (Beck et al., 2002). If these results 
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can be replicated, they suggest that, after injury, PlGF is expressed differently in PNS and 
CNS. 
IV.3. PlGF is a target for NF-κB 
Transcription factors, such as c-Fos, c-Jun, ATF3 and NF-κB, are upregulated during 
WD. They control the changes in gene expression that occur in SCs located in the distal part 
of the injured nerve and induce responses like pro-inflammatory molecule secretion, 
phagocytic phenotype acquisition and migration (Liu et al., 1995; Hunt et al., 2004; Camara-
Lemarroy et al., 2010; Fu et al., 2010). It has been shown that the Pgf gene transcription is 
regulated by several transcription factors such as MTF-1, GCM1, BF-2 as well as NF-κB 
(Green et al., 2001; Zhang et al., 2003; Cramer et al., 2005; Chang et al., 2008). Among those 
factors, NF-κB is the only one involved in both WD process and regulation of PlGF 
expression.  
It was shown previously that the human Pgf promotor contains some NF-κB binding 
sites (Cramer et al., 2005). Our mouse Pgf promoter analysis also reveals the presence of κB 
motifs and our chromatin immunoprecipitation and luciferase assays confirm that PlGF 
transcription could be regulated by the NF-κB signalling pathway during WD. This result 
confirms the important role of the NF-κB signalling pathway in the induction of pro-
inflammatory cyto- and chemokines by SCs during the WD (Fu et al., 2010). 
 
IV.4. Periaxonal PlGF has no role in myelin sheath formation or 
preservation 
Because of the peculiar peripheral localisation in axons, the question arose whether 
PlGF plays a role in the formation and/or the preservation of myelin sheaths. In myelinated 
axons, PlGF is indeed in close contact with the inner lamellae of the myelin sheath and it is 
interrupted at the nodes of Ranvier. As mentioned above (see section IV.1.1), this PlGF 
expression pattern could be due to its ability to bind polyanionic molecules like acidic 
phopholipids of cell membranes. A similar periaxonal localization has been already shown for 
MAP1B, another cytoplasmic glycoprotein able to bind polyanionic molecules (Franzen et al., 
2001). In the latter study, Franzen et al. have shown that MAP1B is a neuronal binding 
partner for MAG, a myelin protein implicated in the stability of myelinated axons. Thus, as 
PlGF has an expression pattern similar to MAP1B, we hypothesized that PlGF might similarly 
play a role in the maintenance of the axon/myelin structure. This hypothesis was not 
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confirmed by our electron microscope analyses of myelin sheath morphology in sciatic nerves 
and spinal cords of Pgf -/- mice where no abnormalities could be detected. Based on these 
results and the fact that PlGF is also expressed in unmyelinated axons, we can conclude that 
PlGF is not essential for the formation and/or the preservation of myelin sheaths. 
Thus, the functional implication of this peculiar periaxonal localization of PlGF remains to be 
determined. 
 
IV.5. PlGF deletion delays the cellular and molecular events of Wallerian 
Degeneration. 
The question whether PlGF has a functional role in WD was examined in Pgf -/- mice. 
In mice lacking PlGF we observed after nerve transection a global delay in the cellular and 
molecular events of WD that retarded axonal regeneration and functional motor recovery. The 
targets of PlGF in WD demonstrated in our work are schematized in figure IV.1 
 
 
Figure IV.1: Model of PlGF involvement in the Wallerian degeneration. Following axonal 
breakdown, the released PlGF can bind to its flt-1 receptor on SCs, which in turn (i) produce PlGF 
and chemokines through the activation of the NF-κB signaling pathway, (ii) proliferate and (iii) align 
to form bands of Büngner, promoting axonal regeneration. PlGF also influences directly monocyte 
chemoattraction, thereby increasing macrophage activity of myelin debris phagocytosis, necessary to 
successful axonal regeneration.  
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IV.5.1. Impaired Schwann cell dedifferentiation and proliferation 
Nerve injury changes the phenotype of SCs that switch to a dedifferentiated, non-
myelinating and proliferative state within 24h after the lesion. In Pgf -/- mice, SC proliferation 
rates are significantly decreased, both in vitro and in vivo. Flt-1, which binds both VEGF and 
PlGF, mediates VEGF-triggered proliferation of astroglial cells (Mani et al., 2005; Krum et 
al., 2008). It is thus likely that in wt animals, the PlGF released by injured axons activates Flt-
1 receptors on SC membranes and induces their proliferation. This is in line with the study of 
Sondell et al. showing the mitogenic activity of VEGF on SC via flk-1 (Sondell et al., 1999a), 
and confirming the biological activity of Flt-1 expressed on SCs (Schratzberger et al., 2000). 
As other mitotic agents can act on SCs during WD (Rogister et al., 1993; Kwon et al., 1997; 
Li et al., 2005; Ogata et al., 2006), the sole absence of PlGF can only decrease SC 
proliferation, but not abolish it.  
Moreover, in Pgf -/- mice, the expression of p75NGFr, a marker of SC 
dedifferentiation, is significantly delayed after injury. The p75NGFr expression is stimulated 
by the fibrin deposit occurring after the lesion (Akassoglou et al., 2002). Recently, it was 
shown that PlGF is an inducer of the plasminogen activator-1 inhibitor (PAI) (Patel et al., 
2010). Thus, in Pgf -/- mice, the absence of PlGF could lead to a decrease in fibrin deposits, 
due to a low PAI induction, resulting in the delay of p75NGFr expression. 
 
IV.5.2. Delayed cyto/chemokine expression 
A large cyto/chemokine network, mainly produced by SCs, regulates the sequential 
WD cellular events. PlGF is able to induce an increase of several of these molecules like 
inflammatory cyto/chemokines (Bottomley et al., 2000; Perelman et al., 2003; Selvaraj et al., 
2003) or enzymes such as MMPs (Hattori et al., 2002). In our cytokine arrays, PlGF has a 
significant effect on the expression of MCP-1 and pro-MMP-9. These molecules are essential 
for early WD events: MCP-1 attracts macrophages (Toews et al., 1998; Siebert et al., 2000; 
Perrin et al., 2005), and MMP-9 is responsible for SC migration (Mantuano et al., 2008). We 
also obtain statistical differences in the expression of IL-10, Il-1α and MIP-1α between wt 
and Pgf -/- mice. However, because of the low reproducibility of our cytokine arrays for these 
molecules, leading to large SE, we were not able to detect the known post-injury evolution of 
these cytokines (Shamash et al., 2002; Perrin et al., 2005) leaving open the question if they 
are significantly influenced by PlGF. 
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IV.5.3. Delayed macrophage recruitment  
Macrophages play an essential role during WD. In addition to rapid clearance of 
axonal and myelin debris, they secrete neurotrophins (Barrette et al., 2008), promoting 
successful axonal regeneration. PlGF is chemo-attractive for macrophages (Clauss et al., 
1996). It is thus not surprising to find a significant delay in macrophage invasion during the 
first week of WD in Pgf-/- mice. As mentioned above, our cytokine array results also showed a 
significant delay of MCP-1 expression in Pgf-/- mice. Post-lesional macrophage invasion can 
therefore be impaired directly by the lack of PlGF, or indirectly via the delay in MCP-1 
expression. 
 
IV.5.4. Delayed myelin clearance, but no effect on the phagocytic phenotype of SCs  
Myelin degradation and its subsequent clearance are mediated by SCs and 
macrophages. The phagocytic phenotype acquired by SCs after the lesion was shown to be 
associated with c-Fos expression in these cells (Liu et al., 1995). However, although our 
results show a delay in myelin clearance when PlGF is absent, they detect no difference in c-
Fos expression between wt and Pgf -/- mice. Thus, the delay observed in myelin degradation 
and clearance is likely due to the reduced number of phagocytic cells within the lesion, 
consequence of the reduced SC proliferation and the delayed macrophage recruitment, rather 
than to a decrease in phagocytic capacity. 
 
IV.5.5. Delayed formation of Büngner’s bands  
In addition to their role in the inflammatory response, SCs migrate and line up to form 
the bands of Büngner. SC migration involves several molecules like cell-signaling factors, 
integrins and proteases (Lauffenburger & Horwitz, 1996). Among them, MMP-9, which is 
over-expressed by SCs after nerve injury and promotes SC migration (Mantuano et al., 2008), 
was found to be a target for PlGF (Hattori et al., 2002). Concordantly, our cytokine arrays 
show a significant decrease of pro-MMP-9 expression 7 days after injury in Pgf -/- mice 
relative to wt mice.  
NGF and its low affinity receptor p75NGFr are also involved in SC migration (Anton 
et al., 1994) and in our study p75NGFr expression after injury is delayed in Pgf-/- mice. 
Moreover, it is known that VEGF promotes SC migration mainly through its Trk receptors 
flk-1 and flt-1 (Schratzberger et al., 2000) and that flt-1, the PlGF receptor, mediates 
migration of ECs (Bae et al., 2005; Li et al., 2006), and retinal pigment epithelial cells 
(Hollborn et al., 2006). The delay of SC alignment observed on p75NGFr immunostained 
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sections of transected Pgf -/- nerves could thus be related either to a direct effect of the PlGF 
deficiency, or to an indirect effect related to the delay of MMP-9 and/or p75NGFr expression 
or to a reduced efficiency of VEGF, of which the effects are normally amplified by PlGF via 
various mechanisms (Carmeliet et al., 2001; Autiero et al., 2003b; Ribatti, 2008). 
 Contrasting with the in vivo experiments, the in vitro migration assay does not reveal a 
significant difference between wt and Pgf -/- mice, although numerical values are 
systematically lower for Pgf-/- cells. This difference could be explained by the poor 
reproducibility of the “scratch” test, and of the size of the cell-free area at the beginning of the 
experiment that can influence the migration ability of cells.  
 
IV.5.6. Delayed axonal regeneration, but normal remyelination 
Since PlGF modulates the early post-axotomy SC proliferation and macrophage 
invasion, it came of little surprise that axonal regeneration was also delayed in Pgf-/- mice. 
Indeed, the delay in clearance of myelin and axonal debris by SCs and macrophages leads to 
an unfavorable environment for regeneration and the retarded SC p75NGFr expression and 
bands of Büngner formation can decrease the beneficial effect that neurotrophins exert on the 
regenerating axons (Taniuchi et al., 1988). It must be pointed, however, that, like the other 
events of WD, axonal regeneration is only delayed so that it does not differ anymore between 
wt and Pgf -/- mice at post-injury day 21.  
The remyelination of regenerating fibers, the last step of nerve repair, is not affected 
by the delayed early events of WD. Nevertheless, because of the decrease in SC proliferation 
in the absence of PlGF, we hypothesized that the internodal length could be affected in 
regenerated Pgf -/- nerves. It is known that, after remyelination, the distance between two 
adjacent nodes of Ranvier is reduced in normal nerves (Hildebrand et al., 1985). In our 
teasing experiments we found no difference in intermodal length between regenerated wt and 
Pgf-/- nerve fibers. This could be due to the fact that Schwann cell proliferation may not be 
necessary for effective axonal regeneration and myelination after peripheral nerve injury, as 
shown by Yang et al. (Yang et al., 2008).  
 
IV.5.7. Lack of functional motor recovery 
Although axonal regeneration and remyelination occur 21 days after injury in Pgf -/- 
mice, functional motor recovery is impaired compared to wt mice in our study. We have no 
proven explanation for this apparent contrast. A major factor that determines functional 
recovery, however, is the correct rewiring of regenerating axons with their peripheral target 
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end-organs. Regenerating motor axons are often misrouted to sensory targets and sensory 
axons may be misrouted to muscle, leading to abnormal sensorimotor activity (Ijkema-
Paassen et al., 2002; Madison et al., 2007; Carlstedt, 2008). 
We speculate that the favourable effect of PlGF on SC proliferation and alignment and 
on axonal regeneration could enhance target organ reinnervation. Such an effect has indeed 
been demonstrated for VEGF. In a model of axonal regeneration through an acellular conduit, 
it was shown that adding VEGF in the silicone chamber stimulated SC and axonal 
regeneration, and that this was associated with an improved target organ reinnervation 
(Hobson et al., 2000). It remains to be demonstrated that PlGF has a similar beneficial effect 
on axonal rewiring. 
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Section V 
 
Conclusion 
and 
Prospects 
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The expression and function(s) of PlGF in the intact and injured PNS were not known 
up to now. Our work is the first demonstration of the involvement of PlGF as a new member 
of the cytokine network regulating WD. We have demonstrated that in the intact mouse sciatic 
nerve PlGF is found in axons underneath the axolemma, while it is expressed by SCs after 
axotomy possibly through a NF-κB-dependent mechanism of transcription. In a second step, 
we have used transgenic knock-out mice for the PlGF gene to show that PlGF plays a 
significant role in the sequence of cellular and molecular events of WD. It stimulates 
proliferation and migration of SCs, as well as the inflammatory response by inducing pro-
inflammatory molecule expression and macrophage recruitment. We have shown that the 
absence of PlGF is associated with a delay in WD events, and in axonal regeneration, as well 
as poor functional motor recovery. 
These results may have therapeutic implications for peripheral nerve injury. PlGF is 
probably dispensable for effective axonal regrowth, as in our study there was only a delay in 
regeneration. The more important aspect in our work is the finding that, despite normal axonal 
regeneration at long delays in the absence of PlGF, motor recovery remains impaired 
compared to wt mice. This suggests that PlGF may be needed for the correct rewiring of 
peripheral axons and its utility for this aspect of post-injury reinnervation should be explored 
in future studies. 
 The novel observation that PlGF is a molecule required for successful and functional 
repair in the PNS may have important consequences and perspectives for regeneration in the 
CNS. As mentioned in section I.1.2, following CNS injury, axonal regeneration aborts due in 
part to a less vigorous macrophage invasion compared to the PNS. In the future, it seems thus 
of interest to explore PlGF expression after CNS injury.  
Axonal regeneration within the CNS is also impaired by an astrocytic gliosis. Interestingly, 
PlGF is expressed by astrocytes in which its expression is increased after brain ischemia 
(Beck et al., 2002). Astrocytes, isolated from Pgf-/- mice cortex, exhibit a higher proliferation 
rate under hypoxic condition than wt-isolated astrocytes (Freitas-Andrade et al., 2008). These 
cells therefore deserve to be explored regarding their PlGF expression pattern after CNS 
lesion.  
The question whether regeneration could be promoted by providing PlGF after a CNS 
lesion is of major importance. In fact, in addition to its potential beneficial effect on the post-
injury inflammatory reaction, PlGF treatment could also enhance neo-angiogenesis (Takeda et 
al., 2009), which is known to be beneficial for axonal regrowth (Hobson et al., 2000; Dray et 
al., 2009). Angiogenic effects may have drawbacks like oedema formation due to vascular 
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permeability increase as it was shown for the therapeutic use of VEGF in brain injury (van 
Bruggen et al., 1999). Concerning PlGF, its effect on vascular permeability remains disputed. 
Some reports have shown that only VEGF analogues activating VEGFR-2 are able to increase 
vascular permeability (Hillman et al., 2001; Brkovic & Sirois, 2007). The lack of an effect on 
VEGFR-2 could make PlGF a more appropriate candidate than VEGF for neurological 
treatment. Experiments using mutant mice in which PlGF is under- or over-expressed have 
not solved the question as they have revealed either a decrease (Luttun et al., 2002a) or an 
increase (Odorisio et al., 2002; Oura et al., 2003) of vascular permeability under pathological 
conditions. One explanation for this discrepancy may be that the PlGF-induced increase in 
vascular permeability is an indirect effect, due to the displacement of VEGF-A from VEGFR-
1 to VEGFR-2, as PlGF competes with VEGF-A for VEGFR-1 in pathological conditions 
(Carmeliet et al., 2001).  
Taken together, VEGF and PlGF, despite proven experimental advantages, could be 
double-sided swords as neuroprotective/neurotrophic treatments for ischemic, degenerative or 
traumatic neurological disorders. We can finally conclude that in future therapeutic studies, it 
might be worthwhile to explore the effect of PlGF combined or not with a VEGFR-2 inhibitor 
to better understand the mechanisms and receptors implicated in the neurotrophic and 
angiogenic effects mediated by VEGF and PlGF. 
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Section VI 
 
Materials 
and 
Methods 
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VI.1. Primary antibodies 
In this work, many Abs have been used. Table VI.1 summarizes information on all 
primary Abs: origin, dilution or quantity used, as well as their cellular or molecular 
specificity. 
 
Ab Name Reference  Company Dilution/Quantity Cellular/Molecular specificity 
PlGF sc-27134 Santa Cruz Biotechnology 1:50 Placental growth factor 
PlGF protein 
NF-H MAB5448 Millipore 1:500 Neurofilament heavy polypeptide 
axon 
S100 ZO311 DakoCytomation 1:200 Low MW Ca++- binding protein 
Schwann cell 
p75 NGFr AB1554 Millipore 1:200 Low affinity NGF receptor 
proliferating Schwann cell  
vWF AB6994 Abcam 1:2000 von Willebrand Factor 
endothelial cell 
Ptc-1 sc-9016 Santa Cruz Biotechnology 1:50 Sonic Hedgehoc receptor 
fibroblast 
CD11b MCA74 Serotec 1:250 Complement receptor type 3 
macrophage 
P0 AB9352 Millipore 1:50 Glycoprotein 0  
PNS myelin  
Nav1.6 ASC-009 Alomones Labs 1:50 Voltage-gated Sodium channels  
nodes of Ranvier 
NeuN MAB377 Millipore 1:250 Neuronal nuclei 
neuron 
Ki67 NCL-Ki67p Novocastra 1:250 Nuclear antigen expressed in all  
proliferating cells 
BrdU OBT0030 Serotec 1:250 Bromodeoxyuridine 
Cells in S phase of mitosis 
c-Fos sc-52 Santa Cruz Biotechnology 1:100 Immediate early gene 
Marker of SC activity 
p65 sc-109 Santa Cruz Biotechnology 4µg NF-κB subunit p65 
Flag M2 F3165 Sigma 4µg synthetic peptide 
 
Table VI.1.:  Primary antibody information. 
 
 
VI.2. Animals and tissue samples 
Adult (10-12 weeks) 50%Swiss-50%129SV female wt and Pgf -/- mice were used 
(kind gift from Pr Peter Carmeliet, Vesalius Research Centre, VIB, KUL, Belgium). Sciatic 
nerves, spinal cords and DRG were harvested. The experiments were performed in 
accordance with the rules and regulations of the Ethical Committee for animal research of the 
Belgian National Fund for Scientific Research. 
 
 
 
 
75 
 
VI.3. Surgical procedure: sciatic nerve complete transection 
Mice were anesthetized by an intraperitoneal (i.p.) injection of a mixture of ketamine 
(75 mg/kg; Ketalar®, Bayer HealthCare, Brussel, Belgium) and xylazine (10 mg/kg; 
Rompun®, Pfizer, Brussel, Belgium). Under aseptic conditions, sciatic nerves were exposed 
and WD induced by a complete section of the nerves at the upper thigh level (figure VI.1). 
Proximal and distal stumps were left in their original position to allow axonal regeneration. 
Muscles and skin were carefully closed in two layers. 
 
 
 
 
 
 
 
Figure VI.1.: Complete section of mouse sciatic nerve 
(white arrows).  
 
 
 
 
 
 
 
 
Table VI.2 summarizes all the techniques performed in this work, the number of animals used 
for each one, as well as their survival times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
Experimental technique Survival time Animal nb 
Motor recovery evaluation 21 days 5 wt and 5 Pgf -/- mice  
Immunostainings   uninjured 6 wt and 5 Pgf -/- mice  
 1 day 6 wt and 10 Pgf -/- mice  
  3 days 11 wt and 7 Pgf -/- mice  
 7 days 9 wt and 7 Pgf -/- mice  
  14 days 10 wt and 8 Pgf -/- mice  
  21 days 11 wt and 12 Pgf -/- mice  
  28 days 8 wt and 6 Pgf -/- mice  
 In situ hybridization  uninjured 1 wt mouse 
Toluidine blue staining uninjured 5 wt and 5 Pgf -/- mice  
  1 day 5 wt and 5 Pgf -/- mice  
  3 days 8 wt and 9 Pgf -/- mice  
 7 days 7 wt and 8 Pgf -/- mice  
  14 days 6 wt and 7 Pgf -/- mice  
  21 days 7 wt and 8 Pgf -/- mice  
 Cytokine arrays uninjured 6 wt and 6 Pgf -/- mice 
  1 day 6 wt and 6 Pgf -/- mice 
  3 days 6 wt and 6 Pgf -/- mice 
  7 days 6 wt and 6 Pgf -/- mice 
Teasing uninjured 3 wt and 3 Pgf -/- mice  
  28 days 3 wt and 3 Pgf -/- mice  
Electronic microscopy uninjured 3 wt and 3 Pgf -/- mice   
Schwann cell culture uninjured 16 wt and 16 Pgf -/- mice 
RT-PCR uninjured 1 wt mouse 
Chromatin uninjured 12 wt mice 
Immunoprecipitation 1 day 12 wt mice 
 
Table VI.2.: Techniques, number of animals and survival times used for this work. 
 
 
VI.4. Motor recovery evaluation 
Prior to the lesion and at 3, 7, 10, 14, 17 and 21 days following unilateral left sciatic 
nerve section, mice had their hind paws inked and were then allowed to walk down a 60cm 
long corridor lined with graph paper. For each animal (5 wt and 5 Pgf -/- mice), at every time 
point, at least four clear footprints were obtained for each foot. Measurements of the printed 
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foot length were then made on the operated side (OPL) and the normal side (NPL). A mean of 
four values was then calculated for the OPL (xOPL) and NPL (xNPL), and a print-length 
factor (PLF) was calculated as follows: PLF = (xOPL – xNPL)/xNPL (George et al., 2003). 
 
VI.5. Immunostainings 
 
VI.5.1. Tissue processing 
Mice were sacrificed after different survival times (1, 3, 7, 14, 21 and 28 days post-
injury) by an overdose of Nembutal (150 mg/kg, i.p, CEVA Santé Animale, Brussel, 
Belgium). The distal parts of the transected sciatic nerves (a 12 to 15 mm long portion) were 
freshly harvested, embedded in Tissue-Tek® O.C.T.™ Compound (Labonord SAS, 
Templemars, France) and directly frozen. Tissues were cut on a cryostat at 10µm thickness. 
Longitudinal or cross-sections were collected onto gelatin-coated slides and stored at -20°C 
until used.  
UI sciatic nerves, DRGs and lumbar spinal cords were also freshly dissected out, 
embedded in Tissue-Tek® and cut at 10 µm (sciatic nerves and DRGs) or 20 µm thickness 
(spinal cords). Sections were collected onto gelatin-coated slides and stored at -20°C until 
used.  
 
VI.5.2. Immunofluorescent staining protocol  
To characterize PlGF expression, we used double immunofluorescence stainings for 
PlGF and several specific cellular markers such as NF-H, S100, p75 NGFr, vWF, Ptc-1, P0, 
Nav1.6, CD11b and NeuN (see table VI.1). After drying, tissue sections were fixed in cold 
acetone for 10 min at 4°C. Nonspecific binding was prevented by 1h incubation in a 10% 
normal serum solution in 0.1% triton-PBS (0.1M, pH 7.4). After overnight incubation at room 
temperature (RT) with the specific primary Abs, sections were rinsed 3 times with PBS and 
incubated for 1h at RT with their respective secondary Abs coupled to rhodamine or FITC 
(1:500, Jackson ImmunoResearch). They were then rinsed twice in PBS, twice in distilled 
water and mounted under coverslips using the “vectashield” (Vector Laboratories) solution. 
Negative controls were obtained by incubation of the primary Ab with its specific blocking 
peptide (sc-27134 P; Santa Cruz Biotechnology) before applying it on the tissue sections. 
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VI.5.3. DAB immunostaining protocol 
Tissue sections, after drying, were fixed with 4% paraformaldehyde (PFA) for 5 min, 
then incubated in a 0.3% H2O2, 0.1% Na azide solution in PBS for 20 min at RT to reduce 
endogenous peroxydase activity. Non-specific binding was prevented by 1h incubation in 3% 
normal serum and 1% bovine serum albumin solutions in 0.1% triton-PBS. Sections were 
then incubated overnight at RT with the specific primary Abs: anti-p75NGFr to study SC 
dedifferentiation or anti-CD11b to study macrophage recruitment (see table VI.1). After 3 
PBS rinses, they were incubated for 1h at RT with their respective secondary biotinylated Abs 
(Vector Laboratories) diluted and centrifuged in a 3% normal mouse serum and 1% bovine 
serum albumin (BSA) in 0.1% triton-PBS solution. After 1h incubation with the avidin-biotin-
peroxydase complex (Vector Laboratories) diluted 1:1000 in PBS, the immunostaining was 
revealed with 3,3'-diaminobenzidine (DAB). 
 
VI.6. Morphometric analyses 
 
VI.6.1. Quantification of in vivo Schwann cell proliferation 
To study SC proliferation, longitudinal sections of sciatic nerves were stained with 
anti-Ki67 Ab (see table VI.1). Because of a conflict between Abs, we were not able to 
perform the double Ki67/p75NGFr immunofluorescent staining. Therefore, longitudinal 
sections of distal parts of sciatic nerves were double-stained with anti-Ki67 and anti-CD11b 
Abs (see table VI.1) and counter-stained with DAPI to detect all cell nuclei. The total number 
of Ki67-positive/CD11b-positive cells (proliferating macrophages) or Ki67-positive/CD11b-
negative cells (proliferating SCs) were manually counted within non-overlapping successive 
fields covering the entire nerve section captured with an Olympus DP50 digital camera 
connected to an Olympus AX-70 microscope (magnification 20 x). The results were 
expressed as a mean number (± SE) of Ki67 positive SC nuclei per mm² of nerve tissue.  
 
VI.6.2. Quantification of Schwann cell c-Fos expression 
As for Ki67 Ab, because of a conflict between Abs the expression of the early-
expressed protein c-Fos in SCs could not be studied with double c-Fos/p75NGFr 
immunofluorescent staining. Instead, longitudinal sections of distal parts of sciatic nerves 
were double-stained with anti-c-Fos and anti-CD11b Abs (see table VI.1) and counter-stained 
with DAPI to detect all cell nuclei. The total number of nuclei and c-Fos-positive/CD11b-
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positive cells (macrophages expressing c-Fos) or c-Fos-positive/CD11b-negative cells (SCs 
expressing c-Fos) (magnification 20 x) were manually counted within non-overlapping 
successive fields covering the entire nerve section, however we didn’t count c-Fos-positive 
nuclei located in the epi-/perineurium to avoid bias due to fibroblasts (Pyykonen & 
Koistinaho, 1991). The results were expressed as the mean percentage (± SE) of c-Fos-
positive SCs amongst the total number of cells.  
 
VI.6.3. Quantification of axonal regeneration 
To evaluate axonal regeneration, longitudinal sections from the distal part of injured 
sciatic nerves were fluorescently stained with anti-NF-H Ab as described above. For the 
quantification, non-overlapping successive fields covering the entire tissue sections (which 
means the whole length of the distal part) were captured at magnification 10x. The mean 
number of fields/section was similar between wt and Pgf -/- mice (7.47±0.76 and 7.54±0.64 
respectively), resulting in comparable total tissue length. Each field was then allocated to one 
of the following group: (i) field containing only debris of degenerating axons; (ii) field 
containing a majority of debris and few regenerating profiles; (iii) field containing scarce 
debris and a majority of regenerating fibres; and (iv) field containing only regenerating fibres. 
Data were expressed as a mean proportion of field numbers in each of those 4 groups per total 
nerve section (%) ± SE.  
 
VI.6.4. Quantification of Schwann cell dedifferentiation  
To quantify SC dedifferentiation, digitalized images obtained with a 20 x microscopic 
magnification were converted to gray scale. A gray colour threshold intensity was set for each 
section. The intensity of immunostaining was then quantified within non-overlapping 
successive fields covering the total nerve tissue area using the Olympus AnalySIS computer 
program. Data were expressed as the mean integral intensity (± SE) of total stained area 
(pixel²) per total area of the nerve section (pixel²). 
 
VI.6.5. Quantification of recruited macrophages  
In order to quantify the recruitment of macrophages, CD11b-positive cells were 
manually counted at 10x magnification within non-overlapping successive fields covering the 
entire nerve section. Results were expressed as the mean number (± SE) of CD11b-positive 
cells per 0.1 mm² of nerve tissue. 
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VI.7. Primary Schwann cell culture 
Adult SCs were isolated from wt and Pgf -/- sciatic and trigeminal nerves, which are 
both an important source of SCs easily accessible, as described previously by others (Bouquet 
et al., 2007). After dissection, the nerves were left for 2 weeks in a degeneration medium: 
DMEM, 10% foetal bovine serum (FBS), Fungizone (2.5µg/ml; GIBCO®, Invitrogen™), 
Forskolin (2µM Calbiochem®), Gentamycine (50µg/ml; GIBCO®) and Heregulin-β1 (10 
ng/ml, HRG; R&D Systems GmbH) at 37°C, 5% CO2. After enzymatic and mechanical 
dissociation, cells were plated on T25 culture dishes pre-coated with poly-L-lysine (50 µg/ml, 
Sigma-Aldrich), laminin (10µg/ml, Sigma-Aldrich), and DMEM supplemented with 10% 
FBS. They were then incubated at 37°C, 5% CO2 in N2HRG medium: 50% DMEM 50% F12 
supplemented with N2 (dilution 100 x; GIBCO®), gentamycin (50µg/ml), fungizone (2.5 
µg/ml), forskolin (2µM), and HRG (10ng/ml). At confluence, SCs were purified by magnetic 
cell-sorting using the anti-p75 NGFr Ab (see table VI.1), according to the manufacturer’s 
instructions (Miltenyi Biotech GmbH, Germany). To assess the degree of purity of our SC 
cultures, we performed p75 NGFr/DAPI immunofluorescent staining and we evaluated the 
percentage of p75 NGFr-positive cells. 
 
VI.8. In vitro BrdU assay 
SCs were plated on coated glass coverslips at a concentration of 25x103cells/300µl. 20 
µM BrdU (Sigma-Aldrich) were directly added to the cultures for 16h before fixation in 4% 
PFA for 10min. Cells were treated in HCl 2N for 10min at 37°C and then washed in borate 
buffer (0.1M; pH 8.5). Cells were permeabilised and nonspecific binding was prevented by 1h 
incubation in a 10% normal serum - 0.1% triton-PBS solution. They were incubated overnight 
with anti-BrdU and anti-p75NGFr Abs (see table VI.1). After 3 PBS washes, cells were 
incubated for 1h at RT with the respective secondary Abs coupled to rhodamine or FITC 
(1:500, Jackson ImmunoResearch). The coverslips were then rinsed twice in PBS, twice in 
distilled water, and mounted on slides using the vectashield solution containing DAPI in order 
to visualise all nuclei of the total cell population. Double-stained p75NGFr/BrdU cells and 
total number of p75NGFr positive cells were manually counted at the 20x magnification 
within non-overlapping successive fields and results were expressed as mean % (± SE) of 
proliferating SCs. 
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VI.9. Schwann cell migration assay 
Purified wt or Pgf -/- SCs were plated on coverslips coated with poly-L-lysine and 
laminin at a density of 25x10³ cells in a 50µl drop of N2HRG medium. After cell attachment, 
culture medium was added and cells were left for 24h without further treatment. A cell-free 
area was generated by a scratch with the tip of a plastic pipette. Migration of SCs into the cell-
free area was monitored every 2h for 28h under a phase-contrast inverted microscope 
(magnification 10 x) equipped with a digital camera. As described by Sakurai and Osumi, 
(Sakurai & Osumi, 2008), the migration ability of SCs was estimated by the size reduction of 
the cell-free area every 2 hours after the scratch.  
 
VI.10. In situ hybridization 
Mice were deeply anesthetized by an i.p. injection of Nembutal (60 mg/kg) and 
perfused with 4% PFA in 0.1 M phosphate buffer, pH 7.4. Sciatic nerves and spinal cord were 
harvested, post-fixed with 4% PFA for 24 h at 4°C and kept for 48 h in 30% sucrose at 4°C 
for cryoprotection. They were then cut transversally at 10 µm on a cryostat and mounted onto 
SuperFrost®Plus slides (Prosan, Merelbeek, Belgium). Sections were post-fixed with 4% PFA 
for 10 min and treated with acetylated triethanolamine 100 mM, PH 8, for 15 min. After 3 
washes with TBS-Tween 0.1%, sections were pre-hybridized with hybridization buffer 
(Amresco, Ohio, U.S.A.) for 1h at 70°C and then hybridized with a digoxygenin-labeled 
antisense PlGF RNA probe overnight at 70°C (the plasmid containing the mouse PlGF-2 
cDNA was provided by P. Carmeliet). Two negative controls were used: sense RNA probes 
and nerve sections from Pgf -/- mice. The next day, sections were washed twice with pre-
warmed washing buffer (formamide 50%, 0.1% Tween, SSC 20× in H20) for 1h at 70°C, 
twice with Tris-Saline buffer (100mM Tris-HCl, 150M NaCl, 0.1% Tween) for 15 min at RT 
and then blocked with 10% goat serum in Tris-Saline buffer for 30min at RT. Sections were 
then incubated overnight at 4°C with an anti-digoxigenin Ab coupled to alkaline phosphatase 
(1:2000, Roche Applied Science) in blocking buffer. After 3 Tris-Saline buffer washes, 
sections were incubated twice with a 100mM Tris-HCl pH 9.5, 100mM NaCl, 50mM MgCl2 
and 0.1% Tween 20 buffer for 30min each at RT. Then sections were overlaid at RT in the 
dark with a 200 µl filtered NBT/BCIP/Tween-20 0.1% solution (Sigma-Aldrich) between 
coverslips for 4 to 6 hours. The reaction was blocked by washes with PBS followed by post-
fixation with 4%PFA for 15 minutes. 
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VI.11. Semi-quantitative reverse transcription PCR 
RNA from DRGs or cultured SCs was extracted with TRIzol® (Invitrogen) and 
isolated according to the manufacturer’s protocol. mRNAs for PlGF and GAPDH, taken as 
internal control, were amplified with aliquots of 20 ng of total RNA using a RT-PCR kit 
(GeneAmp Thermostable rTth reverse transcriptase RNA PCR kit; Applied Biosystems, 
Foster City, CA) and pairs of primers (oligonucleotide sequences shown in table VI.3; 
Eurogentec, Seraing, Belgium).  Reverse transcription was performed at 70°C for 15 minutes 
followed by 2 minutes of incubation at 95°C for denaturation of RNA-DNA heteroduplexes. 
Amplification consisted in cycles of 15 seconds at 94°C, 20 seconds at 58°C, and 20 seconds 
at 72°C. RT-PCR products were resolved on 10% polyacrylamide gel, stained with GelStar 
(Lonza, Belgium). 
 
Gene Primer type Oligonucl. sequence (5'- 3') PCR product size (bp) Cycle nb  
          
mPlGF reverse TTCCCCTTGGTTTTCCTCCTT 130 45 
  forward AGATCTTGAAGATTCCCCCCA     
GAPDH reverse GCCTTCTCCATGGTGGTGAAGAC 210 25 
  forward GACCCCTTCATTGACCTCAACTACATG     
 
Table VI.3.: RT-PCR probe information. 
 
VI.12. Total protein extraction from sciatic nerves 
Fresh sciatic nerves were homogenized in a lysis buffer containing 80% PBS, 10% 
500mM NaF, 0.1% 100mM Na3VO4, 1% triton X-100 and protease inhibitors (Complete™; 
Roche) on ice. The tissue weight/buffer volume ratio was 1/10. After homogenization, 
samples were centrifuged at 13000 rpm for 15 min at 4°C. Clarified cell lysates were 
collected and total protein concentrations were quantified with the BCA protein assay kit 
(ThermoScientific). 
 
VI.13. Cytokine array 
Expressions of IL-1α, IL-1β, IL-6, TNF-α, IL-10, VEGF, VEGFR-1, MCP-1, MIP-
1α and pro-MMP-9 were measured in tissue extracts of normal and injured sciatic nerves 
from wt and Pgf -/- mice using RayBio® Cytokine Antibody Arrays (RayBiotech, Inc.). 200µg 
of total protein were used per sample. The cytokine array membranes were scanned with a 
Las-4000 luminescent image analyser (Fujifilm). The intensity of the signal was measured 
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and compared to that of a positive control with the Quantity One 1-D Analysis software (Bio-
RAD Laboratories, Inc.). The signal intensities of positive controls and samples were 
normalized using background substraction. The results were expressed as the mean relative 
signal intensity, i.e. the ratio of sample intensity/positive control intensity.  
 
VI.14. Prediction of NF-κB binding sites 
The mouse Pgf gene sequence was obtained from the www.ensembl.org web site. To 
identify NF-κB binding sites (referred to as “κB motifs”), computational analysis of the 
promoter sequence of mouse Pgf (Green et al., 2001) gene was performed using four different 
programs designed to look for transcription factor binding sites:  
- MatInspector program (www.genomatix.de/matinspector.html) 
- Match™program (www.generegulation.com/cgi-bin/pub/programs/match/bin/match.cgi) 
- Promo (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) 
- TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html) 
 
VI.15. Chromatin immunoprecipitation assay 
 
VI.15.1. Immunoprecipitation and DNA purification 
Sciatic nerves (from intact and 24h post-injured adult wt mice) were surgically 
removed from four adult mice per condition, minced and immediately fixed in PBS 
containing 1% PFA for 25 min at RT to promote the protein-DNA cross-linking. To stop the 
formaldehyde action, 1.25 M glycine was diluted 10 times in the cross-linking solution, and 
then nerves were washed twice with cold PBS containing protease inhibitors (Roche). Nerves 
were homogenized into 1.5 ml of lysis buffer (1% SDS, 10 mM EDTA pH 8.0, 50 mM Tris-
HCl pH 8.0, protease inhibitors). The lysate was sonicated for 15 min with alternating 30-s 
pulses at high power with a Bioruptor sonicator (Diagenode), and then centrifuged at 13000 
rpm for 5 min at 4°C. To check the fragment size of sheared chromatin (optimal size between 
250-500 bp), 10µl of sheared chromatin was boiled for 5 min to denature proteins, and DNA 
fragments were separated on a 1.5% agarose gel stained with GelRed™ (Biotium). The 
protein concentration of lysates was measured using the BCA protein assay kit (Pierce). 30 µg 
of chromatin was set aside as a tenth of total chromatin input used for IP. Lysates were diluted 
10 times into dilution buffer (1% Triton X-100, 150mM NaCl, 2mM EDTA, 20mM Tris-HCl 
pH 8.0, protease inhibitors). The sheared chromatin (300 µg per IP) was pre-cleared with 100 
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µl of Protein A-agarose (Santa Cruz Biotechnology), diluted in a solution of dilution buffer 
(1% triton X-100, 150 mM NaCl, 2 mM EDTA pH 8.0, 20 mM Tris-HCl pH8.0, protease 
inhibitors) and lysis buffer in 9/1 proportion and subsequently blocked with BSA (100 µg/ml) 
and sheared salmon sperm DNA (500 µg/ml; Invitrogen), for 2h at 4°C under agitation. After 
the Protein A-agarose removal, “cleared” lysates were incubated with 4µg of anti-p65 or anti-
Flag (used as negative control Ab, see table VI.1) at 4°C on a rotating platform overnight. The 
immune complexes were incubated with 100 µl of Protein A-agarose solution for 2h at 4°C. 
The immune complexes were then washed three times with 1 ml low salt washing buffer (1% 
triton X-100, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, protease 
inhibitors), once with 1 ml high salt washing buffer (same buffer but containing 500 mM 
NaCl), once with 1 ml LiCl buffer (0.25 M LiCl, 1% IGEPAL CA630 (Sigma), 1 mM EDTA, 
1% deoxycholic acid, 10 mM Tris-HCl pH 8.0), and finally once 1 ml with TE buffer (10 mM 
Tris-HCl, 1 mM EDTA, final pH 8.0). Immunoprecipitated chromatin was eluted in 250 µl of 
elution buffer (1% SDS, 0.1 M NaHCO3) for 15 min at RT, twice. Chromatin inputs were also 
diluted in elution buffer. Protein-DNA cross-links were reversed by incubation with 20 µl of 5 
M NaCl at 65°C for 4h and then we added 10µl of 0.5 M EDTA, 20µl of 1M Tris-HCl pH 6.5 
and 20µg of proteinase K (Promega), for 1h at 45°C to digest proteins. DNA was purified 
with phenol/chloroform (Sigma) on Phase Lock Gel™ tube (Eppendorf). After a 5 min-
centrifugation at 13000 rpm, the aqueous phase was incubated 1h at -20°C in a solution 
containing 45 µl of 3 M NaAC pH 5.5, 30 µg of glycogen (Roche) and 1 ml of ethanol, and 
then samples were centrifuged 5 min at 13000 rpm. The DNA pellet was washed with 70% 
ethanol, then resuspended in 100 µl of DNase-free distilled water and stored at -80°C until 
use for PCR. 
 
VI.15.2. Quantitative real-time PCR 
Quantitative RT-PCR amplifications were performed in a 96-well plate in the ABI 
Prism® 7000 sequence detector (Applied Biosystems) in a total volume of 20 µl, which 
included 1 µl of DNA sample coming from the Chromatin IP assay and 19 µl of a reaction 
mixture (10 µl of Power SYBR® Green PCR Master Mix [Applied Biosystems], 8.2 µl of 
DNase-free distilled water, and 0.4 µl of each primers [designed to amplify detected κB 
motifs, table VI.4; Eurogentec, Belgium]). Each qRT-PCR amplification was performed in 
triplicate. The cycle conditions were 2 min at 50°C, 10 min at 95°C, and then 45 temperature 
cycles (15 sec at 95°C and 1 min at 60°C). 
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Amplicon Gene Primer  Oligonucl. Sequence (5'-3') 
name localization type   
PlGF -908 reverse ACGTGCCTCCAGAACCGTCC 
κB1 site to -1015 forward CCAGGTGCCCCGAGGTGTTT 
PlGF -1041 reverse CTCCTGTCAGGTCAGGCCAGC 
κB2 site to -1120 forward CCTCTTCTGCTTGGGCTCGGG 
PlGF -996 reverse AAACACCTCGGGGCACCTGG 
κB1-2 sites to -1104 forward TCGGGAGGTGATGCCAGGTTAGT 
PlGF 624 to 753 reverse TTCCCCTTGGTTTTCCTCCTT 
gene  forward AGATCTTGAAGATTCCCCCCA 
 
Table VI.4.: PCR probe information. 
 
 
VI.15.3. Relative quantification of NF-κB binding 
SYBR Green is a fluorescent molecule that binds double-stranded DNA. During the 
PCR reaction, fluorescence increases proportionally to the amount of amplified DNA product. 
For each qRT-PCR amplification, we obtained a sigmoid curve (figure VI.2) and the cycle 
threshold (ct) is determined. The ct corresponds to the cycle number from which the curve of 
amplified product apparition becomes exponential. 
 
 
 
 
 
   
Figure VI.2.: Graph representing   
the qRT-PCR reaction. 
 
 
 
 
 
 
 
 
The relative quantification of NF-κB binding on κB sites is based on the difference between 
the ct of DNA amplification coming from one day-injured sciatic nerves immunoprecipitated 
with p65 Ab and the DNA amplification from uninjured sciatic nerves. 
The complete analysis to quantify NF-κB binding brings into play several normalization steps 
described below. 
For each pairs of primers used (see table VI.4), we amplify immunoprecipitated DNA, from 
UI or injured (I) sciatic nerves, with p65 or Flag Ab, and the two DNA inputs coming from 
also uninjured and injured nerves. After the qRT-PCR, we obtain the ct in triplicate and 
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calculate the mean ct for each condition: ct1 p65 UI, ct1 p65 I, ct1 Flag UI, ct1 Flag I, ct1 
input UI and ct1 input I. Then, the first normalization to apply concerns the amount of 
chromatin used for the IP. So, to remove the possible bias due to protein concentration 
measurement, we substract the ct of inputs of the others ct:  
 Ct1 p65 or Flag UI – ct1 input UI = ct2 p65 or Flag UI 
 Ct1 p65 or Flag I – ct1 input I = ct2 p65 or Flag I 
 
The second normalization concerns the specificity of the IP. As negative control of IP, we 
used anti-Flag Ab that recognizes a synthetic peptide naturally absent in cells. To obtain the 
specific IP with p65 Ab, we calculate the difference between ct2 Flag and ct2 p65: 
 Ct2 Flag UI – ct2 p65 UI = ct3 UI 
 Ct2 Flag I – ct2 p65 I = ct3 I 
 
Then, we can calculate the δ ct = ct3 I – ct3 UI. The fold induction value of NF-κB binding 
after nerve injury compared to the uninjured condition is then calculated with the following 
formula: 
 Fold induction = 2 δ ct 
 
Finally, the last normalization concerns the specific NF-κB binding to a κB site located in the 
gene promoter. We have used a pair of primers to amplify a DNA region comprised in the 
gene and not in the promoter of PlGF (see table VI.3, amplicon name: PlGF). The fold 
induction for the RT-PCR using these primers should be close to 1, corresponding to the 
control condition where there is no NF-κB binding to a promoter. The ratio (R) 1: fold 
induction value obtained with PlGF primers is used to normalize the real fold induction and 
the formula is the following: 
 Real fold induction = 2 δ ct x R 
 
VI.16. Luciferase assay 
The Pgf promoter region including the two κB sites was inserted into the pGL3-
Promoter Vector (Promega). 293 cells (4 × 105 cells per well) were seeded in 6-well (35 mm) 
plates. After 12 h, cells were transfected as described previously (Leonardi et al., 2000) with 
0.5 µg of either the Pgf-κB-luciferase or the Ig-κB-luciferase and with expression plasmids as 
indicated. The total amount of transfected DNA was kept constant by adding empty 
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expression vector DNA as needed. Cell extracts were prepared 24 h after transfection, and 
reporter gene activity was determined by using Dual-Luciferase Reporter Assay System 
(Promega). The pRL Vector (40ng), which provides constitutive expression of Renilla 
luciferase, was used to normalize for transfection efficiencies. 
 
VI.17. Myelin sheath morphology 
 
VI.17.1. Tissue processing 
Mice were perfused with Karnovski buffer containing 1% PFA and 1.25% 
glutaraldehyde in 0.1M Sörensen buffer (solution of Na2HPO4 and NaH2PO4 in proportion 4/1 
diluted in distilled water, pH 7.4). Sciatic nerves were carefully dissected out and post-fixed 
with Karnovski buffer overnight at 4°C. After two washes in 0.1M Sörensen buffer, nerves 
were post-fixed with 1% osmium in 0.1M Sörensen buffer for 1h at 4°C.  
 
 Toluidine blue staining and electronic microscopy  
Sciatic nerves were progressively dehydrated in successive ethanol baths and then 
soaked in epoxy-propane twice during 10 min. Tissues were embedded in epon resin by 
soaking them in a epoxypropane/epon mixture of successive 2/1, 1/1 and ½, proportions, 1h 
each. The resin was harden at 265°C for 2 days. The blocks were trimmed, and semi-thin (1 
µm) and ultra-thin (75 nm) cross-sections were cut with a Leica Ultracut UCT microtome. 
Semi-thin sections were collected onto glass slides, and then dried on a hot plate at 60°C for 
1h. To optimise dye impregnation, sections were treated with 1% potassium tetraborate before 
staining with 0.5% toluidine blue. Ultra-thin sections were collected on copper grids and 
contrasted with 5% uranyle-acetate and lead citrate. 
 
 Teasing  
Karnovski-fixed sciatic nerves were treated with 30%, 60%, 90% and 100% glycerine, 
each for 24h at 37°C. The nerves were placed on a slide with a few drops of 100% glycerine 
under a dissecting microscope. Using ultra-fine forceps, the nerves were then separated from 
proximal to distal into smaller bundles of fibers until individual axons could be identified. 
Slides were then prepared for light microscopy. 
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VI.17.2. Morphometric analysis of myelin sheaths  
 
 Number of intact myelin sheaths 
On semi-thin toluidine blue stained 1 µm sections, intact myelin sheaths 
(magnification 40 x) were manually counted within non-overlapping successive fields 
covering the entire nerve section, and results were expressed as the mean number (± SE) of 
intact myelin sheaths per 0.01 mm² of nerve tissue. 
 
  Myelin sheath thickness  
The myelin sheath thickness in individual axons was determined on ultra-thin cross-
sections at the electron microscopic level. Two sections were selected for each animal (N=3 
per group) and three images per section were taken at a 1000x magnification using a Zeiss 
LEO 906 transmission electronic microscope equipped with a ProgRes MF camera 
(JENOPTIK, Germany) and the ProgRes CapturePro 2.6. software. The axonal area and the 
mean thickness of myelin sheath, measured at four random points of its circumference, were 
determined on five myelinated axons randomly selected per field using the Olympus 
AnalySIS computer program. Results were represented in graphs showing the myelin sheath 
thickness as a function of axonal area. 
 
 Internodal lengths  
Images of each teased axon were taken at the 10x or 20x magnifications. The Olympus 
AnalySIS computer program was used to measure internodal length and results were 
expressed as mean length (± SE) of internodes. 
 
VI.18. Statistical analyses 
Means and SEs for each experimental time point were calculated. Statistical 
significance was set at P < 0.05. ). To evaluate the group effect in motor recovery (section 
VI.4) and in the migration assay (section VI.9) during time, we used Zerbe’s non-parametric 
model, which compares both the global evolution of two groups and the values at the different 
time point separately. For the other experiments, the statistical significance of differences 
between wt and Pgf -/- mice was tested separately at each time points using a Student t-test. 
All quantifications were performed blind to the genotype. Statistical analyses were supervised 
by the Department of Biomedical Statistics of the University of Liege (Pr. A Albert). 
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ABSTRACT
Wallerian degeneration (WD) is an inﬂammatory process of
nerve degeneration, which occurs more rapidly in the pe-
ripheral nervous system compared with the central nervous
system, resulting, respectively in successful and aborted
axon regeneration. In the peripheral nervous system,
Schwann cells (SCs) and macrophages, under the control of
a network of cytokines and chemokines, represent the main
cell types involved in this process. Within this network, the
role of placental growth factor (PlGF) remains totally
unknown. However, properties like monocyte activation/
attraction, ability to increase expression of pro-inﬂamma-
tory molecules, as well as neuroprotective effects, make it a
candidate likely implicated in this process. Also, nothing is
described about the expression and localization of this mol-
ecule in the peripheral nervous system. To address these
original questions, we decided to study PlGF expression
under physiological and degenerative conditions and to
explore its role in WD, using a model of sciatic nerve trans-
ection in wild-type and Pgf 2/2 mice. Our data show
dynamic changes of PlGF expression, from periaxonal in
normal nerve to SCs 24h postinjury, in parallel with a p65/
NF-jB recruitment on Pgf promoter. After injury, SC prolif-
eration is reduced by 30% in absence of PlGF. Macrophage
invasion is signiﬁcantly delayed in Pgf2/2 mice compared
with wild-type mice, which results in worse functional re-
covery. MCP-1 and proMMP-9 exhibit a 3-fold reduction of
their relative expressions in Pgf2/2 injured nerves, as dem-
onstrated by cytokine array. In conclusion, this work origi-
nally describes PlGF as a novel member of the cytokine
network of WD. VC 2010 Wiley-Liss, Inc.
INTRODUCTION
Wallerian degeneration (WD) is the active process of
degradation of the nerve segment distal to the lesion
site. First described in 1850 (Waller, 1850), WD is criti-
cal for successful axonal regeneration and occurs more
rapidly in the peripheral than in the central nervous
system, where axonal regeneration fails (Lawson et al.,
1994; Perry et al., 1987). The sequence of degenerative
events comprises cellular and molecular changes, and
requires effective Schwann cell (SC) and macrophage
responses (Stoll et al., 1989). Indeed, following injury,
SCs dedifferentiate, proliferate, and align in ‘‘bands of
B€ungner’’ providing structural guidance and growth-
promoting substrates to regenerating axons (Vargas and
Barres, 2007). SCs also participate in the clearance of
myelin debris, which occurs during the ﬁrst few days
postinjury (Stoll et al., 1989) and release a wide variety
of chemokines and cytokines, which in turn recruit cir-
culating macrophages to the degenerating nerve (Sha-
mash et al., 2002; Siebert et al., 2000; Tofaris et al.,
2002). Macrophages mediate the second phase of myelin
debris removal, a type-3 complement receptor-depend-
ent mechanism (CR-3/Mac-1/CD11b) (Slobodov et al.,
2001). All these events are orchestrated by a network of
cytokines and chemokines, of which the induction is
partly regulated by the activation of the transcription
nuclear factor kappa B (NF-jB) signaling pathway (Fu
et al., 2010; Subang and Richardson, 2001), as well as
by neurotrophic factors, secreted both by SCs and mac-
rophages: interleukin-1beta (IL1-b) (Perrin et al., 2005;
Shamash et al., 2002), IL-6 (Bolin et al., 1995), tumor-
necrosis factor alpha (TNF-a) (Shamash et al., 2002),
monocyte chemotactic protein-1 (MCP-1) (Perrin et al.,
2005), macrophage inﬂammatory protein-1 alpha (MIP-
1a) (Perrin et al., 2005), nerve growth factor (NGF)
(Funakoshi et al., 1993) and vascular endothelial
growth factor (VEGF) (Scarlato et al., 2003). Placental
growth factor (PlGF), belonging to the VEGF family,
has not been implicated in WD up to now. Identiﬁed in
1991 in the placenta (Maglione et al., 1991), PlGF has
also been detected in heart, lung, thyroid, skeletal mus-
cle (Persico et al., 1999) and brain (Beck et al., 2002).
There are 3 isoforms of PlGF in humans, but only one,
PlGF-2, is present in mice (DiPalma et al., 1996). Mice
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in which the PlGF gene has been deleted (Pgf 2/2 mice)
do not exhibit any defects in development or reproduc-
tion, but show impaired angiogenesis in pathological
conditions (Autiero et al., 2003a,b; Carmeliet et
al.,2001; Ribatti, 2008). PlGF is produced by activated
endothelial cells (ECs), inﬂammatory cells, bone mar-
row cells, as well as neurons (Beck et al., 2002; Luttun
et al., 2002). Interestingly, PlGF displays pro-inﬂamma-
tory properties: it mobilizes macrophages, has a chemo-
tactic activity on blood monocytes (Clauss et al., 1996)
and increases mRNA expression of pro-inﬂammatory
cytokines and chemokines such as TNF-a, IL-1b, IL-8,
MCP-1, MIP-1a, and VEGF (Bottomley et al., 2000; Per-
elman et al., 2003; Selvaraj et al., 2003). Recently, PlGF
was found to have neuroprotective and angiogenic
effects in cerebral ischemia (Liu et al., 2006), but its
precise role in the nervous system remains elusive.
Considering the above-described properties of PlGF,
we decided to study its expression in peripheral nerves
under physiological and degenerative conditions, to
investigate the signaling pathway that regulates its
expression and to explore its role in the inﬂammatory
context of WD, using a model of sciatic nerve transection
in adult wild-type (wt) and Pgf 2/2 mice.
MATERIALS AND METHODS
Animals
Adult (10–12 weeks), 50%Swiss-50%129SV female wt
and Pgf 2/2 mice were used (Vesalius Research Center,
Pr Carmeliet, KUL, Belgium). The experiments were
performed in accordance with the rules and regulations
of the Ethical Committee for animal research of the Bel-
gian National Fund for Scientiﬁc Research.
Surgical Procedure: Sciatic Nerve
Complete Transection
Mice were anesthetized by intraperitoneal (i.p.) injec-
tion of a mixture of ketamine (75 mg/kg; Ketalar, Bayer
HealthCare, Brussel, Belgium) and xylazine (10 mg/kg;
Rompun, Pﬁzer, Brussel, Belgium). Under aseptic con-
ditions, sciatic nerves were exposed and WD induced by
a complete axotomy of the nerves at the upthigh level.
Proximal and distal stumps were left in their original
position to allow axonal regeneration. Muscles and skin
were carefully closed in two layers.
Tissue Processing
Mice were killed after different survival times (1, 3, 7,
14, 21, and 28 days postinjury) by an overdose of Nem-
butal (150 mg/kg, i.p., CEVA Sante Animale, Brussel,
Belgium) and the distal parts of the transected sciatic
nerves were freshly harvested, embedded in Tissue-Tek
O.C.T.TM Compound (Labonord SAS, Templemars,
France) and directly frozen. Ten micrometer-thick longi-
tudinal or transverse sections were collected onto gela-
tin-coated slides, and stored at 220C until used.
Dorsal root ganglions (DRG) from the lumbar segment
were harvested from uninjured mice, directly frozen,
before being cryosectioned for further immunoﬂuores-
cent staining.
Primary Schwann Cell Culture
Adult SCs were isolated from sciatic and trigeminal
nerves of wt and Pgf 2/2 mice as described (Bouquet et
al., 2007). After careful dissection under sterile condi-
tions, nerves were left for 2 weeks in degeneration me-
dium: DMEM, 10% foetal bovine serum, Fungizone (2.5
mg/mL, GIBCO, InvitrogenTM, Carlsbad, CA), Forsko-
lin (2 mM, Calbiochem, Darmstadt, Germany), Genta-
mycine (50 mg/mL, GIBCO) and Heregulin-b1 (10 ng/
mL, HRG; R&D Systems GmbH, Wiesbaden, Germany)
at 37C, 5% CO2. After enzymatic and mechanical disso-
ciation, cells were plated on precoated poly-L-lysine (50
lg/mL, Sigma-Aldrich, Saint Louis, MO) and laminin
(10lg/mL, Sigma-Aldrich) T25 culture dishes and incu-
bated at 37C, 5% CO2 in N2HRG medium: 50% DMEM
50% F12 supplemented with N2 (GIBCO), gentamycin
(50lg/mL), fungizone (2.5 lg/mL), forskolin (2lM), and
HRG (10 ng/mL). At conﬂuence, SCs were puriﬁed by
magnetic cell-sorting using the anti-low afﬁnity NGF re-
ceptor (p75NGFr; AB1554; 1/200; Millipore, Temecula,
CA) antibody (Ab), according to the manufacturer’s
instructions (Miltenyi Biotech GmbH, Bergisch Glad-
bach, Germany).
Immunoﬂuorescent Stainings
To characterize PlGF expression, double immunoﬂuor-
escenct stainings for PlGF (sc-27134; 1:50; Santa Cruz
Biotechnology, Santa Cruz, CA, Taylor and Goldenberg,
2007) and NF-H (MAB5448/clone TA51; 1:500; Millipore,
De Girolamo et al., 2000) for axons, Neu-N (MAB377/
clone A60; 1:250; Millipore, Borsani et al., 2010) for neu-
ronal cell nuclei, S100 (ZO311; 1/200; DakoCytomation,
Gould et al., 1986) for quiescent SCs, p75NGFr
(AB1554; 1/200; Millipore, Runyan and Phelps, 2009) for
proliferating SCs, von Willebrand factor (vWF; AB6994;
1/2000; Abcam, Yin et al., 2010) for endothelial cells,
patched-1 (Ptc-1; sc-9016/H-267; 1/50; Santa Cruz Bio-
technology, Chen et al., 2007) for ﬁbroblasts, CD11b
(MCA74; 1/250; Serotec, Springer et al., 1979) for macro-
phages, P0 (AB9352; 1/50; Millipore) for peripheral mye-
lin, were performed. After drying, tissue sections were
ﬁxed in cold acetone for 10 min at 4C. Nonspeciﬁc bind-
ing was prevented by 1h incubation in 10% normal se-
rum solution in 0.1% triton-PBS (0.1 M, pH 7.4). Sec-
tions were then incubated overnight at room tempera-
ture (RT) with the speciﬁc primary Abs, rinsed 3 times
with PBS and incubated with their respective secondary
Abs coupled with rhodamine or FITC (1/500, Jackson
ImmunoResearch Laboratories, West Grove, Pennsylva-
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nia), for 1h at RT. Sections were then rinsed twice in
PBS, twice in distilled water, and mounted under cover-
slips using vectashield solution (Vector Laboratories,
Burlingame, CA). To assess the speciﬁcity of the anti-
PlGF Ab, negative controls were obtained by incubation
of the primary Ab with its speciﬁc blocking peptide (sc-
27134 P; Santa Cruz Biotechnology) before applying it
on the tissue sections. Also, speciﬁc positive (placenta)
and negative (liver) tissues for PlGF were used to con-
ﬁrm this speciﬁcity (Fig. 1).
Prediction of NF-jB Binding
Sites and Luc Assay
To identify NF-jB binding sites, computational analy-
sis of the promoter sequence of mouse Pgf gene (Green
et al., 2001) was performed using four different pro-
grams designed to look for transcription factor binding
sites (MatInspector program, MatchTM program, Promo,
TFSEARCH).
For luciferase assays, the region including the two jB
sites were inserted into the pGL3-Promoter Vector
(Promega). 293 cells (4 3 105 cells per well) were seeded
in 6-well (35 mm) plates. After 12 h, cells were trans-
fected as described above with 0.5 lg of either the Pgf-
jB-luciferase or the Ig-jB-luciferase (Leonardi et al.,
2000) and with expression plasmids as indicated. The
total amount of transfected DNA was kept constant by
adding empty expression vector DNA as needed. Cell
extracts were prepared 24 h after transfection, and
reporter gene activity was determined by using Dual-Lu-
ciferase Reporter Assay System (Promega). The pRL Vec-
tor (40 ng), which provides constitutive expression of
Renilla luciferase, was used to normalize for transfec-
tion efﬁciencies.
Chromatin Immunoprecipitation
(ChIP) Assay
Sciatic nerves (from uninjured [UI] and 24h postin-
jured wt mice) were surgically removed from four adult
mice per condition, minced and immediately ﬁxed in
PBS containing 1% paraformaldehyde (PFA) for 25 min
at RT. The nerves were washed twice with cold PBS con-
taining protease inhibitors (CompleteTM, Roche Applied
Science, Mannheim, Germany) and then homogenized
into 1.5 mL of lysis buffer (1% SDS, 10 mM EDTA, 50
mM Tris-HCl pH 8.0, protease inhibitors). The lysates
were sonicated for 15 min with alternating 30-s pulses
at high power with a Bioruptor sonicator (Diagenode,
Liege, Belgium), and then centrifuged at 13,000 rpm for
5 min. The protein concentration of lysates was meas-
ured using the BCA protein assay kit (ThermoScientiﬁc,
Rockford, Illinois). Inputs were kept for later analysis.
Lysates were diluted 10 times into dilution buffer (1%
Triton X-100, 150 mM NaCl, 2 mM EDTA, 20 mM Tris-
Fig. 1. Conﬁrmation of PlGF Ab speciﬁcity. (A) PlGF immunostaining on transverse section of sci-
atic nerve. (B) Negative control: nerve section stained with anti-PlGF Ab preincubated with its spe-
ciﬁc blocking peptide. (C) PlGF immunostaining on placenta used as positive control tissue and (D) on
liver used as negative control tissue. Scale bar: 60lm.
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HCl pH 8.0, protease inhibitors). The sheared chromatin
was incubated with 4lg of anti-NF-jB subunit p65 (p65;
sc-109, Santa Cruz Biotechnology) or anti-Flag (used as
negative control; F3165, Sigma-Aldrich) at 4C on a
rotating platform overnight. The immune complexes
were incubated for 2 hours at 4C with Protein A-aga-
rose beads (Santa Cruz Biotechnology) blocked with
BSA (100 lg/mL) and shared salmon sperm DNA (500
lg/mL; InvitrogenTM). The immunoprecipitates were
then washed three times with 1 mL low salt washing
buffer (1% triton X-100, 0.1% SDS, 150 mM NaCl, 2 mM
EDTA, 20 mM Tris-HCl pH 8.0, protease inhibitors),
once with 1 mL high salt washing buffer (same buffer
but containing 500 mM NaCl), once with 1 mL LiCl
buffer (0.25 M LiCl, 1% IGEPAL CA630 (Sigma-Aldrich),
1 mM EDTA, 1% deoxycholic acid, 10 mM Tris-HCl pH
8.0), and ﬁnally once 1 mL with TE buffer (10 mM Tris-
HCl pH 8.0, 1 mM EDTA). Immunoprecipitated (IP)
chromatin was eluted in 250 lL elution buffer (1% SDS,
0.1 M NaHCO3) for 15 min at RT, twice. Chromatin
inputs were also diluted in elution buffer. Protein-DNA
cross-links were reversed by incubation with 20 lL of 5
M NaCl at 65C for 4h and proteins were digested by
addition of 10 lL of 0.5 M EDTA, 20 lL of 1M Tris-HCl
pH 6.5 and 20lg of proteinase K (Promega, Madison,
Wisconsin) and incubation 1h at 45C. DNA was puriﬁed
with phenol/chloroform (Sigma-Aldrich) using Phase
Lock GelTM tube (Eppendorf, Hamburg, Germany). The
aqueous phase was incubated 1h at -20C after the addi-
tion of 45 lL of 3 M NaAC pH 5.5, 30 lg of glycogen
(Roche Applied Science) and 1 mL of absolute ethanol
and then centrifuged 5 min at 13,000 rpm. The DNA
pellets were washed with 70% ethanol, resuspended in
100 lL of DNase-free distilled water. Quantitative PCR
(using SYBR green PCR master mix; Applied Biosys-
tems) was performed to analyse the IP DNA. Signals
were normalized to respective inputs and compared with
negative control (anti-Flag IP). The primers (Euro-
gentec, Seraing, Belgium) used to amplify speciﬁc jB
sites of Pgf gene are resumed in Table 1.
Axonal Regeneration Study
To evaluate axonal regeneration, longitudinal sections
from the distal part of injured sciatic nerves were ﬂuo-
rescently stained with anti-NF-H Ab as described above.
For the quantiﬁcation, nonoverlapping successive ﬁelds
covering the entire tissue sections (which means the
whole length of the distal part) were taken using Olym-
pus DP50 digital camera connected to an Olympus AX-
70 microscope (magniﬁcation 10x). The mean number of
ﬁelds/section was similar between wt and Pgf 2/2 mice
(7.47 6 0.76 and 7.54 6 0.64, respectively), resulting in
comparable total tissue length. Each ﬁeld was then allo-
cated to one of the following group: (i) ﬁeld containing
only debris of degenerating axons; (ii) ﬁeld containing a
majority of debris and few regenerating proﬁles; (iii)
ﬁeld containing scarce debris and a majority of regener-
ating ﬁbers; and (iv) ﬁeld containing only regenerating
ﬁbers. Data were expressed as a mean proportion of ﬁeld
numbers in each of those 4 groups per total nerve sec-
tion (%)6 standard error.
Motor Recovery Evaluation
Before lesion and at 3, 7, 10, 14, 17 and 21 days fol-
lowing unilateral left sciatic nerve axotomy, mice were
allowed to walk down a 60cm long corridor lined with
graph paper after inking their hind paws. For each ani-
mal (5 wt and 5 Pgf 2/2 mice), at every time point, at
least four clear footprints were obtained for each foot.
Measurements of print length were then made on the
operated side (OPL) and the normal side (NPL). A mean
of four values was then calculated for the OPL (xOPL)
and NPL (xNPL), and a print-length factor (PLF) was
calculated as follows: PLF 5 (xOPL – xNPL)/xNPL
(George et al., 2003).
Quantiﬁcation of Schwann Cell Proliferation
In vivo
Longitudinal sections of sciatic nerves were stained
with anti-Ki67 Ab according to the above-described pro-
tocol (NCL-Ki67p; 1/250; NovocastraTM, Leica Microsys-
tems GmbH). Ki67 positive SC nuclei (magniﬁcation
20x) were manually counted within nonoverlapping suc-
cessive ﬁelds covering the entire nerve section, and
results were expressed as a mean number 6 standard
error of Ki67 positive SC nuclei per mm2 of nerve tissue.
In vitro
Cultured SCs were plated on coated glass coverslips
at a concentration of 25,000 cells/300 lL. 20lM bromo-
deoxyuridine (BrdU; Sigma-Aldrich) was directly added
to the cultures for 16h before ﬁxation in 4% PFA for
10min. Cells were treated in HCl 2N for 10min at 37C
and then washed in borate buffer (0.1M; pH 8.5). Cells
were permeabilised and nonspeciﬁc binding was pre-
vented by 1h incubation in 10% normal serum 0.1% tri-
ton-PBS solution. Then cells were incubated overnight
with anti-BrdU Ab (OBT0030; 1/250; Serotec) and anti-
p75NGFr Ab to assess the purity of SC culture. After 3
PBS washes, cells were incubated with their respective
TABLE 1. Quantitative PCR probe informations
Amplicon
name
Gene
localization
Primer
type
Oligonucl.
Sequence (50-30)
PlGF kB1
site
2908 to 21015 Reverse ACGTGCCTCCAGAACCGTCC
Forward CCAGGTGCCCCGAGGTGTTT
PlGF kB2
site
21041 to 21120 Reverse CTCCTGTCAGGTCAGGCCAGC
Forward CCTCTTCTGCTTGGGCTCGGG
PlGF
gene
624 to 753 Reverse TTCCCCTTGGTTTTCCTCCTT
Forward AGATCTTGAAGATTCCCCCCA
382 CHABALLE ET AL.
GLIA
secondary Abs coupled with rhodamine or FITC, for 1h
at RT. Coverslips were then rinsed in PBS and distilled
water, and mounted on slides using vectashield solution
containing DAPI to visualize all nuclei for the determi-
nation of the total cell number. Double-stained
p75NGFr/BrdU cells and total number of p75NGFr posi-
tive cells (magniﬁcation 20x) were manually counted
within nonoverlapping successive ﬁelds, and results
were expressed as a mean % 6 standard error of prolif-
erating SCs.
TABLE 2. RT-PCR probe informations
Gene Primer type Oligonucleotide sequence (50-30) PCR product size (bp) Cycle nb
mPlGF Reverse TTCCCCTTGGTTTTCCTCCTT 130 45
Forward AGATCTTGAAGATTCCCCCCA
GAPDH Reverse GCCTTCTCCATGGTGGTGAAGAC 210 25
Forward GACCCCTTCATTGACCTCAACTACATG
Fig. 2. Double immunoﬂuorescent stainings on uninjured sciatic
nerve (A–D) and dorsal root ganglion (E) sections. PlGF (Rhodamine)
and NF (A, B), P0 (C), Ptc-1 (D), NeuN (E) (FITC) double immunoﬂuo-
rescent stainings, on transverse (A, C, D) and longitudinal (B) sections
of uninjured sciatic nerve. PlGF is expressed in axons and has a peri-
axonal expression pattern (A, B). However, PlGF is not present in the
myelin sheath, as no co-localization could be seen with P0 (C). Finally,
besides its periaxonal localization, PlGF is also expressed by ﬁbroblasts
in the endoneurium (D, arrows show PlGF/Ptc-1 labelled ﬁbroblasts,
and * design axons). Scale bar: A, C, D: 20lm; B: 10lm, E: 50 lm.
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RT-PCR
RNA from cultured SCs was extracted with TRIzol
(InvitrogenTM) and isolated according to the manufac-
turer’s protocol. PlGF and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, as internal control), mRNAs
were ampliﬁed with aliquot of 20 ng of total RNA using a
RT-PCR kit (GeneAmp Thermostable rTth reverse tran-
scriptase RNA PCR kit; Applied Biosystems, Foster City,
CA) and appropriate ‘‘forward’’ and ‘‘reverse’’ primers
(oligonucleotide sequences shown in Table 2; Eurogen-
tec, Seraing, Belgium). Reverse transcription was per-
formed at 70C for 15 minutes followed by 2 minutes of
incubation at 95C for denaturation of RNA-DNA hetero-
duplexes. Ampliﬁcation consisted in cycles of 15 seconds
at 94C, 20 seconds at 58C, and 20 seconds at 72C. RT-
PCR products were resolved on 10% polyacrylamide gel,
stained with GelStar (Lonza, Rockland, Maine).
DAB Immunostainings
Tissues were ﬁxed with 4% PFA for 5 min, then incu-
bated in a 0.3% H2O2, 0.1% Na azide solution in PBS for
20 min at RT to reduce endogenous peroxydase activity.
Nonspeciﬁc binding was prevented by 1h incubation in
3% normal serum and 1% bovine serum albumin solu-
tions in 0.1% triton-PBS. Sections were then incubated
overnight at RT with the speciﬁc Abs: anti-p75NGFr
(AB1554; 1/200; Millipore) to study SC dedifferentiation
or anti-CD11b (MCA74; 1/250; Serotec) to study macro-
phage recruitment. After 3 PBS rinses, they were incu-
Fig. 3. Double immunoﬂuorescent stainings on normal and injured
sciatic nerve sections. PlGF (Rhodamine) and S100 (A, A0), p75NGFr
(B, B0) or NF (C, D) (FITC) double immunostainings, on longitudinal
sections of normal (A, A0) and injured (distal segment, B, B0, C, and D)
sciatic nerves. PlGF is not expressed by myelinating SCs, as no co-local-
ization is observed with S100 (A, A0). SCs, which dedifferentiate and
proliferate after loss of axonal contact, express PlGF from the ﬁrst day
after injury (B, B0). Axonal PlGF expression decreases after injury, fol-
lowing the time course of axonal degradation (C). 28 days postinjury,
PlGF reappears in the regenerating ﬁbres (D). Scale bar: 60lm.
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bated with their respective secondary biotinylated anti-
bodies (Vector Laboratories) diluted and centrifuged in a
3% mouse normal serum and 1% BSA in 0.1% triton-
PBS solution, for 1h at RT. Then sections were incu-
bated 1h with the avidin-biotin-peroxydase complex
(Vector Laboratories), diluted 1/1000 in PBS and the im-
munostaining revealed with 3,3’-diaminobenzidine.
Image Analysis
To quantify SC dedifferentiation, pictures (magniﬁca-
tion 20x) were converted to gray scale. A threshold in-
tensity of gray-colored staining was set and applied to
each slice. Then, immunostaining was quantiﬁed within
nonoverlapping successive ﬁelds covering the total nerve
tissue area using the Olympus AnalySIS computer pro-
gram. Data were expressed as the mean integral inten-
sity 6 standard error of total stained area (pixel2) per
total nerve tissue area (pixel2). For the macrophage
recruitment quantiﬁcation, CD11b-positive macrophages
(magniﬁcation 10x) were manually counted within nono-
verlapping successive ﬁelds covering the entire nerve
section, and results were expressed as a mean number
6 standard error of CD11b-positive macrophages per 0.1
mm2 of nerve tissue.
Toluidine Blue Staining
Mice were perfused with Karnovski solution contain-
ing 1% PFA and 1.25% glutaraldehyde in 0.2M Sorensen
buffer ( 750 mOsm). Sciatic nerves were carefully har-
vested and postﬁxed with Karnovski overnight at 4C.
After two washes in 0.1M Sorensen buffer, nerves were
postﬁxed with 1% osmium in Sorensen buffer for 1h at
4C. Sciatic nerves were progressively dehydrated in
successive ethanol baths and then soaked in epoxypro-
pane twice during 10 min each. Tissues were embedded
in epon resin by soaking in a mixture of epoxypropane/
epon in proportions 2/1, then 1/1 and ﬁnally 1/2, 1h
each. The resin was harded at 265C for 2 days. The
blocks were trimmed and semi-thin transverse sections
(1 lm) were cut with a Leica Ultracut UCT microtome,
picked up onto glass slides, and then dried on a hot
plate at 60C for 1h. To have a good dye impregnation in
the tissue, sections were treated with 1% potassium tet-
raborate before staining with 0.5% toluidine blue. Intact
myelin sheaths (magniﬁcation 40x) were manually
counted within nonoverlapping successive ﬁelds covering
the entire nerve section, and results were expressed as a
mean number 6 standard error of intact myelin sheaths
per 0.01 mm2 of nerve tissue.
Cytokine Array
Expressions of IL-1a, IL-1b, IL-6, TNF-a, IL-10,
VEGF, VEGF receptor-1 (VEGFr1), MCP-1, MIP-1a and
the pro-matrix metalloprotease-9 (proMMP-9) were
measured in tissue extracts of UI and injured sciatic
nerves from wt and Pgf 2/2 mice using RayBio Cyto-
kine Antibody Arrays (RayBiotech, Norcross, Georgia).
200lg of total protein were used per sample. The cyto-
kine array membranes were scanned with a Las-4000
luminescent image analyser (Fujiﬁlm, Tokyo, Japan).
The intensity of the signal was measured with the
Quantity One 1-D Analysis software (Bio-RAD Laborato-
ries, Hercules, CA). The results were expressed as the
mean relative signal intensity, i.e. the ratio of sample
signal intensity/positive control signal intensity. Each
signal intensity of positive controls and samples was
normalized by the background substraction.
Fig. 4. NF-kB binding on Pgf gene promoter after sciatic nerve
injury. (A) The prediction of NF-jB binding sites has revealed two
putative jB motifs (grey letters) located at positions 994-1004 (jB1)
and 1075-1084 (jB2) bps upstream the ATG translation initiation
site of the mouse Pgf gene. (B) p65 is speciﬁcally recruited to the
Pgf gene promoter after injury, as examined by chromatin immuno-
precipitation assays using normal uninjured sciatic nerves (UI) or 1
day-injured sciatic nerves (1d). After normalization to inputs and to
negative ﬂag IP, signal in UI condition was set to 1 and the one
obtained in injured condition was expressed relative to it. Results
are from three independent experiments and error bars denote
standard deviation. We observed no fold induction for the kB1 pri-
mers. (C) The jB sites found in the Pgf promoter are functional in
activating NF-jB, as examined by Luciferase assay. Pgf-kB or Ig-kB
(positive control) vectors were transfected in 293 cells, with or with-
out the p50/p65 expression vectors, as indicated. Signals were nor-
malized by measuring Renilla activity of a co-transfected pRL vec-
tor. For each vector, the value obtained in the absence of p50/p65
was set to 1 and the other was expressed relative to it. Results are
from three independent experiments and error bars denote standard
deviation.
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Statistical Analysis
Means and standard errors for each experimental
time point were calculated. Statistical signiﬁcance was
set at P < 0.05. The statistical signiﬁcances between wt
and Pgf 2/2 mice were tested separately at each time
points using a Student t-test (for CD11b, NGFr immuno-
staining and Toluidine blue quantiﬁcations).
To evaluate the group effect in motor recovery during
time (foot-print data), we used Zerbe’s nonparametric
model, which compares both the global evolution of two
groups and the values at the different time point sepa-
rately. All quantiﬁcations were performed blind to the
genotype. Statistical analyses were supervised by the
Department of Biomedical Statistics of the University of
Liege.
RESULTS
PlGF Expression in Normal and Injured
Adult Mouse Sciatic Nerve
To investigate PlGF expression in the normal nerve
and after axotomy, we performed various double immu-
noﬂuorescent stainings to screen all cell types and/or
structures present in the nerve: axons, myelin, myeli-
nating and proliferating SCs, ﬁbroblasts, ECs, and
invading macrophages.
Based on PlGF/NF double staining, PlGF is found
within the axons of the normal sciatic nerve and more
precisely at the periphery of axons (Fig. 2A,B). This
expression is found in close contact with, but not within
the myelin sheath, as no co-localization can be seen with
the P0/PlGF double staining (Fig. 2C). Fibroblasts
within the endoneurium, labeled with the Ptc-1 Ab,
express PlGF (Fig. 2D). to further assess neuronal
expression of PlGF, we also performed PlGF/NeuN dou-
ble immunoﬂuorescent staining on lumbar dorsal root
ganglion sections, where neuronal cell bodies are
located. This staining clearly shows that PlGF is
expressed within the neuronal cell body (Fig. 2E).
Finally, vWF Ab, used to identify endothelial cells, never
co-localized with PlGF (data not shown). PlGF/S100
staining conﬁrms that myelinating Schwann cells (SCs)
do not express PlGF (Fig. 3A,A0). After nerve transec-
tion, the detection of proliferating SCs by immunostain-
ing with p75NGFr interestingly shows that PlGF is seen
in these cells as soon as 1 day postaxotomy (Fig. 3B,B0)
and persists during the ﬁrst week after injury (data not
shown). Concomitantly, PlGF is no more detectable in
the degenerating ﬁbres (Fig. 3C). When axonal regener-
ation occurs, starting as soon as 14 days postinjury,
PlGF-positive ﬁbres reappear in the distal segment of
the sciatic nerve (Fig. 3D). Finally, after injury, no PlGF
was observed in invading macrophages nor in ECs (data
not shown).
Fig. 5. In vivo cell proliferation. (A) Ki67 immunoreactivity in longitudinal sections of wt and
Pgf 2/2 sciatic nerves 3 days after axotomy (scale bar: 50 lm). (B) Cell quantiﬁcation shows a signiﬁ-
cant difference between wt and Pgf 2/2 mice in the number of Ki67 positive cells 1 and 3 days postin-
jury. **P < 0.01; *P < 0.05 (mean 6 SE; N 5 5 mice per group).
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PlGF Expression Induction:
Role of NF-jB
During WD, one of the main transcription factor that
regulates the cyto- and chemo-kine expression by SCs is
NF-jB (Fu et al., 2010; Subang and Richardson, 2001).
As we demonstrated that PlGF is expressed by SCs in a
postinjury inﬂammatory context, we investigated the
potential implication of NF-jB in the induction of PlGF
expression during WD by ChIP assay. Firstly, we ana-
lysed the Pgf promoter sequence, using transcription
factor binding site prediction programs, to identify puta-
tive jB motifs on the mouse Pgf promoter. We detected
the presence of two putative NF-jB binding sites within
the mouse Pgf promoter region (Fig. 4A). To investigate
the NF-jB binding to these two jB motifs, we immuno-
precipitated the chromatin, from UI and one day-injured
sciatic nerves, using an anti-p65 Ab. DNA fragments of
IP chromatin were ampliﬁed by quantitative PCR, using
primers speciﬁcally designed to amplify predicted jB1 or
jB2 site (Table 1). The Fig. 4B shows a threefold
increase in NF-jB binding to the jB2 site after injury
compared with UI nerve controls, whereas no signiﬁcant
recruitment of NF-jB was observed to the jB1 site. To
further prove that the sites were functional in activating
gene expression, they were inserted into a luciferase re-
porter vector, transfected into 293 cells and NF-jB acti-
vation was assessed upon co-transfection with two NF-
jB subunits, p50 and p65. As shown in the Fig. 4C, the
jB sites found in the Pgf promoter (Pgf-jB) were indeed
functional as the p50/p65 heterodimer induced luciferase
gene expression (about 4-5 fold).
PlGF in WD
Role of PlGF on Schwann cell proliferation and
formation of B€ungners’ bands
The WD process in the distal stump of the injured
nerve is associated with activation and proliferation of
SCs, which form the bands of B€ungner and express
Fig. 6. In vitro Schwann cell proliferation. (A) BrdU (rhodamine)/
p75NGFr (FITC) immunostaining of wt and Pgf 2/2 SCs after BrdU
incorporation (scale bar: 50lm). (B) Quantiﬁcation shows a signiﬁcant
decrease of Pgf 2/2 SC proliferation. *P < 0.05 (mean 6 SE; N 5 3 cul-
ture experiments). (C) Polyacrylamide gel showing PlGF (P) and
GAPDH (G) RT-PCR ampliﬁcation products from wt and Pgf 2/2 cul-
tured SCs. RT-PCR conﬁrmed PlGF expression in wt SCs in culture
conditions and, as expected, no expression in Pgf 2/2 SCs.
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p75NGFr. To assess the role of PlGF in these processes,
we compared the proliferation of SCs within the sciatic
nerves of wt and Pgf 2/2 mice after axotomy. Using im-
munoﬂuorescent staining against Ki67, a nuclear pro-
tein expressed in cells undergoing proliferation, we
quantiﬁed the number of proliferating cells at 1, 3 and 7
days after axotomy in the distal stump of nerves from
wt and Pgf 2/2 mice (Fig. 5A,B). We found a signiﬁcant
decrease of cell proliferation in Pgf 2/2 mice at 1 and 3
days postinjury (Fig. 5B). Because of a conﬂict between
Abs, we were not able to perform the double immunoﬂu-
orescent staining Ki67/p75NGFr to identify the prolifer-
ating cells as SCs. We can nevertheless attest that the
Ki67-positive cells are not inﬂammatory cells, such as
invading macrophages, as they do not express CD11b
(data not shown).
To conﬁrm the in vivo ﬁnding of decreased SC prolifer-
ation in mice lacking PlGF, we compared the prolifera-
tion of primary cultures of SCs isolated from wt or
Pgf 2/2 mice. Using BrdU incorporation and double im-
munoﬂuorescent staining against BrdU and p75NGFr
(Fig. 6A), we counted the mean number of proliferating
SCs. The number of BrdU positive Pgf 2/2 SC nuclei
was signiﬁcantly decreased (Fig. 6B). To attest that SCs
express PlGF in culture condition, which corresponds to
the proliferating state they adopt after a nerve injury,
we performed a RT-PCR for PlGF on RNA extracts from
wt and Pgf 2/2 SC cultures, using GAPDH as house-
keeping gene. The polyacrylamide gel showing RT-PCR
ampliﬁcation products (Fig. 6C) conﬁrmed a PlGF
expression in proliferating wt SCs. We then assessed
p75NGFr expression in wt and Pgf 2/2 mice after sev-
eral post-transection survival times. As illustrated in
Fig. 7, p75NGFr is weakly expressed in UI nerves (Fig.
7A). In wt animals, its expression increases 3 days after
axotomy and reaches a peak at day 7 (Fig. 7B). At that
time, the longitudinal aspect of the p75NGFr staining is
likely due to the alignment of SCs to form the bands of
B€ungner, still observed 14 days after the lesion. In
Pgf 2/2 mice, the peak of expression of p75NGFr is only
Fig. 7. P75NGFr immunostaining and quantiﬁcation. (A) P75NGFr immunoreactivity in longitudi-
nal sections of wt and Pgf 2/2 sciatic nerves before (UI) and after axotomy (scale bar: 100lm). (B)
Image analysis and staining quantiﬁcation show a signiﬁcant difference between wt and Pgf 2/2 mice
in the intensity of P75NGFr staining 7, 21 and 28 days postinjury. **P < 0.01; *P < 0.05 (mean 6
SE; N 5 5–9 mice per group).
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reached 14 days after the lesion, and decreases more
rapidly afterwards. Also, at day 7, the longitudinal as-
pect of the staining is much less pronounced than in tis-
sue sections of wt animals (Fig. 7A).
Role of PlGF on macrophage recruitment and
myelin sheath degradation
The other main cell type involved in the WD process
are macrophages, which accumulate within the degen-
erating nerve segment and facilitate the removal of
axonal and myelin debris. As PlGF plays a role in the
chemo-attraction of macrophages (Clauss et al., 1996),
we ﬁrst quantiﬁed the number of invading macro-
phages within the degenerating segment at several
postinjury times, comparing wt and Pgf 2/2 mice.
CD11b immunostaining of longitudinal nerve sections
revealed a clear delay in the macrophage inﬁltration in
Pgf 2/2 nerves respective to wt nerves (Fig. 8A). While
inﬁltration peaked between the 3rd and the 7th day
postinjury in wt mice, it did so only between 14 and 21
days in Pgf 2/2 tissue (Fig. 8B). To verify if this delay
affects the degradation of myelin sheaths, we stained
the latter with toluidine blue and counted them on
semi-thin transverse wt and Pgf2/2 nerve sections at
various survival times (Fig. 9A). These counts clearly
conﬁrmed that the clearance of myelin sheaths is
slower in Pgf 2/2 mice (Fig. 9B).
Role of PlGF on cytokine and chemokine
expression
WD is orchestrated by a large cyto-/chemo- kine net-
work, which regulates SC and macrophage functions. As
PlGF absence affects more particularly early events of
WD, we compared the expression of 10 cyto/chemokines
in extracts of UI, and 1, 3 and 7 days- injured sciatic
nerves from wt and Pgf 2/2 mice. The following mole-
cules were studied: IL-1a, IL-1b, IL-6, IL-10, TNF-a,
VEGF, VEGFr1, MCP-1, MIP-1a and proMMP-9. The
Fig. 8. CD11b immunostaining and quantiﬁcation. (A) CD11b immunostaining of longitudinal sec-
tions of wt and Pgf 2/2 sciatic nerves before (UI) and after axotomy (scale bar: 200lm). (B) Cell quan-
tiﬁcation shows a signiﬁcant difference between wt and Pgf 2/2 mice in the number of invading mac-
rophages 1, 3, and 7 days postinjury. ***P < 0.001; **P < 0.01; *P < 0.05 (mean 6 SE; N 5 5–12
mice per group).
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quantitative analysis of the signal intensity revealed sig-
niﬁcant decreases in Pgf 2/2 extracts of MCP-1 at 1 day,
and proMMP-9 at 7 days postinjury (P < 0,05) (Fig. 10).
Role of PlGF in axonal regeneration and
functional recovery
As SC and macrophage functions appear to be delayed
during WD in Pgf 2/2 animals, axonal regeneration
might also be altered. To test this hypothesis, we com-
pared the NF-H immunostainings of transected sciatic
nerves in wt and Pgf 2/2 mice. At 7 days postinjury, all
axons are degraded in both wt and Pgf 2/2 nerve distal
parts, as illustrated by the high number of axonal debris
(Fig. 11A). At 14 days, regeneration starts in wt nerves,
as more longitudinal proﬁles can be observed in wt than
in Pgf 2/2 nerves. This observation was conﬁrmed by
counting the proportion of ﬁelds containing either axonal
debris (dotted aspect of NF staining), axonal proﬁles (lon-
gitudinal proﬁles on NF staining), or both (Fig. 11B).
Almost 60% of the total length of the nerve corresponds
to ﬁelds containing only axonal debris in Pgf 2/2 mice,
while debris-containing ﬁelds occupy less than 10% in wt
mice. As a corollary, ﬁelds with higher proportions of
regenerating axons occupy 50% of the nerve length in wt
mice compared with less than 5% in Pgf 2/2 mice. No
ﬁeld containing only axonal proﬁles was observed 14
Fig. 9. Myelin sheath quantiﬁcation. (A) Toluidine blue staining on semithin transverse sections
from wt and Pgf 2/2 sciatic nerves before (UI) and 7 days after axotomy (scale bar: 20 lm). Quantiﬁ-
cation shows a signiﬁcant difference between wt and Pgf 2/2 mice in the number of intact myelin
sheaths (white arrowheads) 3 and 7 days postinjury. *P < 0.05 (mean 6 SE; N 5 5–9 mice per group).
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days postinjury. After 21 days, regenerating proﬁles were
more numerous, reﬂecting the repair progress, and there
were no more difference between wt and Pgf 2/2 mice.
This ﬁnding suggests therefore that absence of PlGF
leads to a transient delay of axonal regeneration. To
assess the consequence of this delayed axonal regenera-
tion on functional recovery, we further evaluated motor
recovery after sciatic nerve axotomy in Pgf 2/2 compared
with wt mice, using the walking track method in which
footprints are analysed (Fig. 12A). The print-length of
uninjured (NPL) and injured (OPL) sciatic nerves were
measured preoperatively, as well as 3, 7, 10, 14, 17 and
21 days after axotomy and were used to calculate the
print-length factor (PLF, described in Methods section).
During the ﬁrst week following injury, this PLF increases
and reaches after 7 days the value of about 0.5 and 0.35
for wt and Pgf 2/2 mice, respectively, indicating a
marked disability in the injured paw. At day 10, the PLF
of wt mice starts to decrease and reaches a value of about
0.3 at 21 days after injury, whereas the PLF of Pgf 2/2
mice continues to get worse and reaches a value of about
0.6 at 21 days. Figure 12B illustrates the recovery of
motor function determined by the PLF. We observe no
functional recovery for the Pgf 2/2 mice. **P < 0.01; *P <
0.05 (mean 6 SE; N 5 5 mice per group).
DISCUSSION
This study provides evidence of a new function for
PlGF within the PNS, where its expression had never
been described. Using immunohistochemistry, double im-
munoﬂuorescent stainings, in vivo and in vitro cell prolif-
eration assays, cytokine arrays, RT-PCR, foot-prints, Luc
assay and ChIP assay, we propose an original model for
PlGF role in the inﬂammatory context of WD (Fig. 13).
PlGF is Expressed in the Peripheral
Nervous System
Since its initial discovery in the placenta in 1991,
PlGF has been found in other organs, including the
brain (Beck et al., 2002). Until now, nothing was known
about its distribution in the PNS. As the goal of our
study was to investigate its potential role in WD in a
model of sciatic nerve injury, the ﬁrst part of our work
focused on the expression of PlGF in the sciatic nerve.
Using immunostaining on intact nerve and DRG, we are
providing evidence that PlGF is expressed in neuronal
cell bodies and axons, but not in SCs, nor in myelin
sheaths. The peculiar peri-axonal localization of PlGF
could be due to its particular basic carboxyl end that
confers him the ability to bind polyanionic molecules
like acidic phopholipids of cell membranes (Autiero et
al., 2003a; De Falco et al., 2002; Persico et al., 1999).
PlGF Expression During WD
Axotomy results in axonal breakdown and disintegra-
tion, which can explain the decrease of PlGF expression
observed in injured axons during the ﬁrst week postin-
jury. Thereafter, WD in the PNS leads to successful axo-
nal regeneration, explaining the re-expression of PlGF
in axons. Our results also show that SCs transiently
express PlGF after nerve injury. An induction of VEGF
expression in injured peripheral nerves has been previ-
ously reported (H€oke et al., 2001; Scarlato et al., 2003).
Axonal rupture causes a loss of contact between the axo-
lemma and its corresponding SC that switches from a
differentiated state to an undifferentiated, proliferating
state. This SC response is, among others, due to a neu-
ronal release of the cytokine TGF-b1, which induces SC
proliferation (Rogister et al., 1993). Interestingly, TGF-
b1 has been shown to activate PlGF expression in cul-
tured keratinocytes (Failla et al., 2000) and in retinal
pigment epithelial cells (Hollborn et al., 2006). Hence,
the transient expression of PlGF in SC observed after
injury might be due to axonal released TGF-b1.
PlGF: A Target of NF-jB
The NF-jB factor plays important roles in immune,
inﬂammatory and apoptotic responses through the
induction of the transcription of numerous genes coding
Fig. 10. Cytokine arrays on sciatic nerve extracts from wt and Pgf
2/2 mice. (A) MCP-1 doesn’t increase its expression in Pgf 2/2 nerve as
much as in wt nerves 1 day after injury. (B) Pro-MMP-9 peaks at 7
days postinjury only in wt nerves. *P < 0.05 (mean 6 SE; N 5 6 mice
per group).
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for pro-inﬂammatory cytokines (Ledeboer et al., 2005;
Vallabhapurapu and Karin, 2009), chemokines (Giraud
et al., 2010; Grove and Plumb, 1993), matrix metallopro-
teases (Hnia et al., 2008; Rhee et al., 2007), and adhe-
sion molecules (Haddad et al., 2010; Moynagh et al.,
1994). After axotomy, activation of NF-jB in SCs is also
implicated in the regulation of the inﬂammatory
response occurring during WD (Fu et al., 2010; Subang
and Richardson, 2001). Previous study has revealed that
human PlGF expression during hypoxia was regulated
by NF-jB (Cramer et al, 2005). Our results of chromatin
immunoprecipitation assay agree with the fact that
PlGF transcription is regulated by the NF-jB signalling
pathway. By Luciferase assay, we further conﬁrmed that
the jB sites found in the Pgf promoter are functional in
activating NF-jB.
PlGF Deletion Causes a Delay in Cellular and
Molecular Events of WD
Lack of PlGF delays Schwann cell
dedifferentiation and decreases their
proliferation
Nerve injury stimulates the generation of proliferative
nonmyelinating SCs within 24h after the lesion. In
Pgf 2/2 mice, SC proliferation rates were shown, both in
vitro and in vivo, signiﬁcantly delayed. Flt-1, which
binds both VEGF and PlGF-2, mediates VEGF-triggered
proliferation of astroglial cells (Krum et al., 2008; Mani
et al., 2005). It is thus possible that in wt animals the
PlGF released by injured axons activates Flt-1 receptors
on SC membranes hence inducing their proliferation. As
Fig. 11. Neuroﬁlament immunostaining and semiquantiﬁcation. (A)
NF immunostaining on longitudinal sections of wt and Pgf 2/2 sciatic
nerves 7 and 14 days after axotomy (scale bar: 100 lm). Inserts illus-
trate representative ﬁelds considered as ‘‘debris (*)’’ or ‘‘ﬁbres (**).’’ (B)
Quantiﬁcation shows that after 14 days, Pgf 2/2 nerves contain a sig-
niﬁcant higher proportion of debris than wt nerves, while more regen-
erating proﬁles are observed in wt nerves than Pgf 2/2 ones. ***P <
0.001; **P < 0.01 (mean 6 SE; N 5 5–7 mice per group).
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other mitotic agents act on SCs during WD (D’Antonio
et al., 2006; Kwon et al., 1997; Li et al., 2005; Ogata et
al., 2006), the sole absence of PlGF can only decrease
SC proliferation, but not abolish it.
Lack of PlGF delays macrophage recruitment
and myelin clearance
Macrophages play an essential role during WD. In
addition to rapid clearance of axonal and myelin debris,
they secrete neurotrophins (Barrette et al., 2008), pro-
moting successful axonal regeneration. PlGF is chemo-
attractive for macrophages (Clauss et al., 1996), and
stimulates chemokine secretion (Selvaraj et al., 2003). It
is therefore not surprising to observe a signiﬁcant delay
in macrophage invasion during the ﬁrst week of WD in
Pgf2/2 mice. This observation is corroborated by our
cytokine array results, where signiﬁcant difference of
MCP-1 expression was observed between wt and Pgf2/2
mice. Indeed, while MCP-1 rapidly increases after injury
in wt nerves, it takes 2 more days before an increase
occurs in Pgf2/2 nerves. MCP-1 mRNA is known to be
induced very early after transection in the distal portion
of the sciatic nerve (Perrin et al., 2005; Toews et al.,
1998). MCP-1 is necessary for speciﬁc and full recruit-
ment of monocytes during WD (Perrin et al., 2005; Sie-
bert et al., 2000).
The delay observed in myelin degradation and clear-
ance, which is dependent on SCs and macrophages, is
therefore the consequence of the delayed recruitment
and reduced activity of these two cell types.
Lack of PlGF delays the formation of
B€ungner’s bands
In addition to their role in the inﬂammatory response,
SCs migrate and line up to form the bands of B€ungner.
SC migration involves several molecules like cell-signal-
ing factors, integrins, as well as proteases (Lauffen-
burger and Horwitz, 1996). Among them, MMP-9, which
is over-expressed by SCs after nerve injury and pro-
motes SC migration (Mantuano et al., 2008), was found
to be a target for PlGF (Hattori et al., 2002). Indeed, our
cytokine arrays show a signiﬁcant decrease of proMMP-9
expression 7 days after injury in Pgf 2/2 mice relative
to wt. NGF and its low afﬁnity receptor p75NGFr are
also involved in SC migration (Anton et al., 1994) and in
our study p75NGFr expression is delayed in Pgf2/2
mice after injury. Interestingly, mice lacking the neuro-
pilin-2 receptor for PlGF-2 do also show a delayed regen-
eration after sciatic crush injury, due to a delayed re-
establishment of contact between axons and SCs (Ban-
nerman et al., 2008). Moreover, it is known that VEGF
has migratory effects on SCs mainly through its tyrosine
kinase receptors ﬂk-1 and ﬂt-1 (Mani et al., 2010;
Fig. 12. Functional recovery. (A) Representative footprints obtained
from wt and Pgf 2/2 mice, 21 days after unilateral left sciatic nerve
transection. Measures of the length of the operated footprints (OPL)
and the normal footprints (NPL) were used to calculate the print-length
factor (PLF). (B) Graph showing the recovery of motor function after
sciatic nerve transection determined by the PLF (described in the
Methods section). Worse recovery is evident in mice lacking PlGF com-
pared with their wt controls.
Fig. 13. Model of PlGF function in the injured peripheral nerve. Fol-
lowing axonal breakdown, the released PlGF can bind to its ﬂt-1 recep-
tor on SC, which in turn (i) produces PlGF and chemokines through
the activation of the NF-jB signaling pathway, (ii) proliferate, and (iii)
align to form bands of B€ungner, promoting axonal regeneration. PlGF
also inﬂuences directly monocyte chemoattraction, thereby increasing
macrophage activity of myelin debris phagocytosis, necessary to suc-
cessful axonal regeneration.
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Schratzberger et al., 2000) and that ﬂt-1, the PlGF re-
ceptor, mediates migration of endothelial cells (Bae et
al., 2005; Li et al., 2006), and retinal pigment epithelial
cells (Hollborn et al., 2006). The delay of SC alignment
could thus also be related to a dampened action of
VEGF, of which the effects are normally ampliﬁed by
PlGF via various mechanisms (Autiero et al., 2003b;
Carmeliet et al., 2001; Ribatti, 2008).
Lack of PlGF delays cyto/chemokine expression
A large cyto/chemokine network regulates the sequen-
tial WD cellular events described above. PlGF is able to
induce an increase of several of these molecules like
inﬂammatory cyto/chemokines (Bottomley et al., 2000;
Selvaraj et al., 2003) or enzymes such as metallopro-
teases (Hattori et al., 2002). In our cytokine arrays
PlGF has a signiﬁcant effect on the expression of MCP-1
and proMMP-9. These molecules are essential for early
WD events: MCP-1 attracts macrophages (Perrin et al.,
2005), and MMP-9 is responsible for SC migration (Man-
tuano et al., 2008). Thus, PlGF lack of expression can
directly affect macrophage invasion as well as MCP-1
and MMP-9 levels of expression. Additionally, as SCs
increase their expression of both MCP-1 (Taskinen and
R€oytt€a, 2000) and MMP-9 (Chattopadhyay and Shu-
bayev, 2009) after injury, their delayed proliferation in
the absence of PlGF can also trigger a decrease in MCP-
1 and MMP-9 expression, leading indirectly to a
decrease of macrophage activation and a delayed axonal
regrowth.
In conclusion, we show that PlGF is involved in the
early postaxotomy SC proliferation and macrophage
chemoattraction, which can explain that in Pgf2/2
mice, axonal regeneration and functional recovery are
delayed. Indeed, the delay in myelin and axonal debris
clearance by SCs and macrophages leads to an unfav-
orable environment for regeneration. Also, the delay of
SC p75NGFr expression and bands of B€ungner forma-
tion could decrease the beneﬁcial effect that neurotro-
phins have on the regenerating axons (Taniuchi et al.,
1988). This work is the ﬁrst demonstration of the
implication of a new member in the cytokine network
regulating WD, the cytokine PlGF, whose function(s)
in the intact and injured nervous system were not
known up to now. The original observation that PlGF
is in particular instrumental in the early events of
WD like Schwann cell proliferation and macrophage
invasion raises important questions and perspectives
for regeneration in the CNS. It is well known indeed
that following injury in the CNS, axonal regeneration
partly fails because of a less pronounced macrophage
invasion compared with PNS. What about PlGF
expression after a CNS injury? Could regeneration be
promoted by providing PlGF after a CNS lesion? In
addition to its potential beneﬁcial effect on the postin-
jury inﬂammatory reaction, PlGF treatment could also
enhances neo-angiogenesis (Takeda et al., 2009), which
is also known to be beneﬁcial to axonal regrowth
(Dray et al., 2009; Hobson et al., 2000).
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Abstract
Placental growth factor (PlGF) is an angiogenic factor
that belongs to the vascular endothelial growth factor
(VEGF) family. Besides its well known capacity to poten-
tiate the angiogenic action of VEGF, PlGF also partici-
pates in inflammatory processes by attracting and
activating monocytes; it plays therefore more specifically
a role in pathological conditions. PlGF and its two recep-
tors, VEGFR-1 and neuropilins (NRPs), are expressed in
the brain and increase after experimental stroke, but their
precise functions in the nervous system remain under-
 explored. In this review article, we summarize present
knowledge on the role of PlGF in various nervous system
disease processes. Given the available data, PlGF has
neuroprotective and neurotrophic properties that make it
an actor of considerable interest in the pathophysiology
and potentially in the therapy of degenerative and
 traumatic brain or spinal cord diseases. 
Key words: PlGF; neuroprotection; trauma; neuro -
degeneration; neuropilins; VEGFR-1.
Introduction
From Andreas Vesalius’ anatomical drawings to
current research, the number of studies highlighting
the parallelism between vessel and nerve patterning
is constantly increasing (1-8). The best known an-
giogenic factors belong to the vascular endothelial
growth factor (VEGF) family. The VEGF family in-
cludes seven secreted glycoproteins, designated
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E,
VEGF-F and placental growth factor (PlGF). They
possess different physical and biological properties
and act, as dimeric glycosylated proteins, through
specific receptors: three protein–tyrosine kinase re-
ceptors (VEGFR-1, VEGFR-2, and VEGFR-3),
present on most vascular endothelial cells and two
non-protein kinase co-receptors, neuropilin-1 and
neuropilin-2 (Fig. 1). Discovered first (9, 10),
VEGF-A is the best characterized VEGF family
member. VEGF-A mediates its effects by interacting
with VEGFR-1 (also referred to as fms-like tyrosine
kinase, Flt-1), and VEGFR-2 (also referred to as fetal
liver kinase, Flk-1/KDR). In addition, VEGF145 and
VEGF165, two isoforms of VEGF-A, can also bind to
neuropilins (NRPs) (11, 12). Numerous reports have
described the role of VEGF in the nervous system
(NS), both during development (3, 6, 8, 13-17) and
in neurogical disorders such as amyotrophic lateral
sclerosis (18-28), Alzheimer’s (29-31) or Parkin-
son’s diseases (32, 33), brain ischemia (29, 34-43)
or spinal cord injury (44, 46). 
While VEGF is important under physiological and
pathological conditions, PlGF (47), much less stud-
ied than VEGF-A, appears to be more specifically
involved in pathological states (15). Although scien-
tific data are scarce, we thought it timely to summa-
rize our present knowledge on PlGF and the nervous
system, as some of the pathological processes that
are influenced by PlGF are relevant for the patho-
physiology of various neurological disorders, and,
possibly in the future, for their therapy. We will re-
view the available information coming from direct
studies of PlGF’s functions in the nervous system
from effects observed after its binding to its two re-
ceptors, VEGFR-1 and NRPs. The major findings on
the known respective roles of VEGF and PlGF in ex-
perimental models of nervous system disorders are
shown in table 1.
PlGF: biochemistry and functions
PlGF is a ~46 KDa dimeric glycoprotein that oc-
curs in 3 isoforms in humans (131, 152 and 203
amino acids). Only one isoform, PlGF-2, is ex-
pressed in mice due to alternative mRNA splicing
from a single gene (48). While PlGF was originally
identified in the placenta (47), it has been detected
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in several other organs including heart, lung, thyroid
gland, skeletal muscles and more recently in brain.
Numerous cell types, like endothelial cells, pericytes,
macrophages, bone marrow cells, tumour cells, as-
trocytes and neurons, produce PlGF especially when
they are activated or stressed like in hypoxia, inflam-
mation or trauma (49-51). 
PlGF potentiates the angiogenic effects of VEGF
such as stimulation of endothelial cell proliferation
and migration, increase of endothelial cell survival,
induction of neoangiogenesis and vessel matura-
tion (51). PlGF is also involved in inflammatory
processes where it stimulates chemotaxis and acti-
vation of monocytes, and increases their secretion of
pro-inflammatory cyto- and chemokines such as
TNF-α, IL-1β and MCP-1 (52-54).
PlGF: a neuroprotective and
neurotrophic factor
Contrasting with VEGF (55-59), there are only
few reports on the potential neurotrophic/neuropro-
tective role of PlGF. The first study showing that
PlGF might play an important role in the nervous
system was performed by Beck et al. (50), who
 explored the expression pattern of NRPs, known to
regulate both angiogenesis and neuronal axon guid-
ance (3, 5, 8), in an experimental model of cerebral
ischemia. Because NRPs have short intracellular
segments without cytoplasmic signal transduction
domains, they require an association with other re-
ceptors to be functional. These putative co-receptors
include plexin A (52) as well as VEGFR-1 and
VEGFR-2 (11, 13). Thus, in addition to NRPs, Beck
et al. (50) also studied the expression of their co-re-
ceptors VEGFR-1 and 2, and their ligands VEGF-A
and PlGF (61, 62). They demonstrated for the first
time that both PlGF mRNA and its protein are
 expressed in neurons in the normal brain, but not in
astrocytes, nor in vessels. They further showed that
3 days following a middle cerebral artery occlusion
(MCAO), the PlGF transcript and protein are upreg-
ulated in vessels inside and around the infarcted area,
as well as in neurons and astrocytes located at the is-
chemic border zone. These results were confirmed
one year later in another report that assessed the ex-
pression of angiogenic genes after experimental
brain ischemia (63). Thus, in addition to providing
further support for the potential neurotrophic and
neuroprotective roles of VEGF, these data suggested
for the first time that PlGF may be implicated in
pathological processes of the nervous system. This
hypothesis was established later, notably thanks to
Cheng et al. (64), who demonstrated that PlGF is
able to exert an anti-chemorepulsive effect on axons
through its NRP binding. NRPs are known to be
Table 1
VEGF and PlGF neurobiological effects in experimental models of neurological disorders.
Normal: beneficial effect; Italic: deleterious effect
Growth factor Experimental models of
 neurological disorders
Neurobiological effect References
VEGF
ALS 
(Mouse, SOD-1)
neuroprotection and neurotrophic action 19; 20; 22; 24; 27; 28
reduction of astrogliosis and increased formation of
 neuro muscular junctions 26
Cerebral ischemia
(Rat, MCAO)
neuroprotection 37; 38; 42; 43
Spinal cord injury
(rat, clip injury)
increased angiogenesis, proliferation of glial progenitors,
 neuroprotection, tissue sparing, improvement of locomotor
 recovery
44; 45; 46
exacerbation of lesion volume 86
Parkinson 
(Rat, 6-OHDA)
neuroprotection, neovascularization and astroglial
 proliferation (anti-oxidant, GDNF source)
32; 33
Alzheimer
(Mouse, APP23Tg)
maintenance of the chronic inflammatory response 31
Peripheral nerve injury increased nerve regeneration, neurotrophic action, mitogenic
activity on Schwann cells
82-84
PlGF Cerebral ischemia neuroprotection 50; 72
Peripheral nerve injury pro-inflammatory effects, mitogenic activity on Schwann
cells
85
 involved in axonal guidance during development,
and the balance between their ligands, semaphorins
and VEGF, plays a crucial role. On the one hand,
NRPs, in conjunction with their co-receptors plexins,
bind Sema3A and transduce repulsive signals to
axons (60). On the other hand, when associated with
VEGFR, NRPs bind VEGF and mediate attractive
signal (13). Cheng et al. (64) analyzed neurite out-
growth in DRG explants and the effect of the NRP
ligands, semaphorins, VEGF and PlGF, on the col-
lapse of growth cones. Only VEGF165 and PlGF were
able to counteract the chemorepulsive effect of
sema3A which supports a specific role for NRPs in
mediating the neurotrophic actions of VEGF165 and
PlGF. More recently, a neuroprotective effect of
PlGF was confirmed in vitro by a study showing that
it promotes the survival of cultured primary cortical
neurons under conditions of oxygen and glucose
deprivation (65).
The neurotrophic and neuroprotective effects of
PlGF, in addition to its already known angiogenic
properties, are of great interest for the treatment of
cerebral ischemia. The beneficial effects of cell ther-
apy in experimental models of cerebral ischemia
were shown in several studies (66-69). In particular,
bone marrow derived mesenchymal stem cell (MSC)
transplantations have beneficial neuroprotective and
angiogenic effects, which are notably mediated by
paracrine mechanisms (70). Among the various fac-
tors released by MSCs, VEGF and PlGF are indeed
good candidates to explain these effects (71). This
hypothesis is supported by a study (72) comparing
the efficacy of systemically delivered human MSCs
transfected or not with an adenoviral vector coding
for PlGF in a rat MCAO model of cerebral ischemia.
Transplantation of both cell types 3 hours after
MCAO reduced the lesion size, induced angiogene-
sis and improved motor function, but greater effects
were observed when rats were treated with the PlGF-
transformed MSCs. These results suggest that PlGF
might be an interesting candidate for neuroprotective
treatment in ischemic stroke. Moreover, PlGF,
 probably via its binding to NRPs, could also be of
therapeutic interest in neurodegenerative disorders
where decreased vascularisation was described, or in
spinal cord trauma where angiogenesis and neuro-
protection are necessary to support and enhance
 axonal regeneration.
PlGF: a glial activator?
The glial response plays an important role after
nervous injury. In the injured central nervous system,
the proliferation and migration of astrocytes result
in a gliotic scar that can exert both beneficial and
detrimental effects. As a matter of fact, this glial scar
isolates the injury site by re-establishing the glia lim-
itans, thus restricting the propagation of secondary
                                                                   PLGF IN THE NERVOUS SYSTEM                                                                 3
FIG. 1. — VEGF family members and receptors. The tyrosine kinase receptor VEGFR-1 binds VEGF-A, VEGF-B and PlGF with
high affinity. VEGFR-2 binds VEGF-A, VEGF-C, VEGF-D, VEGF-E and VEGF-F. VEGFR-3 is a tyrosine kinase receptor with only
six Ig-homology domains, which preferentially binds VEGF-C and VEGF-D. Neuropilin-1 and -2 (NRP-1 and NRP-2), the two non-
tyrosine kinase-type co-receptors, respectively bind VEGF-A165, VEGF-B and PLGF and VEGF-A165, VEGF-C, VEGF-D and PLGF.
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lesions, but it also creates a physical and chemical
barrier to axonal regeneration (73, 74). In central
nervous system injury, the role of VEGF in the glial
response has already been assessed. Several studies
show that VEGF stimulates astroglial proliferation
and migration via its flt-1 receptor, but also that it
facilitates the expression of several growth factors,
such as ciliary neurotrophic factor (CNTF) and basic
fibroblast growth factor (bFGF) (75-77). By contrast,
the influence of PlGF in the formation of the
 astroglial scar remains unknown. However, high-
lights have been recently brought by recent studies
showing that the early growth response (Egr-1) fac-
tor, which regulates the astrocytic expression of
phosphacan, a glial scar component, after experi-
mental stroke (78), is a target gene for PlGF (79).
After peripheral nervous system injury, VEGF is
expressed by Schwann cells (80, 81), stimulating
their proliferation and migration (82-84) which is a
crucial step for efficient axonal regeneration. Re-
cently, we have published the first description of the
expression and function of PlGF in the peripheral
nervous system under normal physiological situation
and after nerve injury (85). In the intact mouse
 sciatic nerve, PlGF is found in axons underneath the
axolemma, while it is expressed by Schwann cells
after axotomy (Fig. 2). Using transgenic knock-out
mice for the PlGF gene (Pgf -/-) and a multidiscipli-
nary approach, we were able to demonstrate that
PlGF plays a role in Wallerian degeneration: it
 stimulates proliferation and migration of Schwann
FIG. 2. — Double immunofluorescent stainings on normal and
injured mouse sciatic nerve sections. PlGF (Rhodamine) and NF
(A) or S100 (B) (FITC) double immunostainings, on cross-
 section of normal (A) and longitudinal section of injured (distal
segment, B) sciatic nerves. In normal sciatic nerve, PlGF is
found in axons underneath the axolemma (A). Schwann cells,
which dedifferentiate and proliferate after loss of axonal contact,
express PlGF from the first day after injury (B). Arrows point to
Schwann cells expressing PlGF 24h after injury.
FIG. 3. — Functional recovery. (A) Representative footprints
obtained from wt and Pgf -/- mice, 21 days after unilateral left
sciatic nerve transection. Measurements of print length were
made on the operated side (OPL) and the normal side (NPL). A
mean of four values was then calculated for the OPL (xOPL)
and NPL (xNPL), and a print-length factor (PLF) was calculated
as follows: PLF = (xOPL – xNPL)/xNPL. (B) Graph showing
the recovery of motor function after sciatic nerve transection de-
termined by the PLF. During the first week following injury, PLF
increases, indicating a marked disability in the injured paw. Later
on, the PLF in wt mice progressively decreases, indicative of
functional recovery. Worse recovery is evident in mice lacking
PlGF compared to their wt controls.
cells, as well as the inflammatory response by induc-
ing MCP-1 expression and macrophage recruitment,
essential for successful repair. Thus, PlGF depletion
in Pgf -/- results in delayed axonal regeneration and
impaired functional recovery (Fig. 3). 
Conclusion
Currently, PlGF has received much less attention
than VEGF-A as a potential treatment for neurolog-
ical disorders. However, this careful analysis of the
literature highlights the fact that the neuroprotective
and neurotrophic effects of VEGF-A are mainly due
to its binding to neuropilins and to a lesser extent to
VEGFR-1, both of which being also PlGF receptors.
It is only recently that specific studies have been de-
voted to PlGF demonstrating that it has its proper
neuroprotective/neurotrophic properties. 
A major drawback of the therapeutic use of
VEGF-A in brain or spinal cord injury is increase in
vascular permeability and oedema formation (87)
because of its pro-angiogenic properties (9, 86). The
effect of PlGF on vascular permeability remains dis-
puted. Some reports have shown that only VEGF-A
analogues activating VEGFR-2 are able to increase
vascular permeability (88, 89). The lack of such an
effect for PlGF could thus make it a more appropri-
ate candidate than VEGF-A for neurological treat-
ment. However, experiments using mutant mice in
which PlGF is under- or over-expressed have respec-
tively revealed a decrease (90) or an increase (91,
92) of the vascular permeability in pathological con-
ditions. One explanation, according to Carmeliet et
al. (93) is that the PlGF-induced increase in vascular
permeability is an indirect effect, consequence of the
displacement of VEGF-A from VEGFR-1 to
VEGFR-2, as PlGF competes with VEGF-A for
VEGFR-1 in pathological conditions. 
Taken together, VEGF and PlGF, despite proven
experimental advantages, could be double-sided
swords as neuroprotective/neurotrophic treatments
for ischemic, degenerative or traumatic neurological
disorders. In future therapeutic studies, it might be
worthwhile to explore the effect of a combination of
PlGF to induce beneficial tissue modelling effects
and a VEGFR-2 inhibitor to block the VEGF-
 dependent angiogenic effect.
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